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Abstract 
 
Oral delivery of therapeutic peptides poses serious challenges in the field of 
drug delivery. The main concerns in developing an oral formulation of therapeutic 
peptide is that the peptide can be susceptible to enzymes in the gastrointestinal tract, 
poor solubility, short circulation time in plasma and fast renal clearance. This study 
focuses on improving the oral availability of therapeutic peptide by its encapsulation 
in a biodegradable polymer called GCPQ. GCPQ has been reported previously to 
solubilize small molecular weight hydrophobic drugs and peptides. GCPQ also 
demonstrated to improve their oral bioavailability.  
In the present study, two therapeutic peptides, Methionine enkephalin (anti-
cancer peptide) and Labyrinthopeptin (anti-noiciceptive peptide) was characterized 
and formulated with GCPQ nanoparticles. Labyrinthopeptin, a hydrophobic peptide 
having poor solubility was solubilized using GCPQ nanoparticles and their oral 
uptake was evaluated in vivo. Anti-noiciceptive activity of Laby GCPQ B2 
formulation was evaluated in rat CFA model and compared against Laby glycofurol 
formulation. Therapeutic effect of Laby GCPQ B2 oral and nasal formulation was 
found to be significantly higher to control at time points 240 min and 40 min 
respectively as demonstrated in rat CFA model. Laby glycofurol formulation also 
showed significant therapeutic effect (40 and 60 min) after nasal administration as a 
result of permeation enhancing property of glycofurol itself. Concentrations of Laby 
in plasma were observed to be higher for Laby GCPQ B3 oral and nasal formulation 
compared to Laby glycofural formulation, suggesting that GCPQ improves oral 
uptake of Laby peptide. However, concentrations of Laby in plasma for Laby GCPQ 
B1 formulation were lower than that it was observed for Laby GCPQ B3 and Laby 
glycofural formulation, suggesting that the characteristics of GCPQ can be modified 
to control the uptake of Laby peptide.  
Similarly, Methionine enkephalin, a peptide having poor stability in the gut 
was formulated with GCPQ B1 & B2 and characterized in vitro and in vivo. Their 
therapeutic effect was evaluated in nude mice tumor xenograft model. Significant 
reduction in tumor volume for mice treated with MENK-GCPQ B2 oral formulation 
was observed compared to MENK formulation and control. The concentration of 
MENK following oral administration of MENK GCPQ B2 formulation (100 mg/kg) 
 v 
were variable and at nanogram levels. However, this concentration could be 
sufficient to cause therapeutic effect in mice xenograft model.  
The concentrations of MENK in plasma were observed to be at nanogram 
levels (298 ng/mL), 180 min after administration of MENK-GCPQ B1 IV 
formulation. Following administration of MENK IV formulation, the concentrations 
of MENK in mice plasma were not detectable after 5 min. This result also suggests 
that only a fraction of MENK was encapsulated in MENK GCPQ B1 formulation. 
Although, there were significant differences in pharmacokinetic effect between 
MENK and MENK GCPQ B1 IV formulations, the therapeutic effect of MENK-
GCPQ B1 IV formulation in tumor xenograft model was only significant to that of 
control but insignificant to that of MENK IV formulation. Excess MENK 
concentration resulting from MENK-GCPQ B1 IV formulation may not have 
improved the therapeutic effect due to saturation of OGFr receptor and clearance 
from the system. An alternative mode of MENK-GCPQ administration such as sub-
cutaneous or intra-peritoneal could delay MENK release in the systemic circulation 
and thereby enhancing the therapeutic effect compared to MENK only formulation.  
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  was	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  for	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  to	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  anova	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  IV	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  (#	  p<	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  sets	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Figure	  4-­‐35	  Survival	  analysis	  of	  MENK	  (15	  mg/kg)	  IV	  (red),	  MENK	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  mg/kg)-­‐GCPQ	  B1	  (1:2.6)	  IV	  
(green)	  and	  control	  (black)	  formulation	  by	  Kaplan	  Meier	  estimator.	  Survival	  line	  drops	  for	  every	  
animal	  that	  reaches	  a	  relative	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  growth	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  mice	  bearing	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  treatment	  period	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  to	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  day	  11	  (*p<0.01),	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  0.01),	  16	  (#	  p<	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  formulation	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  p<	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  and	  16	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  0.01).	  Missing	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  sets	  were	  excluded	  from	  statistical	  
analysis.	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1 Introduction	  
1.1  Therapeutic peptides - Growth, Scope and Market 
Peptides are chains of amino acids ranging between 2 and 50 residues and 
linked by peptide bonds. Chemically, peptide can be placed between small 
molecules, for their size and proteins, for their composition. Peptides act as 
regulatory or signaling molecules with physiological roles in defense, stress, 
immunity, growth, homeostasis and reproduction. With the advent of the modern 
drug era came several therapeutic peptides such as; opioids, cyclic peptides, 
penicillin and insulin. However, due to lack of peptide screening and large-scale 
production technologies at the beginning of twentieth century, the scope for 
marketing of therapeutic peptides were limited. Moreover, peptides lack stability due 
to poor physiochemical properties resulting in poor pharmacological profile for 
clinical use. This has led the pharmaceutical industry to focus more on small 
molecules for their perceived advantages such as stability, superior 
pharmacodynamics profile, suitability for oral administration and overall low 
production cost. In the past decades, small molecules have suffered higher attrition 
rates due to several reasons, such as, inability to prove improved efficacy over 
existing drugs and side effects due to lack of specificity. The success rate of small 
molecules produced by conventional method has been less than 12 % and the 
average time scale required for a drug to enter market is between 8 and 15 years. 
Moreover, an average cost for new drug development is $ 2.6 billion [1]. In order to 
overcome the high cost associated with drug development, the pharmaceutical 
industry has shifted its paradigm to repurposed or orphan drugs. In the year 2015, 
FDA has approved 45 new medicines of which 47% are to treat rare diseases [2]. 
Human genome project has identified 30,000 genes of which only 10% are likely to 
be susceptible to small molecules [3]. With fewer drugs making into the market and 
patent expiry of successful drug, an alternative chemical entity such as peptide could 
be promising.  
Peptide research and development have been gaining increased attention in 
the past decade for its potential ability to improve efficacy, safety and tolerability 
compared to small molecules. Peptides are typically highly selective and effective at 
low concentrations. The simple chemical composition allows researchers to predict 
the metabolism. Unlike antibodies, some peptides can penetrate the cell membrane, 
which opens window for identifying novel target and drug development. With the 
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advent of molecular biology and improvements in synthetic chemistry, overall 
production costs are cheaper, compared to proteins. The success rate of peptides 
entering clinical trials between 1984 and 2000 were reported to be 23 to 26% [4]. 
The average time scale required for clinical development and US approval of 
peptides during the year 2012 was 9 and 2.1 years with medium phase length of 7.8 
and 0.9 years respectively [5]. There are 60 peptide drugs in the market, 140 in 
clinical development and around 500 at the preclinical development stage. LupronTM, 
anti-cancer peptide marketed by Abbott technologies, reached a global sale of US $ 
2.3 billion dollars in 2011. Similarly, LantusTM, insulin glargin marketed by Sanofi, 
reached a global sale of US $ 7.9 billion in 2013 [5]. The projected sale for peptide 
drug is expected to increase from US $ 14 billion in the year 2011 to US $ 25 billion 
in the year 2018. Peptides currently in development have various therapeutic 
applications (Figure 1-1) in metabolic disorders, cancer and as orphan drugs for rare 
diseases, inflammation and infectious diseases [6].  
 
Figure 1-1 Therapeutic peptide market revenue by application [7] 
Most therapeutic peptides (> 75%) are administered via the parenteral route. 
According to transparency market research analysis, the projected market share 
(2018) for injectable peptides was the largest. However, compound annual growth 
rate % (CAGR) of peptides administered by non-invasive routes exceeds that of the 
injectable peptide formulations [7]. An invasive method of drug administration is 
inconvenient to the patient, particularly for chronic conditions, and requires stringent 
manufacturing procedures in order to maintain sterile conditions. Non-invasive route 
of peptide administration can circumvent the aforementioned constraints. Although 
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oral route is the most favored, the oral delivery of peptides are hampered due to poor 
physiochemical properties and the physiological barriers that limit peptide absorption 
from the gastrointestinal tract. In this review, a brief description of nature of peptides 
and its physiochemical properties, physiological factor affecting oral peptide delivery 
and current strategies to overcome biological barrier will be discussed.  
1.2  Anatomy and physiology of the Gastrointestinal tract 
The gastrointestinal tract comprises of oral mucosa, the stomach, the small 
intestine and the large intestine.  
1.2.1 Oral mucosa  
The oral cavity is lined by oral mucosa, which has keratinized, or non-
keratinized squamous epithelium, lamina propia or connective tissue beneath the oral 
epithelium, sub mucosa and bone. The function of oral mucosa is to secrete saliva, 
thermal regulation, protection against microbes and sensation. The oral cavity is 
exposed to mucus and saliva that has enzymes like esterases, oxidases and reductase 
from buccal epithelium and phosphatases and carbohydrases in saliva [8]. The oral 
cavity has relatively smaller surface area (214 cm2) [9] compared to small intestine. 
The drug absorption that occurs through mucosa reaches the systemic circulation 
bypassing first pass metabolism. Drug absorbed through oral cavity also avoids 
gastrointestinal content. However, the efficacy of drug absorption is altered by 
constant movement of drug facilitated by saliva and mucus, which leads to 
swallowing [10].  
1.2.2 Gastrointestinal mucosa 
The mucosal lining of the gastrointestinal tract facilitates absorption of 
nutrients and water as well as act as a protective barrier from external environment. 
The upper gastrointestinal tract consists of mouth, oesophagus and stomach.  
The food in the mouth is chewed to form bolus that is carried via the oesophagus to 
the stomach.  
1.2.2.1 The Stomach 
In the stomach, the bolus is partially digested by acid and enzymes secreted 
by the gastric mucosa. The stomach is divided in to the fundus, the body and the 
pyrolic region [11]. The stomach wall has series of ridges called rugae, which 
expands when the food is consumed and allows mechanical degradation of food.  
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The gastric mucosa has indentation that leads to tubular shaped gastric glands.  
The gastric glands are composed of parietal cells that secrete HCl in to the stomach; 
chief cells that release zymogen, a precursor to pepsin, foveolar cells that produce 
mucus, G cells that secretes gastrin which in turn stimulate the release of histamine 
and enterochromaffin-like cells that produces histamine in the presence of excess 
acid [11, 12]. The histamine promotes the production and release of bicarbonate ions 
from the parietal cells. The mucus protects the gastric mucosa from acid by trapping 
the bicarbonate ions secreted by the parietal cells to neutralize any back diffusion of 
hydrogen ions from the lumen [13]. The volume of the stomach typically ranges 
from 200-300 mL in fasted state to 1400 mL after a meal. Hormones such as GLP-1 
regulate the gastric emptying [14].  
1.2.2.2 The Small Intestine 
The partially digested semi fluid food in the stomach called chyme empties in 
to the small intestine. Small intestine is the major site of food and drug absorption 
and is divided in to duodenum, jejunum and ileum [15]. It constitutes 81% of the 
total surface area of the GI tract [16]. The small intestine has circular folds of 
mucosa or plicae circularis (Figure 1-2) that increases the surface area three fold. 
The plicae circularis further has finger like villi increasing the surface area 30 fold 
(Figure 1-3). The villi, in turn, are covered by microvilli, which increase the surface 
area a further 600 fold. The intestinal wall has single layer of specialized epithelial 
cells and has mucus producing goblet cells and follicle-associated epithelium 
interspersed between epithelial cells [16]. In addition to gut lining, the digestive juice 
aids in digestion of food. Bile juice that contains bile acids and derivatives 
solubilizes lipids in the food by forming micelles. The micelles have larger surface 
area and absorbed by brush border membrane of jejunum. From the ileum 95% of the 
bile acids are reabsorbed and recycled in the liver. 2-5% of bile acids are further 
reabsorbed in large intestine after metabolic transformation by intestinal bacteria 
[17]. Pancreas secretes pancreatic juice, which neutralizes the acidic chyme by 
producing bicarbonates. In addition, the pancreatic juices also contain various 
enzymes such as lipases and proteases that aids in break down of lipids and proteins. 
Once the food constituents are broke down by digestive juices they are then absorbed 
by active or passive mechanism through the enterocytes [16].  
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In addition to digestive and absorption function, intestine is also 
functionalized to offer protection against harmful pathogens. The immune system 
associated with intestinal mucosa is called gut-associated lymphoid tissue (GALT). 
GALT are composed of Peyer’s patch in the ileum and intraepithelial lymphocytes 
basolateral spaces between luminal epithelial cells and lamina propia lymphocytes in 
lamina propia of mucosa [15]. Peyer’s patch are involved in immune surveillance of 
the contents in intestinal lumen and facilitates immune response. M-cells covers 
Peyer’s patch that are know uptake antigen by endocytosis and elicit immune 
response by activating T-cells [15, 16].  
 
 
Figure 1-2 Vertical section of small intestine- plicae cirvularis [18] 
 
 
Figure 1-3 Villi in small intestine [18] 
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1.2.2.3 The large Intestine 
The large intestine extends from ileocaecal junction to the anus. The large 
intestine consists of caecum, colon (ascending, transverse, descending and sigmoid), 
rectum and anus. The main function of large intestine is absorption of water, 
electrolytes, secretion of mucus, formation of faeces and defecation [16]. Large 
intestine also has bacterial flora at an estimated population of 1010-1012 cfu/g that 
break down complex material as well as produce nutrients that are absorbed in the 
colon [19]. Compared to small intestine, large intestine lacks villi resulting in 
reduced surface area for nutrient or drug absorption. Also drug absorbed via large 
intestine avoid first pass effect of liver. The mucosa also lacks most endogenous 
enzymes and P-gp that can reduce the bioavailability of certain drugs [8].  
1.3  Factors affecting the oral delivery of peptides 
Several factors limit the oral bioavailability of peptides. Peptides in the 
gastrointestinal tract are affected by their solubility in the GI medium, their 
susceptibility to enzymes, and their uptake across the enterocytes. The barriers that 
limit the oral uptake of peptides in the gut are discussed in the following sub 
sections.  
1.3.1 Peptide solubility 
To achieve systemic delivery via the oral route of administration, an ideal 
therapeutic drug has to be soluble in the gastrointestinal tract as well as permeable 
through the gut in order to reach the site of action. The pH varies along the length of 
the gastro-intestinal tract, with acidic in the stomach, neutral in the duodenum, 
alkaline in the distal portion of the small intestine and again acidic in the large 
intestine due to the presence of bacteria. The pH at the absorption site and the extent 
of ionization has an effect on solubility and permeability of peptide of interest. 
The physiochemical properties of the peptide, such as the pKa, isoelectric 
point, log P and water solubility determine the bioavailability and efficacy of 
therapeutic peptides. Dissolution is a stepwise process where a solid drug first 
dissociates from the bulk form and accommodates within the water molecules.  
The rate of dissolution (dw/dt) is represented using Noyes-whitney equation that 
depends on saturation solubility of drug in dissolution layer (Cs), diffusion 
coefficient of the dissolved solute (D), thickness of dissolution layer (H) and surface 
area of the solid (A) [20]. 
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dw/dt = D*A*Cs /H 
In a solvent system containing two immiscible solvents, a drug in solution 
partitions into different phases based on their affinity for each phase. This is 
represented as partition coefficient P, where hydrophobicity of a molecule is 
determined by the ratio of concentration of drug in the hydrophobic phase to the 
concentration of drug in the aqueous phase. The log P provides some estimate of the 
bioavailability of a drug molecule. The higher the log P value the more lipophilic is 
the drug molecule and vice versa [21]. For a drug to be orally bioavailable, a drug 
molecule has to be hydrophilic to be solubilized in the gut as well as possess 
lipophilicity for cellular uptake [22].  
1.3.2 Enzymes in the Oral and Gastro-intestinal tract 
The therapeutic peptide first encounters the enzymes in the oral cavity. The 
major enzymes present in the mouth are amylases and lipases that degrade starch 
[23]. Thus, therapeutic proteins or peptides are not degraded in the oral cavity. 
Following that is the gastric medium, which contains pepsin; an enzyme that breaks 
down polypeptides to peptides, cleaving bond at phenylalanine, methionine, leucine, 
tryptophan and other hydrophobic residues to give short chains of amino acids [24]. 
The therapeutic peptide further follows through the small intestine where it 
encounters pancreatic enzyme. Pancreas secretes enzymes (Table 1-1) as non-active 
precursor molecules (zymogens) that are only activated when they come into contact 
with the intestinal wall. Enzymes in the brush border membrane (Table 1-2) such as; 
enteropeptidases are released into the lumen that convert the precursor trypsinogen to 
active trypsin, which in turn activates other pancreatic enzymes like chymotrypsin, 
elastase carboxypeptidase A & B. Here, large proteins and peptides are completely 
degraded to small fragments (tripeptides and dipeptides) [25] [26]. However, some 
small peptides can resist the action of pancreatic enzymes; in particular cyclic hepta-, 
octa- and decapeptides of Amanita mushrooms [27], synthetic hexa- and octapeptide 
analogue of somatostatin [28], vasopressin [29] or cyclosporine A [30].  
At the mucosa, brush border enzymes like endo and exopeptidases are 
produced which further degrades the di, -tri- and tetra peptide into individual amino 
acids. Any peptide that escapes the pancreatic and brush border peptidase is likely to 
be digested by lysosomal enzyme after uptake into enterocytes. The degraded 
peptides, when being internalized into the epithelial cells, pass through endocytotic 
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pathway, fuse with the lysosomes and undergo intracellular hydrolysis. Furthermore, 
when the epithelial cells slough off, lysosomal enzymes are released in to the lumen 
and may digest the therapeutic proteins. However, lysosomal enzymes are less active 
in the intestinal lumen as their optimum activity is only between pH 5-5.5 [31]. 
Table 1-1 Pancreatic enzymes and their site of action [31] 
 
Enzyme Bond*Hydrolysed 
Trypsin !!◉⬇!!"
Arginine,"lysine 
Chymotrypsin !!◉⬇!!"
Phenylalanine,"tyrosine"(leucine,"methionine,"aspar7c"acid,"
glutamine,"tryptophan) 
Elastase !!◉⬇!!"
Alanine,"glycine,"leucine,"valine,"isoleucine 
Carboxypep8dase*A !!!⬇◉"
Phenylalanine,"tyrosine,"isoleucine"(threonine,"glutamic"acid,"
his7dine,"alanine) 
Carboxypep8dase*A !!!⬇◉"
Lysine,"arginine,"hydroxylysine,"ornithine 
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Table 1-2 Brush border enzymes and their site of action [31] 
 
1.3.3 Mucosal Barrier 
Mucus lines the small intestine and act as a physical barrier to drug 
absorption. Mucus enables exchange of nutrients, water, gases, odorants and 
hormones while being impermeant to bacteria and many pathogens. The mucus is a 
complex hydrogel composed of proteins, carbohydrates, lipids, salts, antibodies, 
bacteria and cellular debris [32]. The thickness of the barrier varies along the length 
of the GI tract with the least thickness observed in the jejunum and greatest in the 
colon (Figure 1-5).  
Brush Border Enzymes Bond hydrolysed 
Endopeptidases 
Endopeptidase 24.11 ---⬇◉--- 
hydrophobic amino acids 
Endopeptidase 24.18 ---⬇◉⬇--- 
Aromatic amino acids 
Exopeptidases: Amino terminus 
Aminopeptidase N ◉⬇---- 
Many different amino acids 
Aminopeptidase A ◉⬇---- 
aspartic acid, glutamic acid 
Aminopeptidase P ◉⬇---- 
Proline 
Aminopeptidase W ◉⬇---- 
Tryptophan,tyrosine, phenylalanine 
γ-Glutamyl transpeptidase ◉⬇---- 
γ-Glutamic acid 
Dipeptidyl peptidase -◉⬇---- 
Proline, alanine 
Exopeptidases: carboxy terminus 
Carboxypeptidase P ----⬇◉ 
Proline, glycine, alanine 
Carboxypeptidase M ----⬇◉ 
Lysine, arginine 
Peptidyl dipeptidase A ----⬇◉- 
histidine-leucine 
γ-Glutamyl carboxypeptidase ----⬇◉ 
(γ-Glutamic acid)n 
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Figure 1-4 Mucus layers showing loosely and firmly adherent mucus layer on epithelial cells 
 
Figure 1-5 Thickness of the rat mucus along the Gastro-intestinal tract [33] 
The mucus barrier consists of two layers: an outer sloppy layer that slips 
away with the movement of the chyme and an inner unstirred adherent layer that is 
entangled firmly with the enterocytes (Figure 1-4). The outer layer is constantly 
renewed. The quicker the peptide reaches the unstirred adherent layer the less it is 
removed from the GI tract together with the loose mucus [34] [35]. It must be noted 
that the jejunum has the thinnest layer of loosely adherent mucus, followed by the 
corpus, antrum, duodenum, ileum and colon (Figure 1-5). The main component of 
mucus is mucin, which is composed of a protein backbone linked to 
Goblet'
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Loosely'adherent'
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oligosaccharides. The mucin monomers entangle and cross-link adhesively and 
reversibly forming a viscoelastic gel. Mucus gel entanglement creates a sieve (400 
nm) that limits the penetration of large particles [32]. Viscoelastic properties of the 
mucus are important for its protective and lubricating properties. The viscoelasticity 
of mucus is regulated by water, lipid and ion content. The mucus viscoelasticity is 
regulated for exclusion of particulates and molecules in gastrointestinal tract, lungs 
and vagina. In the lungs, the mucus loosens its viscoelasticity to enable its movement 
towards trachea. In the vagina, the mucus viscoelasticity is regulated between 
ovulation and non-ovulation phase. Thickness of the mucus during non-ovulation 
phase is higher creating a barrier for the penetration of sperms and vice versa. [36].  
More than 20% of the mucus is composed of lipids that can cause 
hydrophobic interaction with foreign particles and pathogens [37]. The glycosylated 
portion of mucin is also capable of forming non-specific hydrogen bonding and 
electrostatic interaction [38].  
Peptides that have poor mucosal permeability and cellular uptake are likely to 
be affected by intestinal transit time. The oral absorption of a drug across the GI tract 
is determined by its residence time in the gut and its absorption in each GIT segment. 
Gastric retention time (Table 1-3) is only 1.5 h after which the drug traverses the 
stomach. The human small intestine has a faster velocity between its proximal and 
distal end with an intestinal transit time around ∾ 3-4h. The intestinal transit time is 
relatively independent of feeding conditions and the physical composition of 
intestinal component [39].  
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Table 1-3 Surface area and physical characteristics of different segments of Gastro-Intestinal 
tract in humans [31] 
 
1.3.4 Peptide uptake across the enterocytes 
1.3.4.1 Passive transport 
Once the peptide crosses the mucosal barrier, absorption can take place by 
two ways i.e. passive diffusion or trans cellular pathway (Figure 1-6). In passive 
absorption, molecules diffuse along their concentration gradients from apical (lumen) 
to basolateral membrane (blood). It is an energy-independent process, and 
physiochemical and diffusive properties such as electrostatic charge, ionization, 
dissociation constant, hydrophilic-lipophillic balance and hydrodynamic size play a 
significant role in passive absorption. Passive diffusion of drug molecules can be 
paracellular (between the cells) or transcellular (through the cell membrane). In the 
paracellular pathway, only hydrophilic molecules smaller than 250Da can diffuse 
through the intercellular spaces. Tight junctions obstruct the transport of large 
peptides by regulating the intercellular spaces. The paracellular route of drug 
absorption accounts for less than 0.01% of total surface area of intestinal membrane 
[40] [41].  
Segment Surface 
Area 
Segment 
length 
Residence 
time 
pH of the 
segment 
Catabolic activity 
Oral cavity 100cm2 - Seconds to 
minutes 
6.5 Polysaccharides 
Esophagus  200cm2 23-25cm Seconds 
Stomach 3.5m2 0.25cm 1.5 h 1-2 Proteases, lipases 
Duodenum 1.9m2 0.35m 0.5-0.75 h 4-5.5 Polysaccharides, oligosaccharides, 
proteases, peptidases, lipases and 
nucleases 
Jejunum 184m2 2.8m 1.5-2 h 5.5-7 Oligosaccharides, peptidases and 
lipases 
Illeum 276m2 4.2m 5-7 h 7.0-7.5 Oligosaccharides, peptidases, 
lipases, nucleases and 
nucleotidases 
Colon and rectum 1.3m2 1.5m 1-60 h (35 h 
average) 
7.0 -7.5 Bacterial enzymes 
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Figure 1-6  Mechanism of intestinal peptide absorption (a) Passive diffusion through 
enterocytes; (b) Passive diffusion via paracellular pathway; (c) Cytotic mechanism; 
(d) Peptide transporters; (e) Efflux transporters 
The transcellular pathway (Figure 1-6) is the major route of absorption for 
most drug molecules. Physiochemical properties such as size (>300Da), lipophilicity 
and hydrogen bonding capacity determine the rate of transport across the apical cell 
membrane. Peptides form hydrogen bonds with water molecules, and for 
transcellular absorption; peptides must desolvate to interact with cell membrane.  
For an optimum transcellular uptake, the energy required to break peptide-water 
bond should be minimal and therefore degree of hydrogen bonding is inversely 
proportional to transcellular absorption. Due to low lipid solubility and large size, 
only break down products of proteins and peptides such as tripeptides, dipeptides and 
amino acids are absorbed through this mechanism [42] [43]. 
1.3.4.2 Active transport 
Active absorption is an energy-dependent and ion gradient driven process that 
utilizes carriers such as transporters to cross the cellular barrier. Physiochemical 
properties of proteins/peptides are determinants of active absorption. The enterocytes 
express transporters on the apical and basolateral membranes for the influx and 
efflux of endogenous substances and xenobiotics. These transporters broadly belong 
to adenosine triphosphate (ATP) binding cassette (ABC) superfamily (those 
transporters that utilizes ATP for transport) and solute carrier (SLC) super families 
(transporters that utilizes ion gradient). PepT1 transporters are H+ dependent di-peptide 
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transporters predominantly localized in duodenum. It uses H+ gradient and inside 
negative membrane potential as a driving force for substrate translocation [44] [45].  
1.3.4.3 Transporters that reduces peptide transport – Efflux transporters 
Efflux transporters belong to the family of ABC transporters, which efflux 
not only endogenous substrates and toxic components, but also therapeutic peptides 
out of the cell against the concentration gradient. The major groups of efflux 
transporters in the intestinal epithelium are P-glycoprotein (P-gp) [46], Multidrug 
resistance-associated protein 2 (MRP2) [47] and breast cancer resistance protein 
(BCRP) [48].  P-gp and MRP2 are located in the apical membrane of enterocytes 
[49]. Peptides such as Metkephamid and D-Ala-leucine enkephalin are substrates for 
the above mentioned efflux pumps [50]. Different strategies are employed to prevent 
efflux action such as, efflux inhibitors, pro-drug modifications, antisense targeting 
and avoiding exposure to intestinal efflux pumps. Efflux inhibitors modulate the 
efflux pump by one of the three mechanisms, 
 
a. By blocking the drug binding site allosterically or competitively 
b. By interfering with ATP hydrolysis 
c. By altering the integrity of cell membrane lipids.   
1.3.5 Bile 
Bile, stored in the gall bladder is released in to the intestine at a rate of  
2-22 mL/kg/day. Bile causes emulsification of fat and increases its absorption 
through the intestine. The bile salts can also form ionic interaction with the peptide 
and re-circulate between the intestine and hepatocytes enhancing oral absorption 
[51]. Insulin encapsulated in liposomes was observed to be susceptible to bile salts. 
However, surface coating of liposomes were observed to be stable against bile salts 
and improved the oral bioavailability of insulin [52]. Radiolabeled GCPQ polymeric 
nanoparticles were reported to recirculate between gall bladder and small intestine 
via bile and with which, it was hypothesized to show improved absorption [53]. 
1.3.6 Lymphatic circulation 
Nutrients absorbed through the villi of intestinal mucosa pass through to either 
blood capillaries or the lymphatic circulation. Peptides that are carried through 
capillary network are subjective to degradation by hepatic first pass metabolism.  
This could be circumvented if the peptide drugs are carried via lymphatic circulation. 
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Although it has been reported in the past that peptides can be carried through to the 
lymphatic circulation via Peyer’s patches in the ileum, approaches to target 
lymphatic circulation has not yet been successfully exploited [51]. 
1.4  Strategies to improve oral bioavailability of peptides 
The strategies to improve oral bioavailability of peptides can be broadly 
classified in to three types, such as; structural modification of therapeutic peptides, 
addition of auxiliary agents and drug carrier system.  
1.4.1 Structural modification of therapeutic peptides 
By natural selection, peptides of biological origin are prone to enzymes in the 
digestive system. Inherently, these biological entities exist as propeptides, an inactive 
protein that undergo post-translational modification to become functionally active. 
Propeptides have a specific role in signaling, by providing steric hindrance that 
provides protection against enzymes and in facilitating transport across all 
membranes. This property has been exploited to modify therapeutic peptides, and 
thus to protect them from enzymatic hydrolysis and to increase their cellular uptake.  
The Peptide structure can be modified to protect them from proteolytic 
enzymes in number of ways. This includes replacement of susceptible amino acids, 
protecting the N or C terminal by attaching a functional group, cyclization of linear 
peptide and conjugation to macromolecules such as PEG (Polyethylene glycol) or 
albumin. Examples in (Table 1-4) provide a detailed summary of different types of 
approaches used to improve the oral bioavailability of therapeutic peptides. However 
there is a key limitation in using this strategy, as the modification should not affect 
the activity of a peptide. From regulatory point of view, synthetic peptides are 
classified as new chemical entity (NCE), which require more trials to achieve 
stringent regulatory approval. 
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Table 1-4 Strategies to reduce enzyme degradation in biological fluids 
Mechanism Protection against Examples Therapeutic benefit 
Structural Modification of peptide 
N-acetylation Weakly inhibiting trypsin Salmon calcitonin [54] Improved oral bioavailability 
Attachment of 
moiety 
exopeptidases Tesamorelin contains a 
hexenoyl group attached 
to N-terminal tyrosine 
amino acid of growth 
hormone releasing 
hormone (GHRH) [55] 
Tesamorelin is resistant to the 
action of dipeptidyl 
aminopeptidase IV. Improves half-
life of GHRH from 6.8 min to 1 h 
Replacement of L-
amino acids with D-
amino acids 
Trypsin 
 
 
 
Desmopression has L-
Arg replaced by D-Arg, 
an analogue of 
vasopressin  
  
Improves half-life from 10 – 35 
min [56] to 3.7 h . 
Endopeptidases 
 
Octreotide an analogue 
of somatostatin [57] 
 
Improves half-life from few min to 
1.5 h 
Replacement of 
susceptible amino 
acids 
Serum enzymes Ipamorelin, a growth 
hormone secretagogue 
in which alanine is 
replaced with 2-
aminoisobutyric acid 
Improves terminal half-life around 
2 h [58] , [59] 
Cyclization by 
lactamization/ 
lactonization/ 
sulphide bridges 
Serum enzymes ALRN-5281, GHRH 
peptide for treating 
orphan endocrine 
disorder [60]  
97% of the ALRN-5281 peptide 
remain pharmacologically active 
after 24 h of incubation in rat 
plasma compared to sermorelin, a 
GHRH analogue which 
completely degrades in 13 h [61].  
Conjugation of 
macromolecules 
(PEG, albumin) 
Dipeptidyl peptidase and 
neutral endopeptidase  
Liraglutide analog of 
GLP-1 can bind to 
albumin 
Increased serum half life from few 
min to 8 h [62] 
Also reduce renal clearance. 
1.4.2 Addition of pH modulators 
Co-administration of pH modulators is one of the methods to enhance oral 
peptide delivery. Auxillary agents are small molecules that either bind with the 
proteolytic enzymes (protease inhibitors) or interact with the cell structure to 
facilitate cellular uptake (permeation enhancer). Most of the carriers currently in 
clinical development are based on protease inhibitors and permeation enhancers. 
However, it should be noted that peptides are susceptible to different classes of 
enzymes and may require more than one protease inhibitors. Also, some of the 
permeation enhancers and protease inhibitors are surfactants, which when used at 
higher concentrations can be toxic. However, reducing the concentrations to non-
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toxic levels may not provide sufficient therapeutic benefit. The Table 1-5 describes 
the list of protease inhibitors and permeation enhancers in preclinical development.  
Table 1-5 Strategies to enhance oral delivery of peptide by co-administration of auxiliary 
agents 
Addition of Auxiliary agents 
Function Target molecule Example Benefit 
As protease 
inhibitors 
Chymotrypsin Soybean trypsin inhibitor Enhanced oral bioavailability of 
insulin [63] 
Trypsin, chymotrypsin and 
plasmin 
Aprotonin  Insulin - Better pharmacokinetic 
results [64] 
serine and 
metallopeptidases 
Puromycin  Better stability of leucine 
enkephalin [65] 
Trypsin, pepsin and 
aminopeptidase N 
Bacitracin Insulin, met-kephamid and 
buserelin [66] [67] [68] 
As permeation 
enhancers 
Tight junction  Fatty acids- Sodium 
caprate [69] 
D-decapeptide and sodium 
caprate were directly delivered 
(non invasively) to rat lumen of 
the terminal rectum. Bioavailability 
of D-decapeptide improved from 2 
to 11% in rat model.  
Uptake via trans-cellular 
route 
Surfactants -DS1, a 
modified Quillaja 
saponin [70] 
Increases uptake of D-
decapeptide (model peptide) in a 
dose dependant manner (in vitro 
Caco-2 model) 
Interacts with membrane 
lipids and proteins 
C8/C10 Mono-/di 
glycerides [71] 
Progesterone [72] 
Co-administration of C8/C10 Mono-
/di glycerides enhanced 
absorption of calcein (fluorescent 
complex) following intradudonal 
administration in rat model 
 Opens tight junctions Zonula occludens toxin-
Insulin [73] 
10 fold increase in insulin 
absorption in rabbit 
 Transcytosis Insulin-TAT conjugate 
[74] 
5-8 times better permeation than 
native insulin 
1.4.3 Drug carrier system 
Nanomaterials have gained attention over the past 40 years in the 
pharmaceutical field for their remarkable potential to improve the poor 
characteristics of therapeutic drugs, thereby helping to meet clinical needs. These 
materials, apart from their size, have unique characteristics, such as their shape and 
surface-to-volume ratio, which give them unique electrical, optical, thermodynamic, 
mechanical and chemical properties. The nanomaterials, due to their larger surface 
area facilitate higher concentrations of therapeutic drug to be entrapped, adsorbed or 
covalently attached [75]. The high loading efficiency of nanoparticles and their 
improved solubility allow drug-nanoparticle systems to be pharmacologically active 
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at their very low concentrations. Their smaller sizes enable drug accessibility to 
cancer cells, inflamed tissue etc. through enhanced permeation and retention effect 
(EPR) [76]. Nanoparticles are formed by top-down approach where larger particles 
are broken down to nano-sized particles or bottom-up approach where small 
molecules undergo controlled assembly to form nanoparticles [77]. An ideal drug 
delivery nanoparticulate system should be biocompatible and safe, improve the 
solubility of a drug, should protect the drug from proteolysis in the gut, liver and 
serum, improve the drug circulation time in plasma and prevent drug loss due to 
renal clearance.  
The nanomaterials used in the pharmaceutical field can be broadly classified 
as self assembled polymers, polymer drug conjugates, polymeric nanoparticles, 
carbon nanotubes, porous silicon nanoparticles, drug nanocrystals, nanoemulsions, 
liposomes, niosomes, low molecular weight micelles, solid lipid nanoparticles and 
polymersomes. Few examples of therapeutic peptide for enhancing oral 
bioavailability of therapeutic peptides are mentioned in Table 1-6.  
Polymeric nanoparticles are versatile structure that can be functionalized to 
enhance the bioavailability of the peptide. Natural and synthetic polymers such as; 
chitosan, dextran, PLA, PLGA were reported to have been modified with conjugates 
that increase the stability of peptide in gastric fluid [78] [79], increased permeation 
by para cellular uptake [80] [81] and trans cellular uptake [82].  
Polymers such as; chitosan [83], thiolated polymers [84], lectins [85], 
hydrogels [86], poly acrylic acid derivatives [87] are reported to have mucoadhesive 
properties. The advantage of using polymeric nanoparticles for encapsulating small 
molecular drugs, proteins and peptides is that their surface characteristics can be 
optimized to enhance mucoadhesion and mucopenetration. An ideal polymer should 
be able to rapidly adhere and interact with mucin epithelial tissue. The polymer’s 
physical properties, such as wettability, swelling and spread ability, along with its 
chemical characteristics, such as polymer chain interpenetration, electrostatic, 
hydrophobic and van der waals interactions, are important determinants of 
mucoadhesion [88]. Mucoadhesive properties of nanoparticles increase their 
residence time in the gut and ideally should be optimal enough to allow the 
nanoparticles to traverse the mucosal barrier without being trapped in the mucus. 
Other than polymers, mucoadhesive patch system (GI-MAPS) has also been 
designed for enhancing oral bioavailability. The patch system consists of drug and 
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additives sandwiched between an enteric pH sensitive top layer and insoluble ethyl 
cellulose bottom layer. In GI tract, the top layer dissolves leaving the drug layer to 
tightly adhere to mucus wall. The concentration gradient between the patch and the 
enterocytes enhances drug uptake [89].  
Liposomes are vesicular structure that can accommodate drugs within the 
phospholipid bilayer and enhance bioavailability of therapeutic peptide. Liposomes 
are transported via peyer’s patch [90]. However, liposomes are characterized by poor 
stability in the gastrointestinal tract an as effect of bile salts, pancreatic lipase and 
gastric pH. Other report suggests that surface coating of liposome can improve its 
stability in the GI tract [52]. 
 Hydrogels are hydrophilic polymeric network known to stabilize peptide in 
gastric medium. Hydrogels swell and accommodate water depending on the pH and 
ionic strength of the medium. In gastric medium the network for hydrogen bonding 
and protect the peptide whereas in intestinal medium the beads swell due to ionic 
repulsion and release the peptide in the intestine [91].  
Solid lipid nanoparticles are formulation that can accommodate drug in solid 
lipid core matrix stabilized by emulsifiers. SLNs have better stability in the 
gastrointestinal tract and cross the epithelium by endocytosis. However, their ability 
to cross mucus still remains a challenge due to electrostatic repulsion between carrier 
and mucin. It was previously reported that CSK peptide ligand has affinity for goblet 
cells [92] [93]. Fan et al reported an increase in the oral bioavailability of calcitonin 
when SLNs are conjugated with peptide ligand CSK [94].  
Self-emulsifying drug delivery system (SEDDS) is composed of oil, non-
ionic surfactants and co-surfactant coated with hard or soft gel capsules. This system 
is known to solubilize hydrophobic drug until absorption. The SEDDS formulation 
spontaneously forms emulsion in the gastrointestinal tract due to gastric mobility and 
agitation in the intestine. Moreover, the system also promotes absorption across 
intestinal epithelium [95]. Sandimmune™, an oral cyclosporine SEDDS formulation 
shown to improve bioavailability of the respective peptide. However, absorption is 
drastic leading to liver and kidney toxicity. Neoral™, a modified SEDDS 
formulation shows better oral bioavailability than sandimmune™.  The toxicity of 
Sandimmune™ is explained by the formation of polydisperse macroemulsion in 
aqueous solution leading to irregular absorption. However, Neoral™ when dispersed 
in an aqueous solution spontaneously forms microemulsion of particle size less than 
  37
100 nm. The small and monodisperse size of the neoral formulation results in 
consistent absorption of cyclosporine leading to greater systemic exposure [96].  
Table 1-6 Drug carrier system for enhancing oral delivery of therapeutic peptides 
Drug carrier system for enhancing oral delivery of peptide 
Strategies Carrier Example Contributing factors for improved 
therapeutic benefit 
Proteolytic 
stability 
Mucoadhesive Permeation 
enhancer 
Polymeric 
Nanoparticles 
PLGA-polyanhydride 
nanoparticles 
Zinc insulin [97] -  mucoadhesive Can cross 
intestinal 
epithelium 
within 1 to 6 h 
of oral 
administration 
[98] 
PLGA/RS-HP55 
(hydroxypropyl 
methylcellulose phthalate) 
[99] 
Insulin Delayed 
release in 
SGF due to 
HP-55 
coating 
mucoadhesive Eudragit RS 
Opens tight 
junction 
Quaternary ammonium 
palmitoyl glycol chitosan 
(GCPQ) nanoparticles 
Leucine 
enkephalin 
Stable in 
SGF and 
SIF 
mucoadhesive transcellular 
uptake 
Dextran- Vitamin B12 
nanoparticles 
Insulin Stable in 
SIF [100] 
- Complexation 
with intrinsic 
factor and 
uptake via 
intrinsic factor 
receptor 
PLA-PEG-IgG Fc 
nanoparticles [101] 
Insulin Stable in 
SGF [102] 
mucoadhesive Receptor 
mediated 
uptake via Fc 
receptor 
Hydrogels Poly[methacrylic acid-
grafted-poly(ethylene 
glycol)] 
Insulin Against 
trypsin and 
∝ 
chymotrypsi
n [103] 
Mucoadhesive 
[104] 
Permeability 
increased 
from 0.77 to 
1.16 × 10-8 
cm/s [105] 
Lipid based 
drug delivery 
system 
PEGlyated Liposome  Insulin Stable 
against 
trypsin and 
∝ 
chymotrypsi
n in GI tract 
[52] 
Mucoadhesive 
- [106] 
No 
permeability – 
modest 
hypoglycemic 
activity [52]  
Liposomes coated with 
Chitosan aprotonin 
conjugate [107] 
Calcitonin Stable 
against 
trypsin  
Mucoadhesive - 
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1.5  Therapeutic Peptides in clinical development 
Peptides currently under clinical development are mostly formulated using 
permeation enhancers while remaining systems use peptide drug conjugates and 
liposomal formulation (Table 1-7). However, in conditions where the drug 
concentrations have to be increased to achieve therapeutic benefit, permeation 
enhancers may cause dose limiting toxicity [113].  This is also one of the reasons 
why formulation like Eligen® fail in clinical development.  
In the Table 1-7, comprehensive examples technologies currently being used 
by different pharmaceutical companies for oral delivery of therapeutic peptides, their 
outcomes and development phase are summarized as follows.  
Dry powder of 
Proliposomes made with 
egg lecithin, lactose and 
chremophor EL [108] 
Cyclosporine - - Improved 
absorption 
Solid lipid 
nanoparticles 
Stearic acid and tripalmitin 
[109] 
Calcitonin (13% 
bioavailability)  
Stable in GI 
tract 
- Clathrin and 
caveolae 
dependant 
endocytosis 
 Cetyl palmitate and 
poloxamer [110]  
Insulin Prevents 
aggregation 
in gastric 
medium 
- Transcytosis 
pathway 
Self 
emulsifying 
drug delivery 
system 
Phospholipid, oil phase, 
surfactant and co 
surfactant 407 
LXT-101 [111] Stable in GI 
tract 
mucoadhesive Predicted to 
show para 
cellular uptake 
due to 
presence of 
permeation 
enhancers like 
fatty acids and 
phospholipids 
and 
transcytosis by 
microemulsion 
Nano 
composites 
Silica-chitosan 
nanocomposites 
containing TAT cell 
penetrating peptide [112] 
Insulin Stable in GI 
medium 
Mucoadhesive 
(in vitro) 
Permeable  
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Table 1-7 Peptides under clinical development 
Peptide under clinical development 
Company Product 
name 
Therapeutic 
peptide 
Technology Benefit Development 
phase 
Biocon (trials in 
partnership with 
Bristol-myers 
Squibb)  
Insulin 
Tregopil 
(formerly 
referred as 
IN-105) 
Oral Insulin 
for Diabetes 
Insulin –amphiphilic 
oligomer conjugate 
(methoxy PEG derivative 
conjugated to LysB (29) 
of human insulin 
Enhanced 
transcellular 
transportation, 
enzyme 
stability [114] 
Rapid 
insulization of 
liver and lower 
propensity to 
cause post 
prandial 
hypoglycemia 
[115]  
Completed 
Phase I 
Tarsa 
Therapeutics, 
Inc. 
TBRIA™ 
(once daily) 
Salmon 
Calcitonin for 
oesteoporosis 
Peptelligence™ 
technology enteric coated 
formulation consisting of 
citric acid (pH lowering 
agent) and acyl carnitine 
(permeation enhancer) 
[116] 
Ca+2 chelator, 
Permeation 
through tight 
junction, 
Positive effect 
on bone 
mineral density 
at lumbar 
spine [117] 
NDA filed for 
review [118] 
Chiasma, Inc.  Mycapssa™ Octreotide for 
orphan 
disease 
acromegaly 
Transient permeability 
enhancer (TPE®) – 
sodium caprylate (C8) 
Temporary 
opening of the 
tight junctions 
NDA filed for 
review [119] 
Generex 
Biotechnology 
Corp. 
Oral-lyn™ 
[120] 
Insulin (pre 
prandial) 
Type I and 
Type II 
Rapid-mist™ device 
Aerosol type device 
(propellant penetration 
enhancer and stabilizer) 
Permeates 
across buccal 
epithelium and 
reaches blood 
circulation 
[121] 
Fast 
absorption 
better than sub 
cutaneous 
formulation  
Phase III 
Diabetology Capsulin Insulin (Type 
I) 
Axcess™ oral delivery 
system 
(Penetration enhancers, 
solubilizer) [122] 
Onset of action 
within 30 min 
and duration of 
action up to 4-
6 h [123] 
Phase II 
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Diasome 
Pharmaceuticals, 
Inc. 
Oral HDV 
Insulin [124] 
Insulin (Pre 
prandial) 
(Type I and II) 
Liposomal insulin made of 
hepatocyte-targeting 
molecule - biotin-
phosphatidylethanolamine 
in phospholipid bilayer 
Stable against 
intestinal 
enzymes, 
selective 
targeted 
delivery of 
insulin to 
hepatocytes 
Phase II 
Oramed 
Pharmaceuticals 
ORMD-0801 Insulin (Type I 
and II) 
Enteric coated capsule 
(SNAC, RDTA, Aprotonin, 
soybean trypsin inhibitor, 
omega 3 fatty acid) 
Stable in GI 
tract and 
permeable 
across the 
enterocytes, 
Effectively 
reduced 
glycemia 
throughout the 
day in type I 
diabetes 
patients [125] 
Phase II 
 
Alternatively, drug carrier system particularly polymeric nanoparticles; pose 
an attractive tool for peptide delivery because of its safety, biocompatibility and 
limited toxicity profile. Despite their advantages, the majority of these materials are 
still under pre-clinical development. Several constraints such as loading efficiency, 
controlled release, stability and accumulation in non-target organs still remain a 
challenge in achieving desired therapeutic benefit [126]. However, preclinical studies 
also suggest these polymeric nanoparticles can be functionalized by several 
mechanisms (Table 1-6). Thus there is scope for improving oral bioavailability with 
carrier materials that is safe for clinical use. The following review focuses on 
polymeric nanoparticles for improving drug delivery. 
1.6  Polymeric nanoparticles 
The polymeric nanomaterial are biodegradable and biocompatible that over 
60% of the nanoparticles in preclinical testing and on going clinical trials are derived 
from polymers. Polymers of natural, semi-synthetic or synthetic origin can be 
fabricated to form nanoparticles that improves poor characteristics of therapeutic 
drugs such as solubility, stability, permeability and release in order to attain its target 
and specific activity at a predetermined rate and time. Polymeric nanoparticles are 
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prepared from amphiphilic polymers, hydrophobic polymers and hydrophilic 
polymers.  
Amphiphilic polymers are self-assembling polymers that have hydrophobic 
and hydrophilic functional groups, and are widely used for the preparation of 
polymeric nanoparticles. Depending on the nature of the solvent, these amphiphilic 
polymers produce regular micelles or reverse micelles. The polymers aggregate in 
solutions due to the hydrophobic effect. They offer a dual advantage, by solubilizing 
hydrophobic drugs as regular micelles and by protecting hydrophilic drugs against 
physiological barrier as reverse micelles. Few examples of amphiphilic polymers are 
quaternary ammonium palmitoyl glycol chitosan (GCPQ) [127] , poly(vinyl-co-
ester) [128] and amphiphilic hyper-branched core shell polymers with foliate 
moieties [129] etc. 
1.6.1 Characteristics of Polymeric nanoparticles 
The advantages of using polymers are that the polymers can be fabricated to 
desired size, hydrophobicity and molecular weight. The size of the polymeric 
nanoparticles increases with increase in molecular weight as seen in chitosan [130] and 
PLGA [131] nanoparticles. Fabricating hydrophobicity of the polymer gives different 
forms such as polymeric micelles and polymeric bilayer vesicles [132]. Polymeric 
micelles are made up of hydrophobic core and hydrophilic shells that can encapsulate 
drugs in the core. Polymeric bilayer vesicles can accommodate hydrophobic drugs 
within the bilayer and hydrophilic drugs in the core (Figure 1-7).  
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Figure 1-7 Schematics of Polymeric nanoparticles showing polymeric bilayer vesicles on the 
left and micelles on the right. 
For example, the amphiphilic variants forming polymeric micelles or 
polymeric bilayer vesicles are based on the hydrophobicity of the polymer. For N-
cetyl-poly(ethylenimine), an amphiphile with greater than 58% hydrophobic content 
yield dense sphere, 45-58% molar hydrophobic content yields vesicles and less that 
45% hydrophobic content yields polymeric micelles [133].  
This is represented as vesicle formation index (F) 
F = H/L√DP 
Where H= mol % of underivatized polymer monomers; L = mol % of 
hydrophobic unit derivatized monomers; and DP = degree of polymerization of 
polymer backbone. An F value greater than 0.11 indicates the formation of vesicles 
in N-cetyl-poly(ethylenimine) [133] .The hydrophobicity not only gives different 
forms but also determines the drug loading efficiency of the polymer. For example, 
GCPQ [134] and N-cetyl N-trimethyl, N-dimethyl, N-monomethyl-
poly(ehtylenimine) [135] polymers with high hydrophobicity exhibits high drug 
loading efficiency.  
The polymer self assembles at its critical micellar concentration (CMC). The 
CMC determines the stability of the amphiphilic aggregates and therefore the drug 
loading efficiency of the polymeric nanoparticles. Below the CMC, the amphiphiles 
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exist as molecular entities and only aggregate above the CMC [136]. Lower the 
CMC of a polymeric nanoparticles higher its stability in physiological medium.  
Depending on the nature of the polymers, polymeric nanoparticles can be 
prepared by dispersion of preformed polymers in aqueous solution [134], 
precipitation of hydrophobic polymers in aqueous solution [137] and stabilization 
with surface active agents or ionic gelation/ coacervation of hydrophilic 
polymers[138], [139]. The method used for preparing nanoparticles formulation 
should be less toxic, and easy to scale up, with good drug loading efficiency and 
yield. Synthetic polymers are prepared by conventional dispersion methods that 
include nano-precipitation [140] [141], solvent evaporation [142] [143], salting out 
[144], emulsification/solvent diffusion and dialysis [145]. All these techniques 
involve usage of solvents, which could be a disadvantage in producing pure 
nanoparticles. A solvent free simple preparation method was reported using 
amphiphillic polymer GCPQ [146] and poly (allyl) amine grafted with palmitoyl and 
quaternary ammonium group [147] where the drug encapsulation was achieved by 
suspension of drug and the respective polymer in aqueous solution.  
 Polymeric nanoparticles have been used to deliver drugs via oral, 
intravenous, nasal, topical and oral routes. Drug-encapsulating polymeric 
nanoparticles have been shown to enhance drug delivery to tumours and across the 
blood brain barrier following oral administration, while also extending plasma half-
life, increasing residence time within ocular tissue, augmenting the oral 
bioavailability of gut-liable peptides and reducing side effects. Selected examples of 
how polymeric nanoparticles have been used to improve the physiochemical 
properties of a drug overcoming biological barriers and site specific targeting are 
listed in Table 1-8. 
Table 1-8 Applications of polymeric nanoparticles 
Application Nanoparticles-Drug Advantage 
Tumour targeting  Abraxane- Nanocrystalline paclitaxel stabilized 
by albumin [148]  
Tumour targeting (binds to secreted 
protein and rich in cysteine) and 
improved solubility. Reduced side 
effect compared to excipient 
(Cremophor EL) based formulation  
PLGA-Vitamin E – Paclitaxel [137] High AUC compared to cremophor 
based formulation 
Chitosan amphiphile-octreotide [149] Tumor targeting via somatostain 
receptor on tumour cells. 
Hyaluronic acid based amphiphile [150] Tumor targeting (CD44 receptor) 
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Poly (ethylene oxide)-block (benzyl-L-
aspartate- Doxorubicin [151] 
Increased blood residence time 
Blood brain barrier Poly (ethylene glycol)-b-poly(lactic acid) 
nanoparticles – Paclitaxel [143] 
Conjugation of F3 peptide (target- 
neurolipin-1 expressed on tumours) 
TP-LENK and LENK –GCPQ nanoparticles 
[53] 
Stable in plasma and increased 
uptake in brain 
Oral delivery LENK nanoparticles [53] Stable against enzymatic 
degradation in the gut 
Eudragit nanoparticles- Insulin [152] Promoted mucoadhesion  
Hydrophobic drug 
solubilization 
Cyclosporin A-GCPQ [153] Increased drug solubilization and 
absorption in the gut 
1.6.2 Chitosan polymers 
Chitosan is a linear polysaccharide consisting of β-(1-4)-linked D-glucosamine 
and N-aetyl-D-glucosamine. The polymer’s reactive functional group such as amino 
group, primary hydroxyl and secondary hydroxyl group can be chemically modified 
to obtain chitosan-based derivatives for drug delivery application [154]. The amino 
group of chitosan is protonated and remains soluble at acidic conditions but insoluble 
at neutral pH as the pKa of D-glucosamine is 6.5 [155]. This cationic property of 
chitosan is exploited for its ability to bind with negatively charged mucus in the gut 
wall [156]. Glycol chitosan is chitosan with 6-O-linked glycol unit, which is soluble 
at neutral pH with a pKa 5.99 [157].  
1.7  Quaternary Ammonium Palmitoyl Glycol Chitosan (GCPQ) 
1.7.1 GCPQ molecular architecture 
GCPQ is a self-assembling amphiphilic polymer previously reported to 
solubilize hydrophobic drugs [146], [153]. GCPQ is a pendant shaped amphiphilic 
derivative of glycol chitosan with palmitoyl chain and quaternary ammonium group 
(Figure 1-8). Some amino groups of glycol chitosan backbone are modified by 
palmitoyl chain and the degree of substitution of palmitoyl chain called as the degree 
of palmitoylation (DP) determines the hydrophobicity of the polymer. Similarly, in 
addition to palmitoyl chain, the amino groups of glycol chitosan were also 
substituted with quaternary ammonium group. Here, the degree of substitution of 
quaternary ammonium group to the glycol chitosan backbone called the degree of 
quaternization (DQ) determines the solubility of GCPQ in an aqueous solution. 
Quaternary ammonium group remains charged above neutral pH and increases the 
solubility of GCPQ in aqueous solution up to a pH of 9 [157]. 
  45
 
Figure 1-8 2-D structure of GCPQ with glycol chitosan chain in black color, palmitoyl group 
shown in blue color and quaternization ammonium group in magenta color 
1.7.2 GCPQ micelle formation 
The polymer in an aqueous environment favors the association of 
hydrophobic pendant group and liberation of water molecules to form micelles of 
size around 20-40 nm [134]. During the process of micellization, hydrophobic drugs 
can be solubilized or directly added to GCPQ solution, where the GCPQ 
accommodate lipophilic drugs in its hydrophobic core. The amount of hydrophobic 
drug incorporation depends on the hydrophobicity of GCPQ polymer. Drug loading 
levels up to 40% are achievable with GCPQ [134]. The CMC of GCPQ is very low 
(19µM) compared to block copolymer amphiphiles [134], meaning that upon dilution 
in physiological condition, the drug solubilizing property may not be lost. 
1.7.3 GCPQ - Physical characteristics 
GCPQ of molecular weight 19.9 KDa with palmitoylation 23 % and 
quaternization 10 % were characterized for its physical properties. The polymer is 
glass at room temperature with Tg of 164.4 ± 8.5 °C and decomposes at 218 ± 4 °C. 
GCPQ is a weak base with a pKa 5.99 ± 0.15. It was also observed that GCPQ forms 
micellar network and exhibit viscoelastic properties at a concentration of 90 mg/mL 
in water. GCPQ also show Newtonian rheological behavior below a concentration of 
70 mg/mL. However, at higher concentrations, GCPQ undergoes sheer thinning 
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because of chain disentanglement due to high shear rates. The storage stability of 
GCPQ was also observed to be lasting for 18 months at room temperature [158]. 
1.7.4 GCPQ - in vitro  
GCPQ is considered as safe for preclinical evaluation. GCPQ below a 
concentration of 0.1 mg/mL show no cytotoxic effect in A431 and A549 cancer cell 
lines. The GCPQ also shows no haemolysis at a concentration of 1 mg/mL and less 
than 20% haemolysis at a concentration of 10 mg/mL [127]. Preliminary experiments 
in vitro cell culture model shows that the polymer is transported via transcellular 
pathway but the exact mechanism is not known. GCPQ neither inhibits the efflux 
activity of the P-glycoprotein efflux pump nor paracellularly transported [146].  
1.7.5 GCPQ – in vivo 
GCPQ nanoparticle has been reported to enhance the delivery of hydrophobic 
drugs via oral, intravenous, intranasal and ocular route [146], [53], [159], [134], 
[153], [135]. Orally delivered GCPQ nanoparticle has been shown to improve 
dissolution of hydrophobic drug in gastrointestinal tract and promotes drug 
absorption via interaction with the intestinal mucosa [146]. Ex vivo imaging of small 
intestine shows that GCPQ traverses the mucosal barrier by adhering to the mucosal 
surface of the villi. GCPQ nanoparticles are observed at the boundary of sub mucosa, 
in the muscularis propia below the base of the villi and within the hepatocytes [160]. 
It is also hypothesized, based on the uptake of radiolabelled GCPQ-LENK 
nanoparticles, that the high molecular weight GCPQ nanoparticles shows better 
plasma stability. Approximately 1-2% of orally administered nanoparticles are found 
in the blood within 15 min, with 2-3% in the liver and gall bladder [53]. 
Radiolabelling experiments have reported that GCPQ accumulates in gall bladder 
two h after oral administration. It has also been hypothesized from this observation 
that the GCPQ nanoparticles could be absorbed in the GI tract via enterocytes in the 
villi, pass into the blood stream and are transported to the hepatocytes and 
hepatocellular spaces of the liver, and then recirculated via bile in the gall bladder to 
small intestine [160]. GCPQ improved oral bioavailability of amphotericin B (24%), 
a nephrotoxic drug. The polymer protected the peptide from gastrointestinal 
degradation, enhanced drug bioavailability of the drug to target organs such as lung, 
liver and spleen and reduced exposure to kidney [161]. 
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GCPQ coating on pro-drug peptide (palmitoyl leucine enkephalin) was 
reported to improve the enzymatic stability of peptide in plasma, increasing the 
plasma half-life by 520% [162]. The polymer does not accumulate in liver following 
intravenous administration. GCPQ coating also promotes its absorption to the 
luminal vasculature surfaces of the brain [160]. This action enhances the uptake of 
prodrug peptide across the blood brain barrier thereby increasing therapeutic effect 
[162]. GCPQ was also shown to promote nasal delivery of hydrophilic peptide 
(leucine enkephalin). The peptide-GCPQ nanoparticles, following nasal 
administration, crossed blood brain barrier and improved anti nociceptive activity in 
rats CFA pain model [163].    
GCPQ was also used to enhance the ocular delivery of cyclosporine A. GCPQ 
polymer improved the mucoadhesion of the peptide that resulted in increase in its 
ocular residence time. GCPQ was also observed to promote ocular absorption and 
thereby increasing the bioavailability of cyclosporine A formulation [164].  
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Aim and Objective 
Aim 
The potential of therapeutic peptides has been exploited in various disease 
conditions. With the increasing demand, possibilities for non-invasive route of 
peptide administration are of great importance, particularly in chronic conditions, 
where drugs require frequent administration and patient non-compliance frequently 
experienced with invasive methods becomes a challenge. Several excipients and 
carrier materials have been reported to enhance the oral bioavailability of peptides by 
different mechanisms. This study focuses on two therapeutic peptides, Methionine 
enkephalin, an anti-cancer peptide for the treatment of pancreatic cancer and 
Labyrinthopeptin, an anti-nociceptive peptide for chronic pain treatment. Both the 
peptides have previously demonstrated significant therapeutic effect after 
intravenous administration [165], [166], [167]. However, their non-invasive and in 
particular oral administrations are hampered due to poor bioavailability and in the 
case of MENK also poor stability. The aim of the current project is to test the 
hypothesis that it might be possible to enhance the oral bioavailability of therapeutic 
peptides using GCPQ nanoparticles.  
Objective 
• Synthesis of GCPQ by two methods and characterize their molecular weight 
and degree of substitution on the polymer backbone.  
• Characterize GCPQ micelles for their size and polydispersity and study their 
colloidal stability under simulated conditions.  
• Formulate peptides (Laby and MENK) with GCPQ; characterize the peptide 
GCPQ nanoparticles for their size, PDI, surface charge, encapsulation 
efficiency and colloidal stability in simulated medium.  
• Validate method for quantification of the peptides in vivo by LCMS. 
• Evaluate in vivo pharmacokinetic of the peptides following oral and nasal 
administration of Laby-GCPQ formulations and oral and intravenous 
administration of MENK GCPQ formulations.   
• Study the anti-nociceptive activity of Laby-GCPQ formulation following oral 
and nasal administration and compare its efficacy with control (Laby 
glycofural formulation). 
• Study the effect of MENK GCPQ IV and oral formulation on mice tumour 
xenograft models.   
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2 GCPQ polymer synthesis 
2.1  Objective 
Objective of this chapter is to, 
1.  Synthesize of GCPQ by old and new methods.  
2. Evaluate the synthesis methods by comparing the molecular 
characteristics of GCPQs such as their molecular weights, 
polydispersity indices and surface modifications.  
3. Evaluate the colloidal stability of GCPQ B2 in water, sodium chloride 
solutions of different concentrations, simulated gastric and intestinal 
fluids in fasted and fed states.  
2.2  Introduction -Polymer Characterization methods 
2.2.1 Structure prediction of polymer by H1 NMR 
Nuclear magnetic resonance spectroscopy is a tool for predicting molecular 
structure based on the magnetic properties of certain nuclei. NMR works by 
measuring the emitting radio frequency from a sample, which is inside a constant 
magnetic field [168]. The underlying principle of NMR is that some nuclei exist in 
specific spin states in an applied external magnetic field. NMR measures the 
transition between the spin states that are specific to particular nuclei and nuclei’s 
chemical environment[169].  
Theory 
Certain nuclei experience charged spin, creating a magnetic moment that 
allows chemist to predict structure, using NMR [169]. The nuclei spin could be no 
spin for those nuclei that have an even number of both protons and neutrons, an 
integer spin for those nuclei that have an odd number of both protons and neutrons, 
or a half integer spin when the number of proton and neutron of nuclei sums up to an 
odd number. These nuclei have a random orientation in the absence of a magnetic 
field [169]. However, when an external magnetic field is applied, the nuclei can 
either experience alpha spin state or beta spin state. In alpha-spin state, the nuclei 
having low energy orient parallel with the applied magnetic field, whereas; nuclei 
with beta-spin state having higher energy orient anti parallel to the applied magnetic 
field [170]. The energy difference (△E) between the alpha and beta spin state 
depends on the external magnetic field strength [170]. 
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Chemical shift 
In H1 NMR, every nucleus can experience different chemical environment 
and resonate at slightly different frequencies [171]. These differences in the chemical 
environment occur when a nucleus is shielded or de-shielded from the neighboring 
nuclei [170]. This is called chemical shift. Protons that are symmetrical (benzene) 
and have the same chemical environment are called chemically equivalent protons. 
Thus, the signal obtained have same chemical shift on a frequency scale. However, 
asymmetrical protons have different chemical environment and have different 
chemical shift on a frequency scale. Electrons can shield a proton from the applied 
magnetic field causing the signal to shift right (up field) on frequency scale. On the 
other hand, electronegative atoms remove the shielding effect of electrons on a 
proton causing the signal to shift left (down field) on a frequency scale. These 
frequency shifts ware very small in comparison to primary NMR frequency 
differences (Hz as compared to MHz). Hence chemical shifts are denoted by the unit 
ppm on NMR spectra [171]. The chemical shift (𝛿) is represented by formula,  
Equation 1 
𝛿 = 𝐻!"# − 𝐻!"#𝐻!"#!!"# ×10! 
Where trimethylsilane is used as a reference standard (Href), Hsub is the 
resonance frequency of a substance and Hmachine is the operating frequency of NMR 
spectrometer. The area under the signal is integrated to obtain the relative number of 
protons causing the respective signal [169, 172] .  
Instrumentation 
There are two NMR spectrometers, Continuous-wave (CW) and pulsed or 
Fourier-transform (FT) NMR. FT-NMR has largely replaced CW-NMR [173]. In 
CW-NMR (Figure 2-1), a sample is placed between strong magnets and from an 
antenna coil, radiofrequency radiation of appropriate energy is directed towards the 
sample. The receiver coil collects the emitted RT energy that is monitored in the 
computer. The spectrum is scanned by two methods, field-sweep method or 
frequency-sweep method. In frequency-sweep method, magnetic field is kept 
constant and RF signal is swept to determine the frequency at which energy is 
absorbed. In field-sweep method, resonance frequency is kept constant and magnetic 
field strength is determined by sweeping magnetic field at varying energy levels 
[173] . 
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Figure 2-1 Schematic of CW-NMR Spectrometer.  
In Fourier-Transform NMR spectrometer (FT-NMR), a pulse of 
radiofrequency radiation is applied that causes nuclei in a magnetic field to excite 
into the higher-energy state [173]. RF pulse lasts between 1 and 10 µs, which is 
sufficient to excite nuclei in all local environments. Between the pulses, the nuclei in 
the excited state re-emit signal at a time interval (T) (this lasts from one to several 
sec) called as free induction decay signal (FID). FID signals are detected by radio-
receiver coil is placed perpendicular to the magnetic field. The FID signals are then 
processed, averaged to get signal to noise ratio. These results are converted in to a 
frequency-domain signal by a Fourier transformation. The output is similar to the 
spectrum produced by a scanning continuous-wave experiment [173] [174].  
The advantage of FT-NMR over the CW-NMR is that FT-NMR saves time as all the 
resonance signals can be collected simultaneously. However, with CW-NMR 
resonance signals are collected sequentially [174]. 
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2.2.2 Molecular weight determination by GPC-MALLS 
 
Figure 2-2 Schematic of GPC-MALLS 
Gel permeation chromatography (GPC) is a type of size exclusion 
chromatography for the separation of molecule based on size [175, 176]. The column 
is packed with porous beads, which constitute the stationary phase, and sample is 
injected along with a suitable solvent, which constitute the mobile phase. When 
polymers of different sizes are injected in to the column, small sized polymers pass 
slowly through the pores of the beads and larger sized polymers escape the pores of 
the beads and pass quickly down the column. Here, the separation of polymers 
within the GPC column takes place with larger molecules preceding the smaller 
molecules and analyzed using multi angle laser light scattering (MALLS) and 
differential refractive index (dRI) detector [175, 176].  
The scattered light intensity is measured as Rayleigh ratio (𝑅!), the excess 
scattering of the sample and solvent over that of the sample alone. Rayleigh ratio is 
directly proportional to the molecular weight of the solute molecule scattering the 
light [177].  
Equation 2 𝐾∗𝐶𝑅! = 1𝑀! 𝑃! + 2𝐴!𝐶 + 3𝐴!𝐶 +⋯. 𝑃! = 16𝜋!3𝜆! 𝑆𝑖𝑛! 𝜃2 < 𝑟 > 𝑍 ! 
Where, Po is scattering function; C is solute concentration; Rθ is the Rayleigh 
ratio; Mw, the weight-averaged molecular weight; λ, the wavelength of incident 
light; θ, π, the scattering angle; <r>z, the z-averaged mean radius of gyration and A2, 
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the second virial coefficient, which quantifies the interaction between the 
macromolecule and the solvent [178].  𝐾∗ is given by the equation, 
Equation 3 
𝐾∗ = 4𝜋2𝜂2𝑁𝑂𝜆4 𝑑𝜂𝑑𝐶 2 
Where, N0 is the Avogadro’s number; η, the refractive index and dη/dc, the 
change in refractive index per unit change in solute concentration. This equation 
simplified. For polymer and solvent combination the refractive index increment is 
considered a constant. Under dilute conditions, the virial expansion that relates to 
intermolecular interactions can be considered zero. The scattering function Po is one 
if the molecule is below 10 nm [178].  
Under these conditions the equation simplifies to, 
Equation 4 Rayleigh's ratio 
Rθ= MwK*C 
Where,     
K* = (dn/dc)2 K 
Therefore, 
Equation 5 
Rθ= Mw K* 
!"!" !C 
So it is clear from the equation that the response from the detector is directly 
proportional to the molecular weight, a constant K, and the concentration of the 
solute [178]. 
The differential refractive index detector calculates the absolute molecular 
weight of an analyte from the concentration used, refractive index (n) and the 
differential refractive index of an analyte [179] 
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In MALLS, monochromatic light is passed through sample and the intensity 
of scattered light is captured by detectors placed at multiple angles around the 
sample. Multi angle light scattering data are analysed using Zimm plot. A plot of K* 
C/Rθ versus sin (θ/2)+C is created and double extrapolated to zero angle and zero 
concentration. From this plot, the intercept is used to calculate the molecular weight 
and from the slope the radius of gyration is obtained. [180] 
2.3  Nanoparticle characterization methods 
2.3.1 Transmission Electron Microscope (TEM) 
Transmission electron microscopy is one of the techniques used for size and 
morphology characterization of nanoparticles. Unlike the light microscope, the TEM 
focuses an electron beam through the sample, which is placed on a TEM grid. This 
interaction causes amplitude and phase variation in the transmitted beam which is a 
function of sample thickness and sample material. The sample is coated as a thin film 
on the TEM grid, where it is dried and negatively stained with uranyl acetate. Uranyl 
acetate has a pH around 4.2 to 4.5 and only interacts with the background leaving the 
sample untouched. Successful imaging of the sample is obtained when a contrast is 
developed against the carbon background that makes up the grid [181, 182]. Samples 
with higher electron densities such as metals, polymeric nanoparticles [183], carbon 
nanotubes, quantum dots [184] and magnetic nanoparticles have smaller mean 
electron free path than lighter atoms. This develops, higher contrast than amorphous 
carbon. The electrons that pass through sample and the image are magnified and 
focused by an objective lens, which appears on an image screen (Figure 2-3). Size 
ranging from 0.1 nm to 2 µm can be measured using TEM. The major advantage is 
that TEM provides information on the sample’s size and shape. Limitations are that 
TEM imaging and analysis can be time consuming. TEM also only provides 
qualitative results [181]. 
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Figure 2-3 Schematic of TEM 
2.3.2 Dynamic Light Scattering (DLS) 
Dynamic light scattering technique is used to determine the size distribution 
of particles in suspension [185]. Particles in suspension exhibit Brownian motion by 
thermally induced collisions between the suspended particles and the solvent 
molecules. When the particles are illuminated with a laser (633 nm), the intensity of 
scattered light fluctuates as the particles move over a timescale that depends on the 
size of the particles (Figure 2-4). From the time dependent fluctuation, the 
translational diffusion coefficient and hydrodynamic diameter is determined using 
Stokes-Einstein equation with the assumption that particles are spherical and 
non interacting [185]. 
Equation 6- Stokes-Einstein equation 𝐷 = 𝑘𝑇3𝜋𝜂𝐷! 
Where D is translational diffusion coefficient, K is Boltzmann’s constant, T 
is absolute temperature, DH is hydrodynamic diameter and 𝜂 is viscosity.  
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Figure 2-4 Illustration of time dependent fluctuation for small and large particles in DLS [185, 
186]  
The time dependent fluctuation is converted in to a correlogram to which 
cumulant analysis is applied to calculate intensity-based distribution using Rayleigh 
scattering principle [185]. The cumulant mean of intensity-based distribution gives 
Z-average size mean.  Z-average size can only be compared to size measurements by 
other methods if the intensity-based distribution is monomodal (single peak). For 
polydisperse sample, different size populations can be analysed from volume and 
number based distribution. These distributions are calculated from intensity-based 
distribution by applying Mei theory. An Illustration showing how different 
distributions (intensity, number and volume) compare to one another is shown in 
Figure 2-5. Particle sizes of two populations, 5 and 50 nm are represented in number 
distribution as ratio 1:1. However the same populations are represented as ratio 
1:1000 (considering volume of sphere) in volume based distribution. Further, the 
populations are represented as ratio 1:1,000,000 (intensity of scattering light is 
proportional to d6) in intensity-based distribution [185].  
  57
 
Figure 2-5 Illustration comparing particles in different weighed distribution in DLS. Number 
based distribution (red), volume based distribution (green) and intensity based 
distribution (yellow) [185]. 
Hydrodynamic diameter is a measure of particle diameter in diffusion. The 
translational diffusion coefficient also depends on the concentration, surface 
structure and types of ions in the medium. As a result, the size obtained in DLS is 
larger than observed in TEM [185, 186].  
Particle sizes ranging from 0.1 nm to 6 µm can be measured using DLS. 
Sample measurement is fast and accurate for monomodal distribution. Limitations 
are that DLS measurements can be inaccurate for polydisperse samples. A small 
fraction of large particles within the population can obscure small particles.  
2.3.3 Surface charge characterization by DLS 
Surface charge of the particles can be measured by analyzing their zeta 
potential [187]. Particle carry net surface charge that attracts counters ions in the 
solution at the surface to form electrical double layer. The electric double layers 
surrounding the particles have two layers; stern layer that consist of those ions 
strongly bound to the particles and an outer diffusive layer. Ions within the diffusive 
layer move with the particles and those outside the diffusive layer stay with the bulk 
dispersant. Zeta potential is the measure of charge at the slipping plane (Figure 2-6). 
Physiochemical parameters like pH, conductivity and particle concentration affects 
the zeta potential of a sample. For the measurement, the sample is taken in a 
capillary cell with electrodes on either end. When a potential is applied, particles 
move towards the electrode and their velocity is measured from which 
electrophoretic mobility and zeta potential is calculated [187].  
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Figure 2-6 Schematic representation showing electrical double layer surrounding the particle 
Colloidal stability of the particles is determined by their surface charge. The 
stability of colloidal particles is explained by DVLO theory.  The stability of the 
colloidal particles is determined by the sum of van der Wall’s attractive force and 
electrical double repulsive force that exists between particles undergoing Brownian 
motion. For particles to be colloidally stable, the repulsive force must be dominant. 
However, when the particles approach each other and if the attractive force 
overcomes the repulsive force between particles, flocculation takes place. Colloidal 
stability can be achieved by electrostatic or charge stabilization which is the effect on 
particle interaction due to distribution of charged species in the system [188]. 
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2.4  Materials 
Table 2-1 List of Materials Used 
Chemical Supplier 
1-Methyl-2-pyrrolidone (99%) Sigma-Aldrich (Gillingham, UK) 
Amberlite IRA-96, free Sigma-Aldrich (Gillingham, UK) 
Calcium chloride Sigma-Aldrich (Gillingham, UK) 
Diethyl ether (99.5 %) Sigma-Aldrich (Gillingham, UK) 
Ethanol (absolute) (99.7 – 100 %) UCL School of Pharmacy 
Glycerol mono-oleate Sigma-Aldrich (Gillingham, UK) 
Glycol chitosan (60 %) Sigma-Aldrich (Gillingham, UK) 
Hydrochloric acid (36.5 – 38%) VWR BDH Prolabo (Fontenay-sous-
Bois, France) 
Iodomethane, reagent plus (99%) Sigma-Aldrich (Gillingham, UK) 
Lecithin Sigma-Aldrich (Gillingham, UK) 
Maleic acid (99%) Sigma-Aldrich (Gillingham, UK) 
Methanol-D4 (99.80%) Cambridge isotope laboratories, Goss 
Scientific Instruments Ltd. (Worleston, 
Nantwich, UK) 
Palmitic acid N-hydroxysuccinamide ester (98%) Sigma-Aldrich (Gillingham, UK) 
Pancreatin from porcine pancreas (4X USP) Sigma-Aldrich (Gillingham, UK) 
Pepsin Sigma-Aldrich (Gillingham, UK) 
Sodium bicarbonate (99.5 %) Sigma-Aldrich (Gillingham, UK) 
Sodium chloride (99%) Sigma-Aldrich (Gillingham, UK) 
Sodium hydroxide (99.13%) Sigma-Aldrich (Gillingham, UK) 
Sodium iodide (99.5%) Sigma-Aldrich (Gillingham, UK) 
Sodium phosphate monobasic monohydrate 
(99%) 
Sigma-Aldrich (Gillingham, UK) 
Sodium oleate (99%) Sigma-Aldrich (Gillingham, UK) 
Sodium taurocholate hydrate (> 97%) Sigma-Aldrich (Gillingham, UK) 
Visking dialysis membrane with a cut-off of 3.5, 7 
and 12-14 K Da 
Medicell International Ltd (London, UK) 
Water deionized Millipore Elix-progaard 2 
Water double deionized (18 ohm) Millipore synergy – simpak1 
Low volume disposable glass cuvette Malvern, UK 
Folded capillary Zeta cell Malvern, UK 
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2.5  Methods 
2.5.1 Synthesis of GCPQ (Batch 1 (B1) &Batch 2 (B2)) – old method 
GCPQ synthesis steps involved acid degradation of glycol chitosan, 
palmitoylation of degraded chitosan and quaternization of palmitoylated glycol 
chitosan. The GCPQ synthesis was carried out as per protocol described in [189], 
[190] and [127]. The protocol is summarized as follows, 
2.5.1.1 Acid hydrolysis of Glycol Chitosan (GC) 
Glycol chitosan (5 g) was dissolved in HCl (4 N, 380 mL) and incubated in a 
pre-heated water bath maintained at 50˚C for 24 h. The degraded product was 
dialyzed (MWCO 3500 Da) against water with six changes over 24 h. The dialysate 
was freeze-dried for further synthesis. 
2.5.1.2 Palmitoylation of Glycol chitosan 
Degraded glycol chitosan (500 mg) and sodium bicarbonate (376 mg) was 
dissolved in a mixture containing absolute ethanol (24 mL) and water (76 mL). 
Palmitic acid N-hydroxysuccinamide ester (PNS) (792 mg) was dissolved in absolute 
ethanol (150 mL) and added drop wise to GC mixture. The reaction was incubated 
for 72 h in dark condition. The palmitoylated product was rotary evaporated at 45˚C 
to remove residual ethanol and the remaining extract was mixed with three fold 
volumes of di-ethyl ether to remove free palmitic acid. This process was repeated 
three times and the aqueous layer collected was dialyzed (12-14 kDa) against water 
with six changes over 24 h. The dialysate was freeze-dried for further synthesis. 
2.5.1.3 Quaternization of Palmitoyl glycol chitosan 
Palmitoyl glycol chitosan (300 mg) was dispersed in 1-methyl-2-pyrrolidone 
(25 mL) and left overnight for 12 h at room temperature. To the above mixture, 
sodium hydroxide (40 mg), methyl iodide (0.44 mL) and sodium iodide (45 mg) was 
added and the reaction was set under the stream of nitrogen maintained at 36˚C for 
3h. The quaternary ammonium product was precipitated and washed with diethyl 
ether. A brown hygroscopic product obtained was dissolved in a minimum volume of 
water and dialyzed against water with 6 changes over 24 h.   
Amberlite resin (IRA-96) was packed in a separating funnel and pre-activated 
with HCl (150 mL, 1 M) followed by washing with distilled water (10 L) to give 
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neutral pH. The dialysate was passed through the resin and eluate was freeze-dried 
and stored in a desiccator until use.  
2.5.1.4 Synthesis of GCPQ Batch 3 (B3) by new method 
GCPQ polymer was also prepared by alternative method. This method 
allowed synthesis of GCPQ with higher palmitoylation. A summary of differences in 
two methods of polymer synthesis is shown in Table 2-2. 
Table 2-2 GCPQ synthesis - Differences and Similarities 
Synthesis steps Old Method New Method 
Degradation of 
GC 
Acid hydrolysis  Acid hydrolysis  
Palmitoylation 
of dGC 
Mass ratios (DGC: PNS) 
Solvent used are ethanol and 
water, which is polar protic. 
PNS soluble in ethanol but 
precipitates during pH 
adjustment. pH adjusted to > 
8 to deprotonate the primary 
amines of GC. pH 8 is also 
necessary to activate the 
PNS. Purification done by 
extraction with ether. 
Dialysed and freeze-dried 
Molar ratios (DGC: PNS) 
DMSO used as solvent. It is a 
polar aprotic and does not 
participate in the reaction. 
Less PNS required now as 
PNS is soluble in DMSO and 
stays soluble throughout the 
reaction. Triethylamine is 
used as the base as sodium 
bicarbonate bonds with 
DMSO. Purification done by 
acetone and ether wash. No 
dialysis, no freeze-drying. 
 
Quaternization 
of PGC 
Methylation 
After quaternization, the 
GCPQ is purified with 
amberlite free-base  
Methylation 
GCPQ is passed through 
amberlite with activated 
chloride 
 
Pros and cons Cannot control palmitoylation 
step 
Can control palmitoylation 
step 
Molecular weight is 
reproducible 
Polymer is polydisperse due 
to aggregation 
In the old method, mass ratio of GC and palmitic acid was used to synthesis 
GCPQ with different degree of palmitoylation. Since it was difficult to control the 
degree of palmitoylation by previous method, the molar ratio of GC monomer and 
palmitic acid was used to synthesis PGC by new method. 
2.5.1.4.a Acid hydrolysis of Glycol Chitosan 
Acid hydrolysis of GC was carried out as method mentioned in section 
2.5.1.1. 
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2.5.1.4.b Palmitoylation of Glycol Chitosan 
Palmitic acid N-hydroxysuccinimide was added to GC, which was dissolved 
in DMSO and triethylamine. The reaction mixture was incubated for 15 h at room 
temperature under dark condition. The polymer was precipitated with a mixture of 
acetone and diethyl ether (1:2) and washed thrice with acetone (1 L). Finally, ether (1 
L) was added to the precipitate and washed thrice. The precipitated product was 
filtered from diethyl ether under high vacuum and stored in a desiccator for drying. 
2.5.1.4.c Quaternization of Palmitoylated Glycol Chitosan 
Palmitoyl glycol chitosan was dispersed in N-methyl-2-pyrrolidone and 
stirred vigorously for 16 h until a foamy dispersion was obtained. Sodium hydroxide 
was added to the above mixture and stirred further for 40 min.  
The reaction vessel was then saturated with nitrogen gas and placed in a pre-heated 
oil bath maintained at 36˚C. Methyl iodide was added to the PGC suspension and the 
reaction was allowed to take place for 3 h. After 3 h, the product was allowed to 
precipitate in diethyl ether. This process was repeated twice and the precipitated 
product was suspended in HCl (0.1 M). The above solution was exhaustively 
dialyzed (MWCO 1 kDa) against NaCl (1% w/w) thrice and then with water (3X).  
The dialysate was freezing dried and stored in a desiccator until use. 
2.5.2 Characterization of GCPQ polymer 
2.5.2.1 Molecular weight analysis by GPC MALLS 
Molecular weight of GCPQ was determined using gel permeation 
chromatography multi angle laser light scattering (GPC-MALLS). A solution of 
GCPQ (5 mg/mL) was prepared by dissolving the polymer in a solvent containing 
35:65 ratios of acetate buffer and methanol. GCPQ solution (20 µL) was injected in 
to GPC column running on the same mobile phase at a flow rate of 0.7 mL/min for  
20 min. The molecular weight was detected using MALLS and dRI detector. Specific 
refractive index increments over concentration (dη/dC) were measured by manually 
injecting a series of standard solutions of the GCPQ at different concentrations (0.1 
to 0.6 mg/mL) prepared in mobile phase. The standards are analysed through the dRI 
detector set at 25°C and a wavelength of 658 nm and a pump flow rate of 0.3 
mL/min. 
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The data obtained from both dη/dC and GPC-MALLS experiment were 
analysed using ASTRA software (Wyatt Technologies).  
2.5.2.2 H1- Proton NMR 
The degree of hydrophobicity and hydrophilicity of GCPQ was determined 
using 1H proton NMR. GCPQ (5 mg) was dissolved in deuterated methanol (700 µL) 
and analysed in Bruker AMX 400 MHz spectrometer (Bruker instruments, UK).  
The NMR spectrum was integrated using topspin program. The palmitoylation and 
quaternization percentage were calculated using the following formula, 
 
 
 
2.5.3 Characterization of GCPQ nanoparticles 
2.5.3.1 GCPQ nanoparticle preparation and characterization by size and charge 
GCPQ B2 polymer suspensions at a concentration of 2.5 mg/mL in water and 
in different salt concentrations (10 mM, 20 mM, 40 mM, 80 mM, 160 mM and 
300 mM) were vortexed and probe sonicated (QSonica, U.S.A) for 15 min at  
25 amps and characterized for their size and polydispersity index by dynamic light 
scattering technique (DLS), and size alone by transmission electron microscope 
(TEM). The surface charge of the GCPQ nanoparticle was also measured at different 
values of pH and characterized by DLS.  
GCPQ B2 polymer was also prepared at concentration 2.5 mg/mL in water 
and probe sonicated at 15 amps for 15 min. The resulting formulation was size 
characterized by DLS and TEM. 
2.5.3.2 Transmission Electron Microscopy (TEM) 
A drop of GCPQ B2 nanoparticle suspension was placed on a grid and 
blotted with a tissue paper. Uranyl acetate (1% w/v) was added to the grid and TEM 
images were taken using FEI CM129 BioTwin transmission electron microscope 
(Phillips, Eindoven, Netherlands) and AMI digital camera. 
€ 
%Palmitoylation = Area of the CH3 signal no of hydrogens CH3Area of sugar chains no of hydrogens of the sugar chain ×100
€ 
%Quaternisation = Area of the N(CH3)3 signal no of hydrogens N(CH3)3Area of sugar chains no of hydrogens of the sugar chain ×100
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2.5.3.3 Size characterization using Dynamic Light Scattering (DLS) 
For DLS (Malvern Zetasizer Nano ZS ZEN3600, Malvern Instruments Ltd, 
Worcestershire, UK) size measurement, 1 mL of GCPQ B2 nanoparticles in 
respective medium was dispensed into a low volume disposable cuvette and three 
measurements were taken per sample. The Z-average, polydispersity Index (PDI) and 
other weighted distributions were recorded.  
2.5.3.4 Surface charge using DLS 
Zeta potential of GCPQ B2 formulations were determined using DLS 
(Malvern Zetasizer Nano ZS ZEN3600, Malvern Instruments Ltd, Worcestershire, 
UK). Formulations (1 mL) were dispensed into a zeta cell and zeta distribution 
graphs were recorded. 
2.5.3.5 Colloidal stability of GCPQ B2 nanoparticle in physiological medium 
 Medium mimicking physiological conditions, namely simulated intestinal 
fluid (SIF), SIF with pancreatin, fasted state simulated gastric fluid (FaSSGF), fasted 
state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF), 
were prepared as per biorelevant media guidelines [191] (Table 2-3). The stability of 
GCPQ nanoparticle (2.5 mg/mL) in the above mentioned mediums were determined 
after incubation for 0, 0.5, 1, 3 and 6 h by DLS. The intensity and volume-based 
distributions were used to predict colloidal stability of GCPQ nanoparticle in 
physiological medium.  
 
Table 2-3 Composition of GI medium 
 
Composition)for)500)ml FaSSGF FaSSIF4V2 FeSSIF4V2 SIF SIF)with)pancreatin
Sodium)taurocholate 22"mg 807"mg 2.688"g
Lecithin 3"mg 30"mg 300"mg
Sodium)monobasic)Po4 3.4"g 3.4"g
Acetic)acid
maleic)acid 1.11"g 3.193"g
HCl
Glycerol)Monooleate 891"mg
Sodium)Oleate 122"mg
NaOH 696"mg 1.633"g 0.3"g 0.3"g
NaCL 999"mg 2.005"g 3.667"g
Pancreatin 100U/ml 5"g
Pepsin 0.1"mg/ml
CaCL2 277g
pH 1.6 6.5 5.8 6.8
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2.6  Results  
2.6.1 GCPQ Polymer Synthesis and Characterization –  
GCPQ polymer (batch 1, 2 and 3) were synthesized and characterized by 
proton NMR. The peaks were assigned to the respective proton in the GCPQ 
molecule (Figure 2-7). The area under the curve for the respective palmitoyl and 
quaternary ammonium group were normalized with the sugar group to calculate 
palmitoylation and quaternization percentage. The degree of palmitoylation and 
quaternization calculated for batch 1, 2 and 3 were summarized in Table 2-4.  
 
Table 2-4 Synthesis and Characterization GCPQ polymers 
GCPQ batches Quantity of GC 
starting material 
used (g) 
Quantity of 
GCPQ finished 
product 
Obtained (g) 
Palmitoylation 
(%) 
Quaternization 
(%) 
GCPQ batch 1 (B1) 
(Figure 2-8) 
5 3.7 16 14 
GCPQ batch 2 (B2) 
(Figure 2-9) 
10 6.54 19 12 
GCPQ batch 3 (B3) 
(Figure 2-10) 
5 3.65 22 8 
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Figure 2-7 H1 Proton NMR of GCPQ with peaks assigned 
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Figure 2-8 H1 proton NMR of GCPQ batch 1. NMR peak spectrum are integrated for 
sugar backbone (100), palmitoyl group (5.34) and quaternary ammonium group 
(14.48) 
  68
 
Figure 2-9 H1 proton NMR of GCPQ batch 2. NMR peak spectrum are integrated for sugar 
backbone (100), palmitoyl group (6.36) and quaternary ammonium group 
(12.02). 
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Figure 2-10 H1 proton NMR of GCPQ batch 3. NMR peak spectrum are integrated for sugar 
backbone (100), palmitoyl group (8.13) and quaternary ammonium group (7.26).
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2.6.2 Molecular weight determination by GPC-MALLS 
The molecular weight of GCPQ batch 1, batch 2 and batch 3 determined by 
GPC-MALLS were 8 kDa, 13 kDa and 33 KDa with polydispersity index 1.221, 
1.061 and 2.560 respectively (Table 2-5). The molecular weights of GCPQ batches 1, 
2 and 3 are determined from the GPC chromatogram showing time on x-axis and 
relative intensity on y-axis. Earlier the peak appears on a chromatogram, larger its 
molecular weight and vice versa. There are three peaks on a GPC chromatogram 
analysed from three detectors i.e. light scattering, quasi-elastic light scattering and 
refractive index detectors. For GCPQ B1 and B2, peaks were eluted at the same time 
(Figure 2-11, Figure 2-13) and hence the polydispersity indices were 1.22 and 1.061 
for the respective polymers. However, for GCPQ polymer B3, the peak obtained 
from light scattering detector eluted earlier than the peak from refractive index 
detector (Figure 2-15). These variations in the elution times of signals obtained from 
light scattering and refractive index detector can be related to the sensitivity of the 
detector, with the former measuring signals from multiple angles compared to the 
later. As a result of different elution times, the molecular weight distribution of 
GCPQ B3 is large and hence its polydispersity (2.56) was also larger compared to 
GCPQ B1 and B2. Quasi-elastic light scattering detector produced poor signal for 
GCPQ B3 due to detector malfunction.  
Table 2-5 Molecular weight determination by GPC-MALLS 
Parameters GCPQ batch 1  
(Figure 2-11, 
Figure 2-12) 
GCPQ batch 2  
(Figure 2-13, 
Figure 2-14) 
GCPQ batch 3 
(Figure 2-15, 
Figure 2-16) 
Polydispersity index 
Mw/Mn 
1.221 1.061 2.560 
Number average molecular 
weight 
Mn (g/mol) 
8.804e+3 1.328e+4 3.389e+4 
Weight average molecular 
weight Mw (g/mol) 
1.075e+4 1.251e+4 8.675e+4 
dn/dc (mL/g) 0.1601 ± 0.0083 0.1735 ± 0.0060  0.1733 ± 0.192 
R2 0.989393 0.997780 0.996695 
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Figure 2-11 GPC chromatogram for GCPQ batch 1 analysed by different detector [Light 
scattering (LS) in red, Quasi elastic light scattering (QELS) in pink and dRI in 
blue]. Signals obtained from different detectors were eluted at the same time.  
 
 
Figure 2-12 Determination of dn/dn from RI - GCPQ batch 1. Graph showing various 
concentrations of GCPQ (0.1 mg/mL to 0.6 mg/mL) on X-axis plotted against 
their respective dRI value on the Y-axis. 
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Figure 2-13 GPC chromatogram for GCPQ batch 2 analysed by different detector [Light 
scattering (LS) in red, quasi elastic light scattering (QELS) in pink and dRI in 
blue]. Signals obtained from different detectors were eluted at the same time.  
 
Figure 2-14 Determination of dn/dc from RI for GCPQ batch 2. Graph showing various 
concentrations of GCPQ (0.1 mg/mL to 0.5 mg/mL) on X-axis plotted against 
their respective dRI value on the Y-axis. 
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Figure 2-15 GPC chromatogram for GCPQ batch 3 analysed by different detector [Light 
scattering (LS) in red, Quasi elastic light scattering (QELS) in pink and dRI in 
blue]. Signal obtained from light scattering detector had elution time earlier than 
the signal obtained in dRI detector. QELS detector did not show stable peak 
due to detector malfunction.  
 
Figure 2-16 Determination of dn/dn from RI - GCPQ batch 3. Graph showing various 
concentrations of GCPQ (0.1 mg/mL to 0.6 mg/mL) on X-axis plotted against 
their respective dRI value on the Y-axis. 
The effect of probe sonication on the molecular weight of GCPQ was also 
determined. GCPQ probe sonicated for 20 min at 15 amps did not affect the 
molecular weight of GCPQ. The results are shown in Figure 2-17.  
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Figure 2-17 Effect of probe sonication on the molecular weight of GCPQ batch 2. 
Chromatogram showing GCPQ before (blue) and after probe sonication (red).  
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2.6.3 GCPQ B2 Nanoparticle Preparation and Characterization 
GCPQ was made in to a suspension in water and different concentrations of 
NaCl solutions. The formulations were vortexed until homogeneous suspensions 
were obtained. The effects of various NaCl concentrations on the size of GCPQ 
particles were characterized by DLS.  
2.6.3.1 Influence of salt on GCPQ B2 suspension 
GCPQ polymeric micelles were prepared by dispersion of the polymer in an 
aqueous medium. GCPQ self-assembles to form micelles in water. The average sizes of 
GCPQ micelles were larger in water (406 nm) and smaller for GCPQ in NaCl 
concentrations from 10 mM to 300 mM (Figure 2-18). The sizes of GCPQ micelles 
observed were inversely proportional to the concentrations of NaCl in the GCPQ 
suspensions. 
 
Figure 2-18 Particle size characterization of GCPQ B2 by DLS. Z-average of GCPQ  
(2.5 mg/mL) prepared in water and NaCl concentrations ranging from 10 mM to 
300 nm 
The size distribution by number (Table 2-6) suggest that GCPQ (2.5 mg/mL) in 
water had two populations with sizes around 303 nm and 817.9 nm that constituted 
59.9% and 40.1% of the total population.  However, for GCPQ in NaCl suspension (10 
mM), the large sized population around size 986.9 nm constituted around 12.9% of the 
total population and the small sized population around size 197.8 nm constituted 87.1% 
of the total population. With the increase in NaCl concentration (20 mM) in GCPQ 
suspension, only one population of size around 72.6 nm was observed. The sizes of 
GCPQ micelles were smaller (12.5 nm and 11.8 nm) when prepared in NaCl solution 
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(40 mM and 80 mM). These results suggest that with increase in the concentration of 
NaCL (10 mM to 80 mM), size reduction of GCPQ micelles from 400 nm to 11.8 nm 
were observed. However, at NaCl concentrations 150 nm and 300 nm, the sizes of 
GCPQ micelles increased again to 16.7 nm and 26 nm.  
Table 2-6 DLS- Peak analysis using number based distribution of GCPQ suspension in 
water and NaCl solution of different concentrations. 
GCPQ in various 
suspensions 
Population 1 Population 2 
Mean size (nm) Area (%) Mean size (nm) Area (%) 
H20 303.1 59.9 817.9 40.1 
10 mM NaCl 197.8 87.1 986.9 12.9 
20 mM NaCl 72.6 99 - - 
40 mM NaCl 12.5 99.8 - - 
80 mM NaCl 11.8 100 - - 
150 mM NaCl 16.7 100 - - 
300 mM NaCl 26 100 - - 
Polydispersity of the GCPQ formulations in water and NaCl solution (10 to 
80 mM) at a concentration of 2.5 mg/mL were around one (Figure 2-19). For GCPQ 
in water and NaCl solution at 10 mM concentration, two population sizes can be 
observed (Table 2-6) and hence their PDI were 1. For GCPQ in NaCl solution (20 
mM and 40 mM), although only one size population was observed (Table 2-6) the 
PDI was still 1. This could be due to artifacts present in the sample itself having a 
micellar population of area 99% (Table 2-6).  However, the PDI dropped to 0.963, 
0.8 and 0.78 for GCPQ in NaCl solution 80 mM, 150 mM and 300 mM. This drop in 
PDI was observed only for GCPQ suspensions that have single micellar population 
of area 100%. (Table 2-6). 
 
Figure 2-19 Particle size characterization of GCPQ B2 (2.5 mg/mL in water and salt 
concentrations) by DLS – PDI 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
 H20 10mM 
NaCl 
20mM 
NaCl 
40mM 
NaCl 
80mM 
NaCl 
150mM 
NaCl 
300mM 
NaCl 
PD
I 
PDI of GCPQ by DLS 
  77
2.6.3.2 GCPQ B2 formulation after probe sonication 
GCPQ B2 formulation was prepared in water (2.5 mg/mL) and probe 
sonicated at 15 amps for 15 min. The sizes of micelles observed were smaller (67.7 nm) 
with low PDI (0.269) compared to GCPQ B2 prepared as suspension (size - 400 nm 
and PDI -1) without probe sonication (Figure 2-20). These small sizes were due to 
the disruption of large micellar clusters during sonication process yielding more 
homogeneous micelles with low PDI.  
 
Figure 2-20 Size characterization of GCPQ B2 by DLS with and without probe sonication 
showing size distribution by number (blue) and PDI (red). 
 
Figure 2-21 TEM of GCPQ B2 micelles (2.5 mg/mL) in water showing particles sizes around 
10 nm.  
Transmission electron microscopic image of GCPQ B2 micelles show sizes 
of approximately 10 nm (Figure 2-21). Although TEM images are not quantitative, 
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the majority of the size distribution was smaller than the results obtained by DLS. 
This could be due to two reasons:  
Micelles in suspension have different surface properties than those on a dried 
grid (Figure 2-22).  
 
Figure 2-22 Schematic representation of possible impact of DLS and TEM on micelle image 
Size obtained from intensity-based distribution could represent an over 
estimated value, even if a small proportion of large aggregates are present in the 
nanoparticle suspension. 
2.6.3.3 Characterization of surface charge of GCPQ B2 
The surface charge of GCPQ B2 was characterized by DLS (Figure 2-26). 
GCPQ at pH 4.3 has the most positive zeta potential (+50 mV) (Figure 2-23), which 
reduced with increase in pH to 7 and 9 to + 25.2 (Figure 2-24) and +14.5 mV  
(Figure 2-25). De-protonation of primary and secondary amines in the GCPQ 
polymer occurs at higher pH leading to decrease in the surface charge of GCPQ 
micelles. 
 
Figure 2-23 Zeta potential distribution of GCPQ B2 (2.5 mg/mL) in water at pH 4.3 
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Figure 2-24 Zeta potential distribution of GCPQ B2 (2.5 mg/mL) in water at pH 7 
 
Figure 2-25 Zeta potential distribution of GCPQ B2 (2.5 mg/mL) in water at pH 9 
 
Figure 2-26 Surface charge of GCPQ B2 (2.5 mg/mL) in water analysed by DLS. Graph 
showing GCPQ prepared at a concentration of 2.5 mg/mL in water at different 
pH plotted against their zeta potential values.  
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2.6.4 Colloidal stability of GCPQ B2 nanoparticle in physiological medium 
Determination of the colloidal stability of GCPQ B2 micelles in physiological 
medium is important to understand the interaction of GCPQ B2 micelles with the GI 
contents after oral administration.  
In simple medium (Figure 2-27), SIF with and without pancreatin, the GCPQ 
micelles was stable at different time points indicating that pancreatin is not causing 
aggregation of GCPQ micelles.  
 
 
Figure 2-27 Stability of GCPQ micelles (2.5 mg/mL) in simple medium (SIF with and without 
pancreatin) incubated and measured at a temperature of 37˚C for time points  
0, 0.5 h, 1, 3 and 6 h.  
The above results were compared with more complex medium (FaSSGF, 
FaSSIF, FeSSIF with pancreatin) (Figure 2-28). The Z-Average result shows 
aggregation of GCPQ micelles over time in FaSSIF and FeSSIF. When compared 
with volume-based distribution (Figure 2-29), one could infer that large aggregates 
do exist, but that these aggregates account for less than 1% of the total population. 
An example comparing intensity and volume-based distribution is shown in Figure 
2-29. It could also be observed that a decrease in micelle size from time 3 h to time 6 
h for GCPQ incubated in FaSSIF and FeSSIF. This could be an indication that some 
micelles that have aggregated at time 3 h (T3) formed sediments at time 6 h (T6).  
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Figure 2-28 Stability of GCPQ nanoparticle in complex medium (Fa SSGF, Fa SSIF V2, Fed 
SSIF V2) incubated and measured at a temperature of 37˚C for time points 0, 
0.5 h, 1, 3 and 6 h. 
 
Figure 2-29 Comparison of size distribution by intensity (left) and volume (right). 
The results obtained from the colloidal stability data shows that the GCPQ 
micelles at pH 7 are stable for 3 h in simple and complex GI medium.   
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2.7  Discussion 
Glycol chitosan is a water-soluble chitosan derivative used as a starting 
material for polymer synthesis. In this study, an amphiphilic derivative of glycol 
chitosan consisting of hydrophobic palmitoyl group and hydrophilic quaternary 
ammonium group were synthesized. Polymer modification with hydrophobic group 
induces self-assembly in an aqueous solution through inter and intra chain 
interaction. Glycol chitosan modified with hydrophobic moiety such as cholanic acid 
[192], fluorescein isothiocyanate (FITC)[193] , N-acetyl-histidine [194] and bile acid 
[180] were previously reported to have application in drug delivery. Polymer 
hydrophobicity has influence on particle aggregation and hence its critical micellar 
concentration [195]. Lower the CMC of a polymer; better its stability upon dilution 
in the gastro-intestinal tract. This implies that a polymer with low CMC has the 
tendency to retain encapsulated material at lower concentration compared to a 
polymer with high CMC. The CMC of GCPQ reported previously was 0.23 µg/mL 
for a GCPQ with palmitoylation percentage of 16% [146]. The CMC of other 
hydrophobically modified glycol chitosan derivatives was reported to be much high 
than GCPQ, with 38 - 260 µg/mL for glycol chitosan-bile acid [180] and 47 -219 µg/mL 
for glycol chitosan-cholanic acid [192]. The palmitoylation percentage of GCPQ 
reported in this study were 16% (GCPQ batch 1), 19% (GCPQ batch 2) and 22% 
(GCPQ batch 3) (Table 2-4). 
Another key factor that affects the colloidal stability of GCPQ is its 
modification by quaternization. Chitosan of poor solubility was previously reported 
to have been quaternized to improve the solubility of a polymer at any given pH 
[196]. Quaternization also enhances the mucoadhesive property of chitosan-derived 
polymers [197]. The quaternization percentage for GCPQ polymer batch 1, 2 and 3 
was 12%, 14 % and 8% (Table 2-4). 
GCPQ B1 and GCPQ B2 prepared by old method had palmitoylation and 
quaterization of 16% and 14% and 19 % and 12%. Their molecular weight analysed by 
GPC-MALLS were 10 and 12 kDa with polydispersity of 1.221 and 1.061 (Table 2-4). 
New method of GCPQ synthesis was adopted in order to be able to control the 
palmitoylation reaction by using molar ratio of GC to palmitic acid  
N-hydroxysuccinimide. The GCPQ batch 3 produced by new method had Mw and 
Mn of 86.5 kDa and 34.5 kDa and PDI of 2.5 with palmitoylation and quaternization 
of 22% and 8 % respectively (Table 2-4).  
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While analyzing GCPQ in GPC-MALLS, the polymer was dissolved in a 
mobile phase composing of methanol and acetate buffer at ratio 65:35 due to its 
solubility in the respective solvent mixture [198]. It was expected that the GCPQ 
polymer get completely dissolved in the respectively mobile phase. However, GCPQ 
B3 formed aggregates (as seen from GPC results) in the respective mobile phase, as 
it has 22% palmitoylation that was higher than the palmitolyation of GCPQ B1 and 
B2 and 8% quaternization that was lower than the quaternization of GCPQ B1 and 
B2. Also, when using solvents such as DMSO (new method) the PGC remains 
soluble throughout the reaction. However, when using ethanol and water for 
palmitoylation reaction, the solubility of PGC reduces resulting in formation of white 
foam during the course of reaction. This changes the way palmitoyl chains are added 
on to GC polymer between the two methods of synthesis.  
This could have resulted in polymer aggregation via intermolecular hydrogen 
bonding in methanol and acetate buffer (65:35) and hence the peak eluted from GPC 
column was observed at earlier time points. In order to confirm the hypothesis, the 
GCPQ polymer B3 could be dissolved in a mobile phase that has organic phase 
percentage higher than 65% methanol and analysed by GPC MALLS. Any shift in 
the peak could verify the hypothesis that this increase in the polydispersity index of 
the polymer is due to intermolecular association between polymers.  
When polymers undergo intermolecular interaction in their respective 
solvent, the results obtained from GPC MALLS are unreliable. The GPC MALLS 
calculate molecular weight under an assumption that under dilute conditions 
intermolecular association does not exist. In this study, since there could be a 
possibility of intermolecular association, GPC MALLS could have resulted in an 
overestimated size (Mw- 86 kDa) for GCPQ B3.  
GCPQ B2 was used for characterization of the polymer. The effect of 
sonication on the molecular weight of GCPQ was tested. Previous report has 
mentioned that the temperature and sonication time has effect on the molecular 
weight of the chitosan polymer. Azar et al previously reported that sonication time 
(10 to 120 min) and temperature (20˚C, 40˚C and 60˚C) decreases the molecular 
weight of the chitosan polymer [199]. Chitosan polymer sonicated for at least  
10 min at 20˚C resulted in decrease in the molecular weight of the polymer from 
3.8E+06 Da to 3.4E+06 Da. Savitri et al has used probe sonication to degrade 
chitosan under mild acetic acid conditions (0.2 to 1% v/v) with pH ranging from 3.2 
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to 4.8 at accelerated temperatures (40˚C and 60˚C) [200]. For GCPQ probe sonicated 
in the presence of ice for 20 min, no changes in the molecular weight was observed 
as compared to the molecular weight of the GCPQ polymer without probe sonication 
(Figure 2-17).  
GCPQ oral formulations were previously made by adding the GCPQ along 
with drug (propofol [201] cyclosporine [146], LENK [198])  in water followed by 
probe sonication. GCPQ was also formulated with amphotericin by formation of 
polyelectrolyte complexes. The drug was prepared in basic condition and added to 
GCPQ, where the carboxylate salts of amphotericin interact with positively charged 
GCPQ to form nanoparticles [153]. For intravenous formulations, GCPQ and the 
drug (TP LENK - LENK ester prodrug – tyrosinyl1palmitate-leucine5-enkephalin) 
was prepared in 0.9% sodium chloride solution [162]. However, the characterization 
results of GCPQ without drug in water and sodium chloride solutions were not 
compared. In this study, GCPQ was prepared in water and sodium chloride solutions 
of different concentrations (10 to 300 mM) and the results were characterized using 
TEM and DLS. The GCPQ in water suspension was also compared before and after 
probe sonication.   
GCPQ micelles measured to 20 nm in TEM (Figure 2-21), as the image was 
recorded after vacuum drying. However, the micelles in aqueous suspension 
measured up to 400 nm (Figure 2-18) with a polydispersity index of 0.9 (Figure 
2-19).  
For the first time we have reported that the sizes of the micellar clusters were 
found to be reducing with the increase in the NaCl concentrations in the aqueous 
medium (Figure 2-18). The DLS results suggest that with the introduction of NaCl in 
GCPQ-water suspension and with increase in the concentration of NaCL (10 mM to 80 
mM), GCPQ micelle sizes reduced from 400 nm to 11.8 nm. These phenomena can be 
investigated in the future to understand the behavior of GCPQ in suspensions. Also, it 
was observed that there was a marginal increase in the GCPQ particle size at NaCl 
concentrations 150 nm and 300 nm. Further increase NaCl concentration is necessary to 
confirm this observation. These observations are contradictory to previously reported 
observations for the effect of salt on nanoparticles. Where, it was described that the like 
charged nanoparticles exhibited stability due to steric or electrostatic repulsion between 
the particles. However, in the presence of salt, the charges on surface of the 
nanoparticles were altered leading to instability and agglomeration [202-204].  
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GCPQ suspension prepared in water after probe sonication, resulted in a 
homogeneous population of micelles of 69 nm with PDI of 0.269 (Figure 2-20). This 
shows that probe sonication is essential for obtaining uniform sized particles.  
The surface properties of GCPQ can greatly influence its interaction with 
proteins present in the luminal contents. The surface charge of GCPQ B2 was 
measured from the zeta potential obtained from DLS analysis at different values of 
pH. At lower pH (4.3), the zeta potential is highly positive (+50 mV) and it decreases 
to +25.2 mV at pH 7 and +14.5 mV at pH (9) (Figure 2-26). This trend is due to the 
neutralization of amines in the GCPQ polymer. This high positive surface charge is 
contributed by quaternary ammonium group of glycol chitosan that remains charged 
at alkaline pH. The surface charges of chitosan at pH 7 of different molecular 
weights (3.3 kDa to 29 kDa) were only between +4.10mV to +1.3mV. The surface 
charge becomes negative with increase in the molecular weight of chitosan above  
29 kDa [205].  
The colloidal stability of GCPQ was also measured in simulated gastric and 
intestinal medium. Incubation of GCPQ in simulated medium (simple SIF with and 
with out pancreatin) did not affect the stability of the micelles as analysed until  
6 h (Figure 2-27). However, there was a fraction (< 1%) of GCPQ micelles that 
aggregated in FaSSIF and FeSSIF indicating that bile components can interact with 
GCPQ micelles (Figure 2-28,Figure 2-29). Previously, Garrett et al observed GCPQ 
in bile and gall bladder through in vivo imaging technique. From this results it was 
also hypothesized that GCPQ could be recirculated via bile in to the small intestine 
[160]. This study supports the above hypothesis that, GCPQ can interact with bile 
components through which micelles can recirculate between gall bladder and 
intestine. Previously, the role bile salts as co-surfactants has been studied to enhance 
the gastro intestinal residence time and oral bioavailability of drugs with carriers 
such as liposomes and surfactants [206-208]. Understand the role of bile components 
in enhancing the oral absorption of drug loaded GCPQ micelles could be investigated 
in the future for optimizing its oral bioavailability.  
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3 Delivery of Labyrinthopeptin for Chronic Pain treatment 
3.1  Objective 
The objective of this chapter is to, 
1. Formulate Labyrinthopeptin using GCPQ (B1, B2 and B3) and 
glycofural formulation for oral and intranasal delivery. 
2. Characterize and compare the colloidal stability of Laby GCPQ (B1, 
B2 and B3) formulations made from different batches of GCPQ in 
SGF, SIF and HBSS. 
3. Evaluate the pharmacodynamics of Laby GCPQ B2 and Laby 
glycofural following oral and nasal formulations in CFA pain model 
in rats. 
4. Validate method for quantification of Laby by LCMS-QQQ 
5. Evaluate the pharmacokinetics of Laby GCPQ (B1 and B3) and Laby 
glycofural formulations.  
3.2  Introduction 
International Association for the Study of Pain (IASP) defines pain “as an 
unpleasant sensory or emotional experience resulting from actual or potential tissue 
damage” [209]. Chronic pain is any pain lasting for more than 12 weeks and 
persisting for months or longer. The nature of chronic pain can be the result of a 
physical injury, post surgical pain, or associated with other illness such as arthritis, 
cancer or diabetes. In case of arthritis, chronic pain lasts until the underlying problem 
of the disease, such as inflammation, persists [210]. In some cases, chronic pain is 
neuropathic; a condition where damage to the nerve that transmits pain can cause 
irreversible pain even after the condition has healed, where, there is no damage to the 
tissue.  
Several pathophysiological and histopathological steps are involved during 
transition from acute to chronic pain [211]. In acute pain, noxious stimuli are 
transduced to the dorsal horn of the spinal cord. Here, amino acid and peptide 
transmitters activate second-order neurones, which then transmit signals to the brain. 
The pain diminishes as healing progresses followed by reduction in sensation of pain 
until no pain is detected. A long lasting pain can change the way in which brain and 
spinal cord perceives signal that results in severe pain with no or little stimulus 
[212]. When persistent pain occurs, secondary mechanisms are triggered [211]. 
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These include upregulation of cyclo-oxygenase-2, interleukin-1beta sensitizing first 
order neurones, which further sensitize second order neurones by activation of  
N-methyl-D-aspartic acid channels and signaling microglia to alter neuronal 
cytoarchitecture. Throughout these processes, prostaglandins, endocannabinoids,  
ion-specific channels and scavenger cells play a role in the transformation of acute to 
chronic pain. These mechanisms occurring in peripheral and central nervous system 
causes allodynia, hyperalgesia and hyperpathia that can diminish normal functioning 
[211].  
 Chronic pain has negative implication on the quality of life. In UK alone the 
prevalence of severe chronic pain is 11% in adults and 8% in children [213].  
The treatment plan for chronic pain is a fragmented approach as pain threshold level 
is subjective from patient to patient. The most commonly used medication for 
chronic pain management falls into one of the categories Table 3-1: a) non-steroidal 
anti-inflammatory drugs, b) antidepressants, c) anticonvulsants and d) opioids.  
Table 3-1 Drugs for Chronic pain treatment 
S.NO Classification Treatment Side effects 
1 Non steroidal 
Anti-
inflammatory 
Drugs and 
Acetaminophen 
(NSAIDS) 
COX inhibitors –arthritis 
[214] 
Affects kidneys, clotting of 
blood and gastrointestinal 
system. Long-term use is 
associated with 
cardiovascular risks. 
2 Antidepressants Tricyclic antidepressant – 
peripheral neuropathic pain 
[215] 
Sedation 
3 Anticonvulsants Pregabalin – postherpetic 
neuralgia, diabetic peripheral 
neuropathy and fibromyalgia 
[216] 
Gabapentin – Low back pain, 
chronic pelvic pain [217] 
Carbamazepine and 
oxcarbazepine – trigeminal 
neuralgia [218] 
Drowsiness and weight gain 
4 Opioids Fentanyl, morphine, 
oxycodone – moderate to 
severe chronic pain [219] 
Constipation, drowsiness and 
nausea 
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The side effects of above-mentioned drugs are due their distribution in non-
target sites. Drug delivery strategies are used in pain therapy to increase drug load, 
reduce toxicity, increase bioavailability, prolong pharmacological effects and target 
delivery to specific sites. Nanomedicines provide unique approaches to these 
changes. Examples of nano carriers used for pain treatment and their advantages are 
summarised in the Table 3-2. 
Table 3-2 Nanocarriers used for pain therapies 
Drugs Nano carrier Delivery 
route 
Advantage 
Opioids (Endomorphin-
1) [220] 
Polysorbate 80- 
coated nanoparticles 
IV • Enhance penetration 
across blood brain 
barrier 
Opioids (palmitoyl Leu- 
Enkephalin) [53] 
GCPQ nanoparticles Oral • Increased stability in the 
gut  
• Penetration across blood 
brain barrier 
Opioids (Loperamide) 
[221] 
ICAM-1 targeted 
nanoliposomes 
IV • Sustained analgesic 
effect at inflammatory 
site 
• Decrease systemic 
toxicity 
Glucocorticoids 
(Methylprednisolone) 
[222] 
PEGylated 
nanoliposomes 
IV • Decrease required 
dosage 
• Improve therapeutic 
benefit 
Local anaesthetics 
(Lidocaine) [223] 
Uni/multilamellar 
liposomes 
Topical • Increase duration of 
action 
• Decrease required 
dosage 
3.3  Labyrinthopeptins- Carbacyclic Lantibiotics  
Lantibiotics are peptides isolated from bacteria and actinomycetes [224]. 
These peptides have been studied mostly for their anti infective properties [225]. 
They share a common unusual amino acid called lanthionine, hence the name 
“lantibiotics”. The labyrinthopeptins are class of carbacyclic lantibiotics first isolated 
from Actinomadura namibiensis [226]. Unlike other lantibiotics, labyrinthopeptin 
has weak antiviral and antibacterial activity. However, its chemical structure is 
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similar to conotoxins [165], an ion channel blockers used to treat chronic pain [227]. 
Hence, labyrinthopeptins have been tested in various pain models and 
labyrinthopeptin A2 was found to be active [165].  
Labyrinthopeptin A2 (laby) is a hydrophobic peptide consisting of 18 
aminoacids [226]. The globular structure of this peptide can be divided into two 
nonapeptides, with each bearing a tetra (ring A) and penta (ring B) peptide that share 
a quaternary αC atom. The two nonapeptides are linked through C-terminal cysteine 
residue to form a disulphide bridge. The A/A’ rings are formed by a methylene group 
between αC atoms of Lab1/Lab10 and Lab4/Lab13. B/B’ rings are formed by 
thioether bridge. The rigid structure of this peptide leads to high metabolic and 
plasma stability [226] (Figure 3-1). 
 
Figure 3-1 Structure of Labyrinthopeptin A2 [226] 
Labyrinthopeptin has a molecular weight of 1924.18 Da and a Log D of 1.87 
at pH 7.4 [165]. The solubility of this peptide in different vehicles is summarised in 
Table 3-3. 
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Table 3-3 Solubility of Labyrinthopeptin in different solvents [165] 
 
Labyrinthopeptin A2 demonstrates efficacy in pre-clinical models of chronic 
pain [165]. Labyrinthopeptin was prepared in ethanol / solutol / phosphate buffer 
saline (1:1:18) and its pharmacodynamic activity was observed to be long lasting, for 
at least 6 h in mice (1.3 mg/kg i.v.) and rat (3mg/kg i.v.). No tolerance was observed 
after 5 days of treatment. At pharmacological doses, no side effects were observed as 
compared to gabapentin. The efficacy was also demonstrated in rats and mice via s.c. 
route [165]. 
However, labyrinthopeptin A2 at a dose of 30 mg/kg in the same diluent 
(ethanol / solutol / phosphate buffer saline (1:1:18)) has oral bioavailability of 0.11 
% [165]. Arturrson et al. reported that drugs or peptides that are absorbed to less than 
1% has a permeability coefficient less than or equal to 1×10-7 cm/s [228]. The 
permeability coefficient of labyrinthopeptin was observed to be 0.5± 0.3×10-7 cm/s at 
pH 7.4 as tested in Caco-2 monolayer model [165]. The peptide is also not a P-
gp/BCRP substrate and does not show paracellular transport. There is no evidence of 
protein binding and the peptide is shown to be stable in SGF (2 h), SIF and mouse 
plasma up to 4 h [165]. The low oral bioavailability (0.11%) of labyrinthopeptin was 
believed to be due to the poor permeability of the respective formulation across the 
gut. Hence, an alternative carrier has to be developed to improve the permeability 
and oral bioavailability of labyrinthopeptin.  
Vehicle Solubility (mg/ml) Solubility (µM) 
0.9% NaCl (physiological Saline) 0.6 336.8 
Glucose 5% 1 505.2 
PBS 10mM, NaCl 0.15M pH 7.4 3.3 1697.5 
Mixture PBS/EtOH/Solutol 
(18/1/1) 9.6 4981.3 
Glycofurol:Phosphate buffer 
0.1M pH 7 50:50 150 77962.6 
Glycofurol:Polysorbate 80: 
Phosphate buffer 0.1M pH 7 
30:20:50 25 12993.8 
Transcutol: Phosphate buffer 
0.1M pH 7 50:50 130 67567.5 
50% w/w Captisol in Phosphate 
Buffer 0.1M pH 7 69 35862.8 
Citrate buffer 0.1M pH 3 0.1 52 
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3.4  LCMS-QQQ 
Overview 
LCMS-QQQ is a robust technique, which operates with four main parts 
(Figure 3-2). 1) Liquid chromatography column, where the extracted samples are 
separated and eluted in a mobile phase, 2) source, that disperses the compounds in to 
fine droplets and ionizes the same, triple quadrupole where compound of interest is 
selected and fragmented based on mass and a detector where the preselected 
compound is quantified [229].  
 
Figure 3-2 LCMS QQQ Schematic representation 
Liquid chromatography 
Liquid chromatography coupled with mass spectrometer generates three-
dimensional data. In addition to measuring strength of the signal, the molecular 
weight, identity and purity of the sample can be obtained. To ensure adequate analyte 
concentration, liquid chromatography could be optimized to minimize co-elution of 
compound that can compete for ionization or suppress signal [229].  
ESI source 
Electron spray ionization works by generating ions in solution before the 
analyte reaches the mass spectrometer. LC eluent is nebulized into fine droplets, 
which is dried using heated drying gas in the presence of an electrostatic field.  
This causes reduction in the size of the droplet as well as accumulation of charge in 
the droplet. As the concentration of charges in the droplet increases, ions are ejected 
in to gas phase due to repulsive force between like charges. These ions are passed 
through a capillary tube in to mass analyzer [229].  
Quadrupole mass analyzer 
 Quadrupoles are four rods arranged in square through which the ions can pass 
through the filter at a given time. Quadrupole analyser has same dc charge applied to 
opposite rods and adjacent rods carries opposite charge. Radiofrequency signal are 
Q1 – selected 
precursor ion Q2 – Collision cell Q3 – selected product ion 
ESI source LC Column 
Detector 
LC   SOURCE    MRM   
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swept in the presence of an applied dc charge. Ions that are stable for a given 
frequency are directed towards the detector [230].  
There are three different modes; scan mode, which monitors a range of mass 
to charge ratio. In selective ion monitoring (SIM) mode only monitors selected mass 
to charge ratio. Highly selective monitoring is carried out in multiple reaction-
monitoring (MRM) modes. Here, quadrupoles screen the compound of interest by; 
where the first quadrapole selects the compound of interest, preselected compound is 
collided in to fragments in the second quadrapole and the fragment of interest is 
selected in the third quadrapole. This selectivity is required for quantifying 
therapeutic compound in the presence of biological matrices [229]. 
Collision induced dissociation 
 Collision induced dissociation fragments selected analyte by applying 
collision energy. The fragmentation patterns are specific for a particular analyte at 
that specific collision energy. The collided fragments are screened and a single 
fragment is selected based on sensitivity and quantified. Collision induced 
dissociation takes place at the second quadrupole of MRM where only a selected 
precursor ion is fragmented for further screening [229]. 
Ion detector and data acquisition 
 Preselected ions are drawn in to the detector and strike a detector’s membrane 
surface causing electron to be released from the other side. The electron strikes the 
coated walls of the detector that will in turn release multiple electrons on each impact. 
The electrons are further amplified and the signals are transferred to data system [230].  
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3.5  Materials and Methods 
3.5.1 Materials  
Chemicals Supplier 
Labyrinthopeptin Sanofi  
DMSO Sigma-Aldrich (Gillingham, UK) 
Methanol (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Acetonitrile (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Water (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Acetonitrile (HPLC grade) Sigma-Aldrich (Gillingham, UK) 
Methanol (HPLC grade) Sigma-Aldrich (Gillingham, UK) 
Trifluroacetic acid (99%) Sigma-Aldrich (Gillingham, UK) 
Formic acid (⪰ 95%) Sigma-Aldrich (Gillingham, UK) 
Glycofurol Sigma-Aldrich (Gillingham, UK) 
Sodium chloride Sigma-Aldrich (Gillingham, UK) 
Sodium hydroxide Sigma-Aldrich (Gillingham, UK) 
Hydrochloric acid Fisher, UK 
Monobasic potassium phosphate Sigma-Aldrich (Gillingham, UK) 
HBSS Invitrogen, UK 
Water Sigma-Aldrich (Gillingham, UK) 
Pentifylline MP Biomedicals, CA, USA 
K2 EDTA BD Vacutainer™ (3 mL) Fisher Scientific, UK 
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3.5.2 Methods 
3.5.2.1 Analytical method for quantification of Labyrinthopeptin 
3.5.2.1.a Preparation of Stock and Working standards: 
Labyrinthopeptin was quantified using high-performance liquid 
chromatography (HPLC). A stock solution of Labyrinthopeptin was prepared by 
dissolving the peptide (2 mg/mL) in DMSO. Calibration standards were prepared by 
diluting stock solution to working standards (S1 to S8) of concentrations ranging 
from 200 µg/mL to 1.56 µg/mL with equal ratios of methanol and water containing 
0.1% trifluroacetic acid (TFA). The standards were analysed by HPLC. All test 
compounds were quantified as method mentioned above. 
3.5.2.1.b HPLC Set up and analysis 
HPLC chromatogram for Labyrinthopeptin were acquired using the following 
setup:  
Table 3-4 HPLC instrument condition for the quantification of labyrinthopeptin. 
HPLC Setup 
Instrument Agilent Technologies 1200 Series HPLC system 
Column Onyx C18 monolithic column (5 µm; 100 × 4.6 mm; Phenomenex 
UK) and fitted with guard cartridge (10 × 4.6 mm, 5 µm) 
Column 
temperature 
37˚C 
Mobile phase A: Water + 0.1 % TFA 
B: Acetonitrile + 0.1 % TFA 
Gradient condition Time 
(min) 
Mobile 
phase A (%) 
Mobile 
phase B (%) 
0 95 5 
1 95 5 
5 25 75 
6 25 75 
6.5 95 5 
7 95 5 
 
Flow rate  1.2 mL/min 
Injection volume 20 µL 
UV wavelength 220 nm 
Sample diluent 50% Methanol: 50% Water (0.1% TFA) 
Calibration curve was obtained by plotting the concentrations of standards 
and its respective peak area from the chromatogram. The linear equation y= mx+c 
was used to calculate the concentration of unknown analyte.  
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3.5.2.2 Preparation of Laby formulations 
Laby GCPQ formulations was prepared and compared to Laby Glycofural 
formulation. From the solubility data, it was known that glycofural and phosphate 
buffer (0.1 M) prepared at ratio 1:1 has solubility of 150 mg/mL. Glycofural 
formulation was used as a control in this study.  
3.5.2.2.a Preparation of Laby-Glycofural formulation 
Laby (10 mg) was added to a solution (1mL) containing glycofurol and 
phosphate buffer saline (PBS - 0.1M, pH 7) prepared at a ratio 1: 1. The formulation 
was vortexed and allowed to dissolve completely at room temperature for 30 min. 
3.5.2.2.b Preparation of Laby-GCPQ (B2) formulation 
 Laby (10 mg) were mixed with GCPQ (B2) as powder at different weight 
ratios (1:1, 1:2, 1:3, 1:4 and 1:5) and added to water (1 mL). The mixture was 
vortexed and allowed to rest on a table to form a suspension. The suspension was 
then probe sonicated in the presence of ice water at 15 amps for 15 min using a probe 
sonicator (Q Sonica, U.S.A).  
A schematic representation of formulation preparation is shown in (Figure 
3-3). 
3.5.2.2.c Preparation of Laby-GCPQ (B1 & B3) formulation 
Laby-GCPQ (B1 & B3) formulation at weight ratio 1:3 was prepared as 
method mentioned in 3.5.2.2.b. 
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Figure 3-3 Preparation of Laby-GCPQ formulation. 
3.5.2.3 Characterization of Laby formulation 
3.5.2.3.a Morphology 
Morphology of the Labyrinthopeptin GCPQ (B1, B2 & B3) formulations was 
determined using transmission electron microscope (Philips CM 120 Bio Twin 
Transmission electron microscope) with an AMT digital camera (5 mega pixels; 
AMT Deben, UK Ltd). A drop of Labyrinthopeptin GCPQ (B1, B2 & B3) formulation 
was placed on a grid and excess fluid was blotted with a tissue paper. A drop of 
uranyl acetate (1% w/v in water) or paraformaldehyde staining solution was also 
added to the grid and TEM images were recorded.  
3.5.2.3.b Particle size 
Particle sizes of Labyrinthopeptin GCPQ formulations (B1, B2 & B3) were 
characterized by dynamic light scattering (DLS) technique (Malvern Zetasizer Nano 
ZS ZEN3600, Malvern Instruments Ltd, Worcestershire, UK). Formulations (1 mL) 
were dispensed into a low volume disposable cuvette and size distribution graphs 
were recorded. 
3.5.2.3.c Charge 
The zeta potential of Labyrinthopeptin GCPQ formulations (B1, B2 & B3) 
were determined using DLS (Malvern Zetasizer Nano ZS ZEN3600, Malvern 
1.  Add peptide 
and GCPQ 
as powder 
2.  Add 
Water 
3.  Allow peptide 
and GCPQ to 
disperse in 
water for one 
hour at room 
temperature 
4.  Probe 
sonicate at 
15 amps for 
15’ in ice 
water 
5.  Labyrinthopeptin-
GCPQ 
formulation 
Preparation of Labyrinthopeptin GCPQ formulation 
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Instruments Ltd, Worcestershire, UK). Formulations (1 mL) were dispensed into a 
zeta cell and zeta distribution graphs were recorded. 
3.5.2.3.d Encapsulation efficiency of Labyrinthopeptin GCPQ (B1, B2 & B3) 
formulations. 
Encapsulation efficiency of Labyrinthopeptin was determined by 
centrifugation method. Laby precipitates above a concentration of 0.6 mg/mL in 
sodium chloride (0.9%) solution. To determine the encapsulation efficiency of Laby 
GCPQ formulation, formulation was centrifuged to pellet out unencapsulated laby 
leaving Laby GCPQ nanoparticle in the supernatant. The concentration of Laby in 
the supernatant was normalized against the laby concentration before centrifugation 
from which encapsulation efficiency of the Laby formulation was determined.  
A schematic representation of the separation of peptide-loaded nanoparticles 
from free peptide is illustrated in Figure 3-4. Labyrinthopeptin GCPQ (B1, B2 & B3) 
formulations were centrifuged at 5000 RPM for 10 min at room temperature.  
The supernatants were passed through 0.8 µm filter and reconstituted (50 µL) in 
sample diluent (950 µL). The solutions were vortexed and analysed by HPLC. 
Encapsulation efficiency of Laby GCPQ (B1, B2 & B3) formulations were 
calculated using the formula,  %  𝑬𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅  𝒑𝒆𝒑𝒕𝒊𝒅𝒆= 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧  𝐨𝐟  𝐩𝐞𝐩𝐭𝐢𝐝𝐞  𝐚𝐟𝐭𝐞𝐫  𝐜𝐞𝐧𝐭𝐫𝐢𝐟𝐮𝐠𝐚𝐭𝐢𝐨𝐧  𝐚𝐧𝐝  𝐟𝐢𝐥𝐭𝐫𝐚𝐭𝐢𝐨𝐧  𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧  𝐨𝐟  𝐩𝐞𝐩𝐭𝐢𝐝𝐞  𝐛𝐞𝐟𝐨𝐫𝐞  𝐜𝐞𝐧𝐭𝐫𝐢𝐟𝐮𝐠𝐚𝐭𝐢𝐨𝐧   ×  𝟏𝟎𝟎 
 
Figure 3-4: Purification of peptide loaded nanoparticles 
 
 
0.8 µm filter 
1.Centrifugation 
5000 rpm for 10’ 
2.Filtration 
Supernatant – Nano 
formulation 
Pellet– non-
encapsulated peptide 
Peptide 
encapsulated 
in GCPQ 
STEP 1 : Centrifugation 
STEP 2 : Filtration 
Purification of GCPQ Encapsulated Peptide 
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3.5.2.4 Colloidal stability of Laby-GCPQ formulations 
Labyrinthopeptin GCPQ formulations were diluted 1 in 20 times with SGF, 
SIF and HBSS respectively. The particle size recorded at different time points using 
DLS. The solutions were maintained at 37˚C throughout the experiment.  
The compositions of simulated fluids are as follows,  
SGF and SIF were prepared by protocol described in United States 
Pharmacopeia 33-28NF (2010) and European Pharmacopeia 7.0 (2010). 
3.5.2.4.a SGF 
Sodium chloride (2 g) was dissolved in water (500 mL). The pH of the 
solution was adjusted to 1.2 with HCl (7 mL) and made up to 1000 ml with water. 
3.5.2.4.b SIF 
Monobasic potassium phosphate (6.8 g) was first dissolved in water (250 mL) 
and 0.2 N sodium hydroxide solution (77 mL) was added. The pH of the solution 
was adjusted to 6.8 with sodium hydroxide (0.2 N) or hydrochloric acid (0.2 N) and 
finally diluted to 1000 mL. 
3.5.2.4.c HBSS 
HBSS (10X) concentrated liquid (Invitrogen, U.K.) was diluted to 1X 
concentration with water. The HBSS (10X) solution consists of sodium chloride  
(80 g/L), potassium chloride (4 g/L), potassium phosphate monobasic (0.6 g/L), 
glucose (10 g/L) and sodium phosphate dibasic (0.479 g/L). 
3.5.2.5 LCMS-QQQ detection of Laby peptide in vivo 
Labyrinthopeptin was quantified in plasma using LCMS QQQ. The 
configurations are listed as follows: 
3.5.2.5.a Instrument configuration 
Pump : Agilent G1312B 
Autosampler : Agilent G1367E 
Column : Agilent G1367E 
Mass spectrometer : Agilent 6460 triple quadrupole LCMS system 
Software : Agilent chem station (B.06.00) 
Several parameters were optimized to get optimum Laby signal. This 
includes liquid chromatography optimization in order elute Laby peak from 
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background matrix and mass spectrometer optimization in order to enhance the 
sensitivity of the laby peptide signal.  
3.5.2.5.b Chromatography 
LC parameters for separation and identification of labyrinthopeptin is as 
follows: 
Parameters Plasma Brain 
Column Onyx monolithic C18 column 
(100×2 mm) 
Agilent Zorbax C18 column 
(50×2 mm) 
Oven temperature 40˚C 40˚C 
Injection volume 5 µL 5 µL 
Mobile phase  Solvent A: 0.1% FA in water 
Solvent B: Acetonitrile 
Solvent A: 0.1% FA in water 
Solvent B: Acetonitrile 
 100 
Gradient program 
Plasma 
Time (min) 0 1 4 4.5 5.5 5.7 7 
% of solvent B 20 50 74 90 20 20 20 
Flow rate 0.4 mL/min 
Brain 
Time (min) 0 0.5 2 2.2 2.4 3 4 
% of solvent B 20 50 74 90 20 20 20 
Flow rate 0.4 mL/min 
3.5.2.5.c Source Optimization  
Agilent uses jet-streaming technology to maximize desolvation of ions in the 
source. The parameters for jet stream includes sheath gas temperature, sheath gas 
flow, drying gas temperature, drying gas flow, nebulizer gas and nozzle voltage. 
Labyrinthopeptin and internal standard (pentifylline) were optimized using a source 
optimizer program in LCMS. The parameter that gave the highest peak area was used 
to develop LCMS method.  
3.5.2.5.d MS Optimization  
Optimum fragmentor voltage and collision energy for the peptide and internal 
standard was optimized manually by running a default method with varying 
fragmentor voltage (50 to 300) and collision energy (10 to 200) respectively. 
Parameter that gave the highest peak area was used to develop LCMS method. 
3.5.2.5.e Signal Optimization  
EMV and MS resolution were varied to get best S/N noise ratio and optimum 
parameter was analyzed. 
The optimum parameter from source, MS and signal optimization were listed 
as follows: 
3.5.2.5.f Mass Spectrometry 
Source Parameters 
Ionization mode ESI jet streaming positive 
Sheath gas temperature (˚C) 400 
Sheath gas flow (L/min) 12 
Drying gas flow (L/min) 10 
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Drying gas temperature (˚C) 340 
Nebulizer gas (psi)  20 
Nozzle voltage (V) 2000 
EMV (V) 200 
 
Test item Labyrinthopeptin Pentifylline MENK 
 Quantifier Internal standard 
for plasma 
sample 
Internal standard for 
brain sample 
MRM transition 962.64- 159.2 265.09 – 138.2 574 - 425 
Fragmentor voltage 
(V) 
140     140 130 
Collision energy (eV) 60      50 10 
MS1 and MS2 
resolution (nm) 
Wide Unit Unit 
Cell acceleration 
voltage (V) 
6 6 7 
Dwell time (ms) 200 200 200 
3.5.2.6 Development of analytical method for Labyrinthopeptin by LCMS-QQQ 
Labyrinthopeptin peptide quantification by LCMS-QQQ was validated 
according to the guidelines in prepared by European Medical Agency [231]. 
3.5.2.6.a Preparation of standards 
A stock solution of labyrinthopeptin was prepared by dissolving the peptide 
(2 mg/mL) in DMSO. Seven calibration standards of concentrations ranging from 
12800 ng/mL to 200 ng/mL were prepared by dilution of stock solution in 0.1% 
formic acid (FA). A stock solution of internal standard (pentifylline) was also 
prepared in acetonitrile (200 ng/mL) to achieve a final concentration of 20 ng/mL in 
plasma. 
3.5.2.6.b Preparation of plasma for calibration standards 
Sprague Dawley (SD) rat was culled in a CO2 culling chamber and blood was 
withdrawn by cardiac puncture. Blood sample was collected in a vacutainer (BD 
Vacutainer™ - spray coated with anti-coagulant K2 EDTA) and centrifuged at 2000 
g for 10 min at 4˚C. Plasma was carefully withdrawn and stored at – 80˚C in a 
freezer until LCMS analysis. 
3.5.2.6.c Preparation and extraction of calibration standards from 
plasma matrices 
 Internal standard (5 µL) and calibration standards (5 µL) were spiked into 
each tubes containing plasma (50 µL). Blank was prepared by spiking only internal 
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standard (5 µL) in plasma (50 µL). For extraction, methanol (140 µL) was added to 
QC standards to precipitate plasma proteins followed by vortexing for 30 min.  
The precipitated plasma proteins were removed by centrifugation at 10000 RPM for 
10 min and the supernatant was quantified by LCMS.   
3.5.2.7 Validation of analytical method 
3.5.2.7.a Preparation of quality control standards (QC) 
Labyrinthopeptin of four different concentrations (lowest limit of quantification 
(LLOQ) - 20 ng/mL, low – 80 ng/mL, medium – 320 ng/mL and high – 1280 ng/mL) 
with IS extracted in plasma matrix were used for validation analytical method.  
3.5.2.7.b Variability with-in and between days 
QC standards (LLOQ, low, medium and high) prepared in triplicates ran 
thrice on the same day and on different days were compared to assess the intra and 
inter-variability of samples.  
3.5.2.7.c Matrix effect 
Effect of plasma matrix on sample ionization was assessed by comparing 
variability in concentration of QC standards (high and low) with and without plasma 
matrix. QC standards and IS (5 µL each) were spiked in plasma or solvent (50 µL) 
and extracted with methanol (140 µL). Matrix effect was calculated using the 
formula: 
 𝑀𝑎𝑡𝑟𝑖𝑥  𝑒𝑓𝑓𝑒𝑐𝑡 = !"#$%#&'(&)"#  !"  !"!#$%"  !"#$  !"#$%&!"#$%#&'(&)"#  !"  !"!#$%"  !"#$%&#  !"#$%&×100 
3.5.2.8 Oral administration of labyrinthopeptin GCPQ formulation 
SD rats (male) were fasted overnight and divided in to three groups (n=5) 
each receiving 30 mg/kg oral dose of Labyrinthopeptin GCPQ (B1 & B3) or 
Labyrinthopeptin glycofurol formulations. At each time point (30’, 1 h, 2 h, 4 h, 6 h 
and 8 h) blood samples (250 µL) were withdrawn from tail vein and collected in a 
vacutainer (BD Vacutainer™ - spray coated with anti-coagulant K2 EDTA). Plasma 
samples (50 µL) were collected by centrifugation at 2000 g for 10 min and stored at 
– 80˚C in a freezer until LCMS analysis. 
Labyrinthopeptin was extracted from plasma by a liquid-liquid extraction 
method. Specifically plasma samples were defrosted in ice and then at RT before 
extraction. An internal standard (pentifylline) of concentration 200 ng/mL in 
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acetonitrile was spiked (5 µL) in each plasma sample and precipitated with methanol 
(145 µL). The samples were vortexed for 30 min at RT followed by centrifugation at 
10000 RPM for 10 min at RT. The supernatant was quantified using LCMS.  
The samples were run as method mentioned in the previous section. 
Labyrinthopeptin and internal standard peak area were integrated and their ratios 
were substituted in linear equation to get the concentrations of labyrinthopeptin in 
the unknown plasma samples. A schematic representation of the study is presented in 
Figure 3-5. 
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Figure 3-5 Schematic of pharmacokinetics of Laby formulations 
3.5.2.9 Pharmacokinetics of Laby in brain sample – LCMS 
Overnight fasted SD rats were administered nasally (3 mg/kg) or orally  
(30 mg/kg) with Laby GCPQ B3 formulation. Animals were euthanized at time point 
30 min and 2 h for nasally administered formulation and at 2 h and  
1.  Oral administration of 
Labyrinthopeptin-GCPQ 
formulation 
2.  Withdrawal of blood at 
different time point 
3.  Separation of plasma from blood by 
centrifugation and spike Internal 
standard (200 ng/ml, 5 µl volume) 
4.  Extraction of analyte from 
plasma using methanol. 
5.  Vortex for 30’ at RT 
6.  Precipitation of plasma protein by 
centrifugation at 10,000 RPM for 10’ 
at RT 
Proceed to LCMS 
Pharmacokinetics of Labyrinthopeptin-GCPQ formulation 
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4 h for orally administered formulation. Brain tissues were extracted, flash frozen 
with liquid nitrogen and stored in -80 C until use.  
Brain samples (1g/10 mL) in methanol were macerated and probe sonicated 
in the presence of ice to obtain a homogeneous suspension.  A good internal standard 
must have the same solubility properties in the extraction solvent as that of the 
labyrinthopeptin. Since pentifylline is soluble in diethyl ether, MENK was used as an 
internal standard. A stock solution of MENK (4 ug/mL) was prepared in DMSO and 
MENK solution (10 uL) was added to brain suspension (1 mL). The sample solution 
was vortexed and centrifuged at 13,000 RPM for 10 min. The supernatant was 
transferred in to a new micro centrifuge tube and dried in a speed vac for three h at 
45˚C. To the dried pellet, diethyl ether (1 mL) was added and vortexed for 5 min. The 
mixture was centrifuged again at 13,000 RPM for 10 min. The supernatant was 
decanted and the pellet was dried at room temperature. The pellet was  
re-suspended again in methanol (200 uL) and centrifuged again at 13,000 RPM for  
10 min. The supernatant was analysed by LCMS-QQQ.  
 For the standards, untreated brain extracts were spiked with Laby of different 
concentrations (10 ng/ng to 640 ng/g) and internal standard (MENK) and processed 
as above. Standard curve was plotted using concentrations of Laby spiked, against 
area ratio of Laby to MENK. Unknown samples were substituted in the linear 
equation to get the concentration of Laby in the respective brain samples. 
3.5.2.10 Pharmacodynamics of Laby-GCPQ B2 formulation 
The anti-nociceptive effect of labyrinthopeptin in the presence and absence of 
GCPQ was tested in complete Freund’s adjuvant (CFA) chronic pain model. Animals 
were habituated to Von Frey hair (VFH) grids, boxes, and procedure room before the 
start of experiment. The animals were then presented with 6 VFH (4, 6, 8, 10, 15, 26 g) 
until a withdrawal reaction was obtained. The hairs were then presented in a 
descending order until no response and then increased until withdrawal response was 
observed. The paw withdrawal was thus recorded. The animals were then injected 
into plantar surface either with incomplete or complete Freund’s adjuvant (100 µl 
using 25 G needle). Inflammation was allowed to develop for 24 h. The animals were 
habituated to VFH boxes for 5 min tested for post CFA withdrawal (1.4, 2, 4, 6, 8, 
10, 15, 26 g starting with 10 g hair and going up or down accordingly). The animals 
were randomized in to three groups and received nasal (15 mm PE10 tubing on 
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insulin syringe) or oral formulation. The paw withdrawal was assessed at 0.5 h, 1, 2 
and 3 h in the same manner as the baseline.  The dosing conditions and methodology 
are outlined in the Table 3-5 and Figure 3-6: 
Table 3-5 In vivo dosing condition for CFA anti-noiciceptive studies 
 Oral  Nasal 
Treatment Group (no of rats) 6 per group, 3 groups 6 per group, 3 groups 
Group 1: Vehicle 50% glycofurol and 50% 
phosphate buffer (0.1 M at 
pH 7) 
50% glycofurol and 50% 
phosphate buffer (0.1 M at 
pH 7) 
Group 2: Labyrinthopeptin  13.8 mg/mL of labyrinthopeptin 
in 50% glycofurol and 50% 
phosphate buffer (0.1 M at 
pH 7) 
13.8 mg/mL of 
labyrinthopeptin in 50% 
glycofurol and 50% phosphate 
buffer (0.1 M at  
pH 7) 
Group 3: Labyrinthopeptin 
GCPQ B2 (ratio 1:3) 
13.8 mg/mL of 
labyrinthopeptin and 41.4 
mg/mL of GCPQ B2 in water 
13.8 mg/mL of 
labyrinthopeptin and 41.4 
mg/mL of GCPQ B2 in water 
Administration volume 250 µL 60 µL 
Dosing in Rat 15 mg/kg 3 mg/kg 
Time point 0, 20’, 40’, 1 h, 1.5 h, 2 h, 3 
h, 4 h, 6 h 
0, 20’, 40’, 1 h, 1.5 h, 2 h, 3 
h, 4 h, 6 h 
 
  107
 
Figure 3-6 Pharmacodynamics of Laby GCPQ formulation 
1.  Baseline : Assessment of 
pain threshold using von 
frey hair 
2.  CFA induction in rat’s hind 
paw. 
3.  Post inflammation pain 
threshold level using von 
frey hair. 
4.  Oral or nasal administration 
of Labyrinthopeptin GCPQ 
formulation. 
5.  Measurement of pain 
threshold level using von 
frey hair after treatment. 
24h 
Pharmacodynamics of Labyrinthopeptin GCPQ formulation 
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3.6  Results 
3.6.1 Laby Glycofural formulation 
From the solubility data (Table 3-3), Laby (10 mg/mL) was prepared in 1:1 
ratio of glycofural and PBS (0.1 M, pH 7). This formulation is used as a control and 
compared with Laby GCPQ formulations for in vivo studies.  
3.6.2 Screening and size characterization of Laby GCPQ Formulations by 
TEM and DLS 
Laby GCPQ formulation was initially screened to know what is the minimum 
amount of GCPQ required to solubilize Laby in water. For this, Laby and GCPQ 
were added as powder at different weight ratios in water and the particles were 
characterized by TEM and DLS.  
3.6.2.1 Morphology 
The sizes of the Laby GC P(19%) Q(12%) B2 formulations prepared at 
different ratios were characterized by TEM and compared with Laby only 
formulation. Laby only formulation at a concentration 5 mg/mL in water showed 
thread like aggregates (Figure 3-7). With the addition of GCPQ to Laby at ratio 1:1, 
very large aggregates and particles were observed (Figure 3-8). However, on 
increasing GCPQ (10 mg/mL) concentration, only particles were observed for Laby 
GCPQ B2 formulation (1:2). Further increase in GCPQ concentration from 15 
mg/mL up to 25 mg/mL gave particles of two sizes; around 20 nm and between 100 
to 300 nm for Laby GCPQ formulation with weight ratio 1:3 (Figure 3-10), 1:4 
(Figure 3-11) and 1:5 (Figure 3-12). It was also observed that the larger particles 
observed in Laby GCPQ (1:3) ratio reduced with increase in GCPQ concentrations at 
ratio 1:4 and 1:5.  
TEM only gives an indication of the morphology of the particles. However, 
quantitative method such as DLS is required to understand what proportion of 
different sized particles were present in Laby GCPQ formulations prepared at 
different ratios.  
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Figure 3-7  TEM images of Laby (5 mg/mL) showing precipitates in water 
  
Figure 3-8 TEM images of Laby-GCPQ B2 formulation prepared at ratio 1:1. Concentration 
of laby and GCPQ used was 5mg/mL and 5 mg/mL. Large aggregates of sizes 
ranging from 740 nm to 2800 nm and particles of sizes ranging from 25 to 150 nm 
were observed. 
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Figure 3-9 TEM images of Laby-GCPQ B2 formulation prepared at ratio 1:2. Concentration 
of laby and GCPQ used was 5 mg/mL and 10 mg/mL. Particles of sizes ranging 
from 10 to 50 nm were observed. Few large aggregates were observed. 
  
Figure 3-10 TEM images of Laby-GCPQ B2 formulation prepared at ratio 1:3. Concentration 
of laby and GCPQ used was 5 mg/mL and 15 mg/mL. Two size populations 
were observed; sizes around 20 to 40 nm and sizes around 100 to 250 nm. 
Large particles appear dense on TEM image. 
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Figure 3-11 TEM images of Laby-GCPQ B2 formulation prepared at ratio 1:4. Concentration 
of laby and GCPQ used was 5 mg/mL and 20 mg/mL. Two size populations 
were observed; sizes around 20 to 40 nm and sizes around 100 to 250 nm. 
Very few large particles appeared on TEM image. 
  
Figure 3-12 TEM images of Laby-GCPQ B2 formulation prepared at ratio 1:5. Concentration 
of laby and GCPQ used was 5 mg/mL and 25 mg/mL. Sizes around 10 to 100 
nm appeared on TEM. 
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3.6.2.2 Size characterization by DLS 
TEM results suggest different size populations for different ratios of Laby 
GCPQ B2 formulations. To confirm which size populations are predominant, Laby 
GCPQ B2 formulations of different weight ratios were quantified by DLS (Figure 
3-13). Particle size analysis shows that Laby GCPQ B2 formulation prepared from 
ratio 1:1 to 1:5 formed particles around 20 nm. The polydispersity of the Laby 
GCPQ B2 formulations with ratio 1:1, 1:2, 1:4 and 1:5 was high (above 0.4) whereas 
Laby GCPQ B2 formulation of ratio 1:3 had the least PDI (0.382). From the PDI, it 
could be inferred that Laby GCPQ B2 formulation (1:3) has the most homogeneous 
population of nanoparticles compared to other ratios.  
The size of GCPQ B2 micelles alone in water (2.5 mg/mL) was 67 nm with 
PDI 0.269 (Figure 2-20). The size of Laby GCPQ B2 particles (around 20 nm) at a 
given ratios (1:1 to 1:5) was observed to be smaller than the size of GCPQ B2 
micelles (67 nm). However, with the introduction of Laby in GCPQ B2 formulations, 
the PDI was larger (ranging from 0.382 to 0.911) than GCPQ B2 micelles (0.269). 
The size of Laby alone formulation was 600 nm with PDI 0.8. Very large 
precipitates around 2 µm were observed in TEM. This differences in the size of Laby 
formulation between DLS and TEM images are due to the sedimentation of large 
precipitates leaving only particles around 600 nm to be detected by DLS.  
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Figure 3-13 Characterization of Laby (2.5 mg/mL) GCPQ formulation at different weight 
ratios (1:1 to 1:5). Laby GCPQ B2 formulations compared with Laby only formulation for size 
distribution by number and PDI. 
3.6.2.3 Size characterization of Laby GCPQ formulation at ratio 1:3 using 
different batches of GCPQ 
 Laby GCPQ B2 formulation (1:3) resulted in a clear suspension after probe 
sonication. An example on the appearance of Laby GCPQ at weight ratio 1:3 before 
and after probe sonication is shown in Figure 3-14. 
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Figure 3-14 Laby GCPQ (1:3) formulation before and after probe sonication. Suspension 
appeared clear after probe sonication.  
Laby GCPQ formulations were made at ratio 1:3 and compared between 
different batches of GCPQ and with Laby and Laby PGC formulations (Figure 3-15). 
Laby alone formed aggregates around 800 nm with PDI 0.6. Formation of Laby-PGC 
nanoparticles of size around 200 nm with PDI 0.672 suggests that hydrophobicity is 
essential for particle formation. When comparing different batches of GCPQ, one 
could infer that the particle sizes significantly drops with increase in the degree of 
palmitoylation of GCPQ. For Laby GCPQ formulation B1 with palmitolytion of 
16%, the particles sizes analysed were 572 nm with PDI 0.125. However, with 
increase in palmitoylation of GCPQ to 19% and 22% the particle size measured were 
less than 100 nm. There was an increase in the size and PDI of Laby GCPQ 
formulation with B2 and B3. This increase in the particle size from palmitoylation 
19% to 22% could be due to increase intermolecular association between the 
polymers.  
Before probe sonication 
 
After probe 
sonication 
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Figure 3-15 Comparison of Laby (2.5 mg/mL) GCPQ formulation at ratio 1:3 between 
different batches of GCPQ and with Laby (2.5 mg/mL in water) and Laby  
(2.5 mg/mL) PGC (7.5 mg/mL) formulation of ratio 1:3. 
TEM images of Laby GCPQ formulations of different batches 1, 2 and 3 
were compared. The TEM images correlated with results obtained in DLS. 
Aggregate of particles were observed in Laby GCPQ formulation B1 with 
palmitoylation of 16% (Figure 3-16). With increase in palmitoylation, homogeneous 
population of Laby GCPQ B2 nanoparticles of size 20 nm was observed (Figure 3-17). 
With further increase in palmitoylation to 22% for Laby GCPQ B3 formulation, the 
laby GCPQ particle aggregation was observed in TEM (Figure 3-18) and in DLS 
with a PDI of 0.572.  
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Figure 3-16 TEM image of Laby GCPQ B1 with degree of palmitoylation of 16% showing 
aggregates of nanoparticles of sizes ranging from 14 nm to 188 nm. 
 
Figure 3-17 TEM image of Laby GCPQ B2 with degree of palmitoylation of 19% showing 
nanoparticles around 20 nm. 
 
Figure 3-18 TEM of Laby GCPQ B3 formulation with degree of palmitoylation of 22% and 
quaternization of 8% showing small micelles around 20 nm and large particles 
around 200-300 nm 
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3.6.3 Charge and stability  
Surface charge of Laby GCPQ B1, B2 & B3 formulations were assessed by 
measuring its zeta potential using DLS (Figure 3-19). Laby had negative zeta 
potential (-34.6 mV), Laby formulated with PGC had positive zeta potential around 
+10 mV and Laby GCPQ B1 formulation with degree of quaternization of 14 % had 
the most positive zeta potential (+48 mV) followed by Laby GCPQ B2 formulation 
(+46 mV) with quaternization percentage 12% and Laby GCPQ B3 formulation (+39.8 
mV) with quaternization percentage 8%. The surface charge of Laby GCPQ 
formulations were observed to be increasing with increase in degree of quaternization. 
All measurements were carried out at pH 4.5 and temperature 25°C. The presence and 
absence of degree of quaternization could affect the stability of Laby formulations. TEM 
images show presence of precipitates in Laby-PGC formulation. This could be a result of 
low surface charge (+10 mV) that induced aggregation and precipitation of Laby-PGC 
particles. However, Laby GCPQ B1, B2 & B3 formulations were stable due to large 
positive zeta potential. This suggests that charge plays an important role in maintaining 
the stability of GCPQ formulations. From the above results, it is evident that the Laby 
with a negative surface charge was encapsulated in the GCPQ B1, B2 & B3 
formulations resulting in positive surface charges. 
 
Figure 3-19 Zeta potential of Laby (2.5 mg/mL), Laby (2.5 mg/mL) with PGC formulation 
(1:3), Laby (2.5 mg/mL) with GCPQ formulations (B1, B2 and B3) prepared at 
ratio 1:3 and characterized DLS. 
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3.6.4 Encapsulation efficiency of Laby GCPQ Formulations 
3.6.4.1 Analytical method for quantification of Laby by HPLC 
Encapsulation efficiencies for Laby GCPQ formulations were analyzed using 
HPLC. Standard curve for laby was plotted with lowest and highest concentration 
being 0.79 µg/mL and 200 µg/mL. Laby was eluted at a retention time of 5.5 min 
(Figure 3-20) with lowest limit of detection (LLOD) and quantification (LLOQ) as 
1.56 ug/mL. Along with Laby peak, trifluroacetic acid peak was also eluted at 1.5 in 
mobile phase (water and methanol (50:50) containing 0.1% TFA). The HPLC 
method was validated for variations in analysis within a day and between days.  
 
Figure 3-20 HPLC chromatogram for Laby eluted at retention time of 5.5 min and 
trifluroacetic acid peak eluted at time 1.5 min in 1:1 ratio of water and methanol 
containing 0.1% TFA. Small shoulder peak eluted with Laby peak indicates the 
presence of impurities in the sample. 
To assess the variations within and between runs, percentage relative 
standard deviation was calculated by dividing standard deviation by mean area under 
the curve. The acceptable criteria for % RSD for standards are less than 15%. Linear 
equation for the calibration curve obtained from standards run on the same day was 
y=40.16x+103.09 and r2 = 0.99573 (Figure 3-21). At lower concentrations (3.125 and 
1.56 µg/mL), relative standard deviations (% RSD) were observed to be larger, 12% 
and 13% than the % RSD for higher concentrations (Table 3-6).  
Labyrinthopeptin 
↘"
  119
 
Figure 3-21: Calibration curve for laby showing concentrations of Laby ranging from  
1.56 ug/mL to 200 ug/mL on x-axis plotted against area under the curve on  
y-axis. Three different samples sets were compared on the same day. Graph in 
red box showing linearity observed with lower concentrations of Laby from  
1.56 ug/mL to 25 ug/mL 
Similarly, linear equation for calibration curve obtained from standards run 
on the same day was y=35.388x+89.89 and r2 = 0.9989 (Figure 3-22). For standards 
analysed at different days, % RSD was found to be greater than 15% at 
concentrations 200 µg/mL, 100 µg/mL and 50 µg/mL, 12% for the lowest 
concentrations 1.56 µg/mL and 3.125 µg/mL and less than 10% for remaining 
concentrations (Table 3-6).  
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Figure 3-22 Calibration curve for laby showing concentrations of Laby ranging from 1.56 
ug/mL to 200 ug/mL on x-axis plotted against area under the curve on y-axis. 
Three different samples sets were compared on different days. Graph in red 
box showing linearity observed with lower concentrations of Laby from  
1.56 ug/mL to 25 ug/mL. 
These results suggest that variation in analysis could be minimum (% RSD < 
15%) when a standard curve is run every time along with sample analysed on the 
same day.  
Table 3-6 RSD % of Laby at different concentrations analysed on same day and at different 
days 
Concentration of 
Laby (ug/mL) 
RSD% - within a 
day run 
RSD% - between 
days run 
200 1% 18% 
100 0% 20% 
50 0% 19% 
25 2% 7% 
12.5 2% 1% 
6.25 1% 6% 
3.125 12% 12% 
1.56 13% 12% 
3.6.4.2 Encapsulation efficiency of Laby-GCPQ B1, B2 & B3 formulations 
Encapsulation efficiency of Laby (2.5 mg/mL) - GCPQ (7.5 mg/mL) 
formulations (1:3) were determined using HPLC. The formulations were centrifuged 
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to precipitate the un-encapsulated Laby peptide. The Laby GCPQ nanoparticles in 
the supernatant were quantified by HPLC. The encapsulation efficiency of Laby 
GCPQ B1, B2 & B3 formulations at ratio 1:3 had encapsulation efficiency around 
89% (Figure 3-23). The same can be expressed in moles encapsulated per particle. 
Moles of Laby encapsulated in GCPQ of batches 1 (10.75 kDa), 2 (12.51 kDa) and 3 
(86.75 kDa) were 1.88, 2.17 and 13.37 moles. This shows that laby encapsulation in 
GCPQ increases with increase in the molecular weights of the GCPQs.  
 
Figure 3-23 Encapsulation efficiency of Laby GCPQ formulations 
3.6.5 Colloidal stability of Laby-GCPQ B1, B2 & B3 formulations in simulated 
medium 
Colloidal stability of Laby GCPQ B1, B2 & B3 (1:3) formulations were 
observed in vitro in simulated gastric medium (SGF), simulated intestinal medium 
(SIF) and Hank’s balanced salt solution (HBSS) by characterizing their sizes over 
time using DLS.  
3.6.5.1 SGF 
Laby GCPQ B1, B2 & B3 formulations were incubated for 2 h at 37˚C and 
characterized by DLS for their size and polydispersity index. The samples were 
measured at time point 30 min, 1 and 2 h. For Laby-GCPQ B1 formulation, the 
particle size reduced from 572 nm to 140 nm after dilution in SGF (Figure 3-24). The 
size of Laby GCPQ B2 (20 nm) remained the same after dilution in SGF (Figure 3-24). 
Laby GCPQ B3 formulation of size around 84 nm also reduced in size to 10 nm after 
dilution in SGF (Figure 3-24). This shows that larger particles reduce in size upon 
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dilution in SGF medium. The stability of Laby GCPQ formulations in SGF was also 
due to the protonation of amines present in GCPQ formulations at acidic pH that 
prevents particles from aggregating to each other. An increase in the polydispersity 
index of Laby GCPQ formulations (B2 and B3) at 2 h time point suggest that few 
particles may have aggregated (Figure 3-25) and a decrease in the PDI of Laby 
GCPQ formulation B1 at 2 h suggest that few particles may have precipitated in SGF 
medium (Figure 3-25).  
 
Figure 3-24 Graph showing size distribution of Laby GCPQ formulations of different batches 
measured using DLS as an indication of their colloidal stability in simulated 
gastric fluid (SGF) maintained at 37˚C and measured up to 2 h.  
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Figure 3-25 Graph showing polydispersity index of Laby GCPQ formulations of different 
batches measured using DLS as an indication of their colloidal stability in 
simulated gastric fluid (SGF) maintained at 37˚C and measured up to 2 h.  
3.6.5.2 SIF 
Colloidal stability of Laby GCPQ B1, B2 and B3 formulation in SIF (pH 6.8) 
incubated at 37˚C for 4 h were characterized for size and polydispersity index by 
DLS. Laby GCPQ B1 and B3 formulations of size 10 and 100 nm aggregated gradually 
to size 33 nm and 168 nm in SIF medium (Figure 3-26). There was also an increase in 
the polydispersity index for both the formulations (B1 & B3) (Figure 3-27). Particle 
aggregation with Laby GCPQ B2 formulation was not observed (Figure 3-26). 
However, PDI of Laby GCPQ B2 formulation decreased indicating that few large 
size particles may have settled down the cuvette (Figure 3-27). 
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Figure 3-26 Graph showing size distribution of Laby GCPQ formulations of different batches 
measured using DLS as an indication of their colloidal stability in simulated 
intestinal fluid (SIF) maintained at 37˚C and measured up to 4 h 
 
Figure 3-27 Graph showing polydispersity index of Laby GCPQ formulations of different 
batches measured using DLS as an indication of their colloidal stability in 
simulated intestinal fluid (SIF) maintained at 37˚C and measured up to 4 h 
3.6.5.3 HBSS 
Colloidal stability of Laby GCPQ formulations B1, B2 and B3 incubated in 
HBSS (pH 7.4) at 37˚C was characterized for size and polydispersity index by DLS. 
Particle aggregation was observed for all formulations in HBSS. The sizes of Laby 
GCPQ formulations (B1 and B2) were less than 40 nm at 4 h time point (Figure 
3-28). PDI of Laby GCPQ formulation B1 had large error bar only at 4 h suggesting 
that the particle aggregation may have taken place at later time points (4 h) (Figure 
3-29). However PDI of Laby GCPQ B2 formulation suggest that particle aggregation 
has initiated at earlier time points (Figure 3-29). Particle size of Laby GCPQ B3 
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formulation increased steadily to 1 µm over a period of 4 h (Figure 3-28). PDI of the 
particles also increased with increase in the size of the error bar over four h (Figure 
3-29). This indicates that the particles have increased in size consistently as well 
sedimented over time. 
Aggregation of Laby GCPQ formulations in HBSS was due to deprotonation 
of amines in GCPQ at alkaline pH. From the size and PDI of Laby GCPQ B1, B2 
and B3 formulations, it could be inferred that the aggregation of particles takes place 
at different rate with Laby GCPQ B3 formulation aggregating faster in HBSS 
followed by Laby GCPQ B2 and Laby GCPQ B1 formulation (Figure 3-29). This 
trend is observed due the differences in the degree of quaternization for each batch of 
GCPQ (GCPQ B1- 14%, GCPQ B2- 12% and GCPQ B3 – 8%). As a result, lower 
the degree of quaternization of GCPQ faster their aggregation in HBSS and vice 
versa.  
 
Figure 3-28 Graph showing size distribution of Laby GCPQ formulations of different batches 
measured using DLS as an indication of their colloidal stability in HBSS 
maintained at 37˚C and measured up to 4 h 
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Figure 3-29 Graph showing polydispersity index of Laby GCPQ formulations of different 
batches measured using DLS as an indication of their colloidal stability in HBSS 
maintained at 37˚C and measured up to 4 h. 
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3.6.6 Pharmacodynamics and pharmacokinetics of Laby GCPQ formulations 
From the above in vitro results, it is evident that Laby GCPQ B3 formulation 
has poor colloidal stability in HBSS. For in vivo studies, Laby GCPQ B1 or B2 can 
be used formulations, as the formulations had colloidal stabilities in all three 
simulated fluids (SGF, SIF, HBSS). The pharmacodynamics study was carried out in 
one of the stable formulations (Laby GCPQ B2) and compared with Laby glycofural 
formulation.  
3.6.6.1 Pharmacodynamics of Laby GCPQ B2 formulations 
Pharmacodynamics of Laby formulations was tested in a Complete Freund’s 
adjuvant (CFA) induced chronic pain rat model. As a control, Laby (10 mg/mL) was 
dissolved in 50:50 ratios of glycofurol and PBS (0.1M, pH 7) and glycofurol alone as 
vehicle. The formulations were administered orally or nasally to rats induced with 
inflammation on its hind paw. Rats that could withstand different pain threshold 
level after subjecting them to Von Frey hairs were recorded. Maximum therapeutic 
effects for nasally administered formulations were observed at early hours  
(Figure 3-30). Both Laby glycofurol and Laby GCPQ B2 nasal formulation 
withstand pain threshold level that was significantly higher than glycofurol (vehicle). 
Significantly higher therapeutic effect was observed between Laby GCPQ B2 
formulation and glycofurol with maximum effect at 40 min and between Laby 
glycofurol formulation and vehicle with maximum effect at 40 and 60 min.  
No significant difference was observed between Laby GCPQ B2 and Laby 
glycofurol nasal formulation.  
The maximum therapeutic effect of orally administered formulations were 
observed at later time points from 60 to 360 min after an initial lag time of around 60 
min for the Laby GCPQ B2 and Laby glycofurol oral formulation (Figure 3-31). 
However, statistical significant difference between Laby GCPQ oral formulation and 
control was only observed at 240 min. No statistically significant difference was 
observed between Laby glycofurol and glycofurol only formulation and between 
Laby GCPQ B2 and Laby glycofurol formulation. 
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Figure 3-30 Pharmacodynamics of Laby GCPQ Nasal formulations. 
(24 h indicates paw withdrawal reaction before administration of CFA. Time point from 0 to 
360 min indicates paw withdrawal reaction after administration of CFA. Formulations were 
administered at time zero. (Subject – SD Rats, Dose – 3 mg/kg of Laby with Glycofurol or 
GCPQ B2, n=6. Two way repeated anova (green house geisser corrected) - Overall 
significant difference between Laby GCPQ B2 and glycofurol only formulation and between 
Laby glycofurol and glycofurol only formulation. ** Laby-GCPQ B2 formulation significantly 
different from control (glycofurol) at time point 40 min. * Laby-glycofurol formulation 
significantly different from control at time point 40 and 60 min). 
 
Figure 3-31 Pharmacodynamics of Laby GCPQ Oral formulation.  
(24 h indicates paw withdrawal reaction before administration of CFA. Time point from 0 to 
360 min indicates paw withdrawal reaction after administration of CFA. Formulations were 
administered at time zero. (Subject – Rats, Dose – 15 mg/kg of Laby with Glycofurol or 
GCPQ B2 and glycofurol only formulations, n=6. Two way repeated anova (green house 
geisser corrected) – Overall significant difference between Laby GCPQ B2 and glycofurol 
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only formulation. ** Laby-GCPQ B2 formulation significantly different from control at time 
point 240 min).  
3.6.7 Pharmacokinetics of Laby GCPQ formulations 
3.6.7.1 Analytical method for quantification of Laby in vivo 
Mass spectrometer parameters such as source, MRM and signal parameters 
were optimized to selectively measure laby in plasma sample.  
3.6.7.1.a Source Optimization 
Source optimization enables optimum dissolvation of samples to maximize 
signal to noise ratio. The source parameters were optimized to maximize the signal 
obtained for the respective Laby and internal standard (pentifylline) fragments 
(Figure 3-32). Each fragment was run under different source conditions of different 
range. The ESI consist of parameters such as drying gas temperature, drying gas 
flow, nebulizer, capillary voltage, nozzle voltage, sheath gas flow and sheath gas 
temperature. The parameter that gives the optimum signal was used to create source 
method.  
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Figure 3-32 Source Optimization of Laby in plasma matrix. Peak area for Laby (blue) and 
internal standard (red) plotted with source parameters plotted on x-axis against 
area under the curve on y-axis. 
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3.6.7.1.b MRM Optimization 
Fragmentor voltage accelerates the compounds to collision cell and collision 
energy fragments the compound of interest (Figure 3-33). Fragment less than a mass 
of 100 produces noise whereas fragments larger than 400 produces poor signal. 
Fragmentor voltage and collision energy optimization is necessary for producing 
better signal with minimum noise.  
 
Figure 3-33 MRM Optimization of Laby in plasma matrix. Peak area for Laby (blue) and 
internal standard (red) plotted with MRM parameters plotted on x-axis against 
area under the curve on y-axis. 
3.6.7.1.c Signal Optimization 
Signal optimization can be further improved by optimizing cell acceleration 
voltage (Figure 3-34) and electron multiplier voltage (Figure 3-35). Cell acceleration 
voltage (CAV) accelerates the fragment out of the collision cell. CAV is important to 
avoid cross talk between analyte and internal standard when two peaks are eluting 
close to each other. 
 
Figure 3-34 Cell acceleration voltage (CAV) for Laby in plasma showing acquisition time on 
x-axis and area under the curve on y-axis 
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Electron multiplier voltage (EMV) multiplies the signal obtained from all the 
parameters mentioned above. EMV can be set between 100 and 400, higher the EMV 
more the signal obtained and vice versa. Increasing the EMV could also increase the 
background noise, which can interfere with peak integration. So an optimum EMV 
parameter was chosen based on the peak resolution. 
 
Figure 3-35 Electron multiplier voltage (EMV) for Laby in plasma showing acquisition time on 
x-axis and area under the curve on y-axis 
3.6.7.1.d Calibration Curve for Laby in plasma 
With the parameters optimized, Laby and pentifylline (internal standard) peak 
were obtained at elution time of 4.46 and 4.8 min (Figure 3-36). Calibration curve 
was plotted with standards ranging from 20 ng/mL to 1280 ng/mL (Figure 3-37). The 
linear equation for the calibration curve was y= 0.0041x+ 0.2111 with R2 = 0.99496.  
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Figure 3-36 Chromatogram for Laby (4.46 min) and Pentifylline (4.8 min) in plasma plotted 
with time on x-ais against area under the curve on y-axis 
 
Figure 3-37  Calibration curve for Laby in plasma with concentrations (20 ng/mL to 1280 ng/mL) 
of Laby (ng/mL) plotted on x-axis against peak area of Laby/IS on y-axis 
The LLOQ for the calibration curve was found to be 20 ng/mL with signal 
five times greater than blank. This method was validated to know if the samples 
could be compared between days and within a day. Samples run between days had 
higher coefficient of variation (> 20%) whereas sample run within a day had CV less 
than 5%. For pharmacokinetic studies, a new standard curve was run every day to 
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compare samples analyzed on different days (Table 3-7). Plasma matrix did not 
interfere with the test analyte as the matrix effect obtained by taking ratio of plasma-
extracted sample to blank sample had CV around 15% (Table 3-8).  
Table 3-7 Validation of Laby Standards (n=3) 
Laby concentrations 
(ng/mL) 
Same sample 
run on same day 
Same sample run 
on different days 
Different 
sample run on 
different days 
LLOQ 20 4.82 27.42 13.67 
Low 80 4.61 21.99 7.94 
Medium 320 2.63 7.42 9.82 
High 1280 3.34 25.86 2.88 
Table 3-8 Plasma Matrix effect 
Laby concentrations  Matrix effect - Laby Matrix effect - Pentifylline 
Low (80 ng/mL) 12.23 11.05 
High (320 ng/mL) 8.96 12.39 
3.6.7.1.e Calibration curve for Laby in Brain tissue sample 
Calibration curve was plotted with standards ranging from 20 ng/g to 640 ng/g 
(Figure 3-38). The linear equation for the calibration curve was y= 0.0036x+ 0.0327 
with R2 = 0.99767. 
 
Figure 3-38 Calibration curve for Laby extracted from brain homogenate with Laby 
concentrations ranging from 20 ng/g to 640 ng/g plotted on x-axis against peak 
area of Laby/IS on y-axis 
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3.6.7.2 Pharmacokinetics of Laby GCP (16%)Q (14%) (B1) formulations in 
plasma – Comparison of oral and nasal formulation 
Laby GCPQ B2 and Laby glycofural formulations exhibited anti nociceptive 
activity in rats. The concentrations of Laby in plasma and brain following oral and 
nasal delivery of Laby GCPQ and Laby glycofural formulations were tested. For 
pharmacokinetics studies, Laby GCPQ B1 oral formulation having similar colloidal 
stability was studied. This is because of the constraints in reproducing GCPQ B2 
polymer of same specifications (palmitoylation -19%, quaternization -12% and 
molecular weight- 12.5 kDa). The pharmacokinetics results were also compared to 
Laby GCPQ B3 oral formulation that has poor colloidal stability in HBSS (pH 7.4). 
This is to understand whether the pH induced aggregation of Laby GCPQ B3 
formulation has any influence on the uptake of laby compared to colloidally stable 
Laby GCPQ B1 formulation. 
Laby GCPQ B1 formulation was compared with Laby GCPQ B3 and Laby 
glycofurol formulation. Concentrations of laby in plasma for Laby-GCPQ B3 
formulation increased at initial time points (30 min, 60 min and 120 min) with a 
maximum concentration of 1042 ng/mL at 120 min time point. The laby 
concentrations subsided at later time points (240 min to 480 min). Next to Laby-
GCPQ B3 formulation, Laby-glycofurol formulation had increasing concentrations 
of laby in plasma from time point 30 min to 240 min. The maximum concentration of 
304 ng/mL was observed for Laby glycofurol at time point 240 min after which the 
concentrations subsided at later time points. Least concentrations of Laby in plasma 
were observed for Laby-GCPQ B1 formulation that increased only to a maximum of 
117 ng/mL at 240 min. Overall significant differences were not observed between 
the treatments, Laby GCPQ B1 formulation and Laby glycofurol formulation 
 (Figure 3-39). However significant differences in Laby concentrations were 
observed between Laby GCPQ B1 and Laby GCPQ B3 formulations at 60 min time 
point. Laby GCPQ B3 formulation was also significantly different from Laby GCPQ 
B3 and glycofurol formulation at 120 min time point.  
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Figure 3-39 Pharmacokinetics of Laby GCPQ B1 & B3 oral formulations against Laby 
glycofurol oral formulation. (Subject – Rats, Dose – 30 mg/kg, repeated 
measure, n=5) Two-way anova - *(p = 0.0398), Laby GCPQ B3 formulation 
significantly different from Laby GCPQ B1 formulation at time point 60 min. ** 
(p= 0.0046), Laby GCPQ B3 formulation significantly different from Laby 
GCPQ B1 formulation at time point 120 min ♯ (p= 0.324), Laby GCPQ B3 
formulation significantly different from Laby glycofurol formulation at time point 
120 min.   
Table 3-9 Pharmacokinetics of Laby Oral Formulations 
Pharmacokinetic 
parameters 
Laby GCPQ B3 Laby Glycofurol Laby GCPQ B1 
AUC (ugh/L) 3207.88 ± 5783.95 1542.18 ± 1707.10 424.34 ± 300.59 
Cmax (ng/mL) 1042.99 ± 874.52 304.82 ± 230.28  117.12 ± 34.24 
Tmax (min) 120  240  240  
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Since, Laby GCPQ B3 oral formulation had higher concentrations in the 
blood compared to Laby GCPQ B1 oral formulation. The pharmacokinetics of Laby 
GCPQ B3 nasal formulation and Laby glycofural formulation were compared.   
Laby GCPQ B3 and Laby glycofurol formulation were compared after nasal 
administration in rats. The concentration of Laby measured from time point  
30 min to 360 min after nasal administration of Laby GCPQ B3 formulations were 
consistently higher (677 to 396 ng/mL) than the concentrations observed for Laby 
glycofurol formulation (418 to 71 ng/mL). For nasal formulations, overall significant 
difference was observed between Laby GCPQ B3 and Laby glycofurol formulation 
(Figure 3-40). The area under curve (AUC), Cmax and Tmax are summarized in 
(Table 3-9) and (Table 3-10). 
 
Figure 3-40 Pharmacokinetics of Laby GC P(21%) Q(8%) B3 Nasal formulation (Subject – 
Rats, Dose – 3 mg/kg, repeated measure, n=5). Two way anova- (p = 0.0490), 
Laby GCPQ B3 formulation significantly different from Laby glycofurol 
formulation.   
Table 3-10 Pharmacokinetics of Laby Nasal Formulations 
 Laby Glycofurol Laby GC P(21%) Q(8%) B3 
AUC (ugh/L) 1346.59 ± 981.56 3390.76 ± 1515.54 
Cmax (ng/mL) 418.65 ± 126.23  795.38 ± 137.13 
Tmax (min) 30  60  
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3.6.7.3 Pharmacokinetics of Laby GCPQ B3 formulations in Brain tissue sample 
To understand whether Laby exhibit peripheral or central action, distribution 
of Laby in brain following nasal and oral administration were studied. No detectable 
Laby peak was observed in the brain tissue sample for Laby GCPQ formulations 
administered nasally or orally.   
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3.7  Discussion  
GCPQ is an amphiphilic polymer that has been reported to solubilize 
hydrophobic drugs by micelle formation. Small molecular weight hydrophobic drugs 
and peptide such as cyclosporine [146], amphotericin B [153] and its pro drug form 
of leucine enkephalin (LENK) called TP-LENK [53] has been previously 
encapsulated with GCPQ. The resulting micelles had shown improved oral 
availability and therapeutic effect in vivo in rats and murine model.  
In this study, poorly soluble labyrinthopeptin peptide was formulated with 
GCPQ to improve its oral bioavailability and the therapeutic effect of the peptide. 
GCPQ of three different batches were formulated with Laby and characterized in 
vitro and in vivo. Laby GCPQ B1 and Laby GCPQ B2 were prepared by old method 
of synthesis and GCPQ B3 was prepared by new method of synthesis. Their in vitro 
and in vivo results within and between the different methods of synthesis were 
compared. 
From the solubility data, it was known that Laby has poor solubility in 
physiological saline (0.6 mg/mL). In order to improve the solubility of Laby in 
aqueous solution, Laby was formulated with GCPQ. Firstly, the minimum 
concentration of GCPQ that is required to solubilize Laby was evaluated by keeping 
the Laby concentration constant (2.5 mg/mL) and by adding different concentrations 
of GCPQ in water. Weight ratios of Laby to GCPQ (from Laby GCPQ of 1:1 to 1:5) 
was used and evaluated by TEM.  
Laby GCPQ B2 formulation at different ratios was characterized. TEM 
analysis shows that at peptide polymer ratio 1:1, large aggregates (0.9 to 2 µm) and 
particles (20 to 750 nm) were formed (Figure 3-8). However, increasing the GCPQ 
concentration in the formulation with ratios ranging from, 1:2 to 1:5, resulted in no 
micron sized aggregates (Figure 3-9, Figure 3-10, Figure 3-11, Figure 3-12). In DLS, 
only small particles (around 20 nm) were observed at any given ratios. Laby GCPQ 
B2 formulation of ratio 1:3 also produced least PDI of 0.382 compared to PDI of 
other Laby GCPQ ratios, such as; 1:1, 1:2, 1:4 and 1:5 that were larger than  
0.4 (Figure 3-13). This ratio (1:3) is observed to be lower than previous oral 
formulations made at 1:5 ratios [53]. For further studies Laby GCPQ formulation 
prepared at weight ratio 1:3 were used. 
The above Laby GCP (19%) Q (12%) (B2) formulation prepared at ratio 1:3 
was also compared with Laby GCPQ B1 and B3 formulation, Laby and Laby PGC 
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formulation (Figure 3-15). GCPQ with low palmitoylation of 16% had particle sizes 
analysed by DLS was observed to be significantly higher (572 nm) than the size of 
Laby GC P (19%) Q(12%) B2 formulation with size 13.43 nm and Laby GC P (22 
%) Q(8%) B3 formulation with size 84 nm. The size characterization of different 
batches of GCPQ with different degree of palmitoylation follows a trend with low 
palmitolation GCPQ forming large particles (572 nm) and the particle size reduces 
down to 11 nm with GCPQ of degree of palmitoylation 19%. Further increase in 
palmitoylation (22%) induces aggregation of Laby GCPQ nanoparticles to size 
around 84 nm. TEM image also suggest that these large particles are aggregated from 
small particles and appears dense (Figure 3-18).  
Particle sizes of Laby GCPQ formulations were also compared with Laby-
PGC formulations by DLS (Figure 3-15). At any given ratio (1:3), Laby PGC 
formulations formed particles around 200 nm, when analysed by DLS immediately 
after probe sonication. However, the particles precipitated within one hour. This 
suggests that quaternization is important for maintaining the stability of GCPQ 
nanoparticles. 
GCPQ has better solubility than its preceding chitosan based polymers due to 
the presence of quaternary ammonium group that remains charged independent of 
the pH of their solution. Surface charge of laby GCPQ B1, B2 & B3 formulation 
increased with increase in the quaternization of the GCPQ polymer. Laby GCPQ B1 
formulation with the highest quaternization of 14% had zeta potential of +48mV 
followed by Laby GCPQ B2 (Q-12%) and B3 (Q-8%) formulation with zeta 
potential of +46 mV and +39.8 mV respectively (Figure 3-19). The surface charge of 
Laby GCPQ formulations was observed to be much higher than Laby PGC (+10 mV) 
or Laby only formulation (-34.6 mV). The lower surface charge of Laby PGC 
formulation could be the reason for aggregation and precipitation of the formulation. 
A change in the negative zeta potential of laby from -34.6 mV to above + 39mV with 
any GCPQ polymer of B1, B2 and B3 suggest that the peptide was encapsulated in 
the GCPQ polymer.  
Laby GCPQ nanoparticles that were characterized by size and charge were 
also estimated to know the peptide loading efficiency of the polymer. Encapsulation 
efficiency of hydrophobic drug is determined by hydrophobicity of polymer. GCPQ 
batches B1, B2 and B3 having degree of palmityolation 16%, 19% and 22% had 
encapsulation efficiency of around 89% (Figure 3-23). It was previously reported 
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that the drug (propofol) incorporation with GCPQ nanoparticles was reported to be 1 
order magnitude higher than it was seen with pluronic block copolymer [134]. Kim 
et al reported an encapsulation efficiency of 85% for hydrophobic RGD peptide 
loaded in to HGC (hydrophobic modified glycol chitosan) nanoparticles [232].  
The colloidal stability of Laby GCPQ B1, B2 and B3 formulation in 
simulated gastric medium, simulated intestinal medium and HBSS was 
characterized.  
Laby GCPQ B1 formulation that had particle size around 572 nm, reduced in 
size to 140 nm in SGF or less (20 nm) in SIF and HBSS. The size of Laby GCPQ B2 
formulation remains same (20 nm) after dilution in SGF, SIF and HBSS. At a given 
pH, 1.2 (SGF), 6.8 (SIF) and 7.4 (HBSS), the formulations were observed to be 
colloidally stable (Figure 3-24, Figure 3-26, Figure 3-28). In vitro results suggest that 
Laby GCPQ B1 and B2 formulation in simulated medium has similar characteristics.  
However, when the Laby GCPQ B3 formulation was dispersed in simulated 
medium, polymer synthesized by new method (GCPQ B3) exhibited different 
colloidal stability compared to polymers synthesized by old method (GCPQ B2).  
In SGF (Figure 3-24), Laby GCPQ formulation B3 was stable for at least 2 h. Their 
stability in SGF is due to the protonation of amines in acidic pH. However, Laby 
formulation with GCPQ B3 synthesized by new method aggregated in 
SIF (pH 6.8) (Figure 3-26) and precipitated in HBSS (7.4) within 4 h (Figure 3-28). The 
major differences between the two methods of GCPQ synthesis were that the 
polymer (GCPQ B3) obtained by new method was more polydisperse (2.5), which 
could be due to the aggregation of polymer as a result of their hydrophobic and 
hydrophilic characteristics. Laby GCPQ B3 formulation had degree of palmitoylation 
of 22% higher than the palmitoylation percentage of Laby GCPQ B1 and B2 
formulation. It was previously reported that polymer hydrophobicity has influence on 
aggregation of GCPQ polymer [134]. This could be the cause for aggregation of 
Laby GCPQ (new method - B3) nanoparticles in SIF and HBSS. The degree of 
quaternization of Laby GCPQ B3 formulation was also observed to be lower (8%) 
than it was for GCPQ polymer B1 (14%) and B2 (12%) formulation. Laby GCPQ B3 
formulation in SIF and HBSS resulted in aggregation due to deprotonation of GCPQ 
polymer at alkaline pH when the quaternization was only 8%. As the Laby GCPQ B1 
and B2 formulation had similar colloidally stability at different simulated medium, 
pharmacodynamics was studied on one of the formulations.  
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Previously reported laby formulation was intravenously administered at a 
dose of 3 mg/kg on spared nerve injury mouse model of neuropathic pain.  
The efficacy was stable over a period of 6 h and disappeared completely after 
24 h [226]. The dose of Laby GCPQ oral formulation (15 mg/kg) was improved by 5 
folds compared to laby intravenous formulation (3 mg/kg) [226]. For in vivo, 
pharmacodynamics of Laby GCPQ B2 formulation was tested by non-invasive 
methods such as nasal and oral administration. Laby GCPQ B2 formulation was 
tested against Laby glycofurol and glycofurol formulations. Laby dissolved in 
glycofurol was used as a control. Laby GCPQ B2 formulation exhibited significant 
therapeutic effect at later time point (240 min) following oral administration (Figure 
3-39). However, nasal administration of Laby GCPQ B2 and Laby glycofurol 
formulation exhibited significant therapeutic effect at earlier time points (40 and 60 
min) (Figure 3-40). This therapeutic effect was observed to be short lived compared 
to previously made laby intravenous formulation, which had significant therapeutic 
effect lasting for 6 h from the time of administration [226]. These data suggest that 
prolonging the circulation time of Laby GCPQ nanoparticles during systemic 
circulation can improve the therapeutic effect of Laby GCPQ formulation.  
It was previously reported that nasal administration of glycofurol leads to 
enhanced and prolonged absorption of T1 peptide [233]. The therapeutic effect 
observed with Laby glycofurol oral formulation could be due to the permeation 
enhancing characteristics of glycofurol itself. No therapeutic effect was observed for 
glycofurol only formulation.  
Pharmacokinetics was only tested on Laby GCPQ B1 formulation due to 
constraints in reproducing Laby GCPQ B2 polymer with same specification. Here 
the comparison between two formulations i.e Laby GCPQ B2 pharmacodynamic 
data and Laby GCPQ B1 pharmacokinetic data were based on the in vitro results 
that, both the formulations were identical. Also the dose of Laby in glycofural or 
GCPQ oral formulations used in pharmacokinetics studies were twice (30 mg/kg) 
that of the concentrations used for oral pharmacodynamics studies (15 mg/kg). Oral 
dosages of Laby GCPQ B1 and Laby glycofurol were increased in order to detect 
measurable quantities of laby following oral administration. On the contrary, poor 
concentrations of Laby in blood were observed for Laby GCPQ B1 formulation 
(Figure 3-39). The formulation was also observed to be insignificant to Laby 
glycofurol formulation. It could be possible that the laby GCPQ B1 nanoparticles are 
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cleared faster from blood and distributed in the tissue. Bio-distribution studies for the 
above formulation have to be carried out in the future. Also, Laby GCPQ B1 
formulation had lower palmitoylation percentage (16%) compared to Laby GCPQ B2 
formulation (19%) that shows therapeutic effect in pharmacodynamic studies. 
 Pharmacokinetics of Laby GCPQ B3 oral formulation was also compared to 
Laby GCPQ B1 formulation to understand if pH induced aggregation of Laby GCPQ 
B3 in simulated medium has any influence on the uptake of Laby across the gut. 
Pharmacokinetics of Laby GCPQ B3 formulations was tested in vivo after oral and 
nasal administration. Laby GCPQ B3 oral formulations exhibited higher 
concentrations of Laby in plasma at earlier time points that are significantly different 
from laby GCPQ B1 at 1 and 2 h and from Laby glycofurol at 2 h (Figure 3-39). This 
was observed to be similar to pharmacokinetics of oral dose of gabapentin in rats that 
showed maximum concentration in plasma within 1 to 3 h after administration and 
eliminated between 2 to 3 h [234]. The hydrophobic nature of GCPQ B3 polymer 
(palmitoylation- 22%) could have resulted in enhanced absorption of laby GCPQ B3 
formulation across the enterocytes. Hang et al reported that polymer hydrophobicity 
has positive effect on oral absorption of cyclosporine- poly(ethylenimine) 
nanoparticle [135]. Effect of palmitoylation on oral absorption of GCPQ nanoparticle 
could be studied in future.  
It could also be possible that the interaction between quaternary ammonium 
group of GCPQ and mucus membrane had an effect on uptake of Laby GCPQ 
nanoparticles across the enterocytes. Chitosan and chitosan derived polymers are 
mucoadhesive in nature where the positively charged amines in chitosan polymers 
interact with negatively charged carboxyl or sulphate group of mucin proteoglycan 
polymer [235]. Wang et al reported that cationic nanoparticles at higher 
concentration could collapse mucus gel forming large channels that increases the 
bioavailability of target drugs [236]. This could be the reason for Laby GCPQ B3 
formulation (P 21% and Q 8%) showing better concentration of Laby in plasma.  
However, this was not the case with respect with Laby GCPQ B1 
formulation, which has degree of quaternization of 14%. One possible hypothesis is 
that GCPQ B1 with high quaternization of 14% could have bound to negatively 
charged mucin polymers and excess positive charge could have resulted in 
detangling of mucin polymers due to electrostatic repulsion. This results in removal 
of outer mucus layer along with bound nanoparticles during gastrointestinal transit. 
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The effect of different quaternization of GCPQ on mucus could be studied in the 
future. 
Since, the concentrations of Laby for Laby GCPQ B3 oral formulations were 
higher than Laby GCPQ B1 formulation, pharmacokinetic studies were only carried 
out in Laby GCPQ B3 and Laby glycofural nasal formulations. Laby GCPQ B3 nasal 
formulation also exhibited significantly higher laby concentration in plasma 
compared to Laby glycofurol formulation. No detectable Laby concentrations were 
observed in brain after nasal or oral administration. This suggests that Laby could 
have acted peripherally to exhibit analgesic effect.  
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3.8  Summary and future work 
For the first time, an oral formulation of labyrinthopeptin was prepared using 
GCPQ nanoparticle. The solubility of Laby in aqueous solution was improved  
10 times using GCPQ nanoparticles with better loading efficiency. Therapeutic effect 
of Laby GCPQ and Laby glycofurol formulation was demonstrated in rat CFA model 
following oral and nasal administration. High degree of palmitoylation and low 
quaternization GCPQ polymer could have an effect on the uptake of Laby GCPQ 
formulation across the enterocytes. Also anti nociceptive action of laby glycofurol 
formulation was observed due to penetration enhancing properties of glycofurol.  
In future, it is important to understand the uptake of Laby GCPQ 
formulations from different palmitoylation GCPQ polymers following oral 
administration. Since it was observed that high palmitoylation GCPQ polymer has 
better concentration of Laby in plasma compared to low palmitoylation GCPQ 
following oral administration, it would be interesting to observe if the 
pharmacodynamics of Laby GCPQ B3 (P 21% and Q 8%) formulation shows better 
therapeutic effect compared to Laby GCPQ B2 (P 19% and Q 12%) formulation. 
Further, differences in the uptake mechanism of low and high palmitoylation GCPQ 
polymer and their respective Laby GCPQ formulations could be studied in vitro. 
Laby GCPQ B1 and B3 formulation also had different degree of quaternization of 
14% and 8% respectively. It was hypothesized that the degree of quaternization has 
effect on interaction of Laby GCPQ nanoparticles with the mucus and hence their 
differences in the bioavailability of Laby. The interaction of Laby GCPQ formulation 
having different degree of quaternization and palmitoylation with the mucus should 
be studied in the future. Laby concentrations were not observed in brain. However, 
its concentration in spinal cord can be measured to understand if Laby has peripheral 
or central action. Further, tolerance to Laby GCPQ formulations could be tested 
against control such as morphine.  
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4 Oral Delivery of Methionine Enkephalin peptide for the treatment of 
pancreatic cancer 
4.1  Objective 
The objective of this chapter is to, 
1. Characterize MENK peptide for size and critical micellar 
concentration.  
2. Formulate MENK-GCPQ (B1 & B2) IV and oral formulation by 
various methods. 
3. Characterize MENK-GCPQ (B1 & B2) IV and oral formulation for 
size, charge, encapsulation efficiency and colloidal stability.  
4. Evaluate the pharmacokinetics of MENK-GCPQ oral and IV 
formulations. 
5. Evaluate the pharmacodynamics of MENK-GCPQ oral and IV 
formulation in mice tumour xenograft model. 
4.2  Met-Enkephalin (MENK) 
Met-enkephalin is an endogeneous pentapeptide with amino acid sequence 
YGGFM (Figure 4-1). The peptide was first discovered and characterized by 
Hughes, Kosterlitz, et al. in 1975 [237]. Met-enkephalin has various role in 
physiological process as analgesic [238], as immune modulators [239] and as growth 
regulators [240].  
 
Figure 4-1 2-D structure of Methionine Enkephalin 
4.2.1 Biosynthesis of MENK 
MENK is produced by proteolytic cleavage of proenkephalin, a precursor 
peptide hormone [241]. Proenkephalin is converted to an intermediate upon action of 
endopeptidases. This intermediate is further cleaved by carboxypeptidases to 
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methionine enkephalin [242] [243]. Each proenkephalin produces four copies of 
Met-enkephalin, one copy of leu-enkephalin and two copies of extend Met-enkephalin 
[244]. The enkephalins are stored in synaptic vesicles and released into synapse 
where they bind to Mu (µ) and delta (δ) opioid receptor where they modulate pain [245]. 
4.2.2 Methionine Enkephalin as analgesic 
Met-enkephalin (MENK) is an endogeneous penta-peptide distributed in 
adrenal medulla, central nervous system and dorsal horn of the spinal cord [246]. 
MENK binds to opioid receptors such as Mu (µ)-receptor and delta (δ)-receptor to 
exhibit analgesic effect [247]. Met-enkephalin has high affinity for δ receptor and 
low affinity for µ receptor [248]. The opioid receptors are G-protein coupled 
receptors located mostly on prejunctional neurons. The activation of opioid receptors 
(µ & δ) reduces intracellular cAMP formation and opens K+ channels. These action 
causes neuronal hyperpolarization resulting in reduced availability of intracellular 
Ca2+ ions, which further decreases neurotransmitter release from CNS leading to 
analgesia [248].  
4.2.3 MENK as immunomodulators 
MENK also act as immunomodulators. MENK binds to delta (δ)-receptor on 
immune cells such as T cell [249], natural killer cells [250], dentritic cells (DCs) 
[251] and macrophage [252]. MENK was reported to exert positive modulation to 
pathway between dentritic cells (DCs) and CD4+ T cells [239]. The pathway 
between DCs and CD4+ T cells is important in maintaining balanced immunity in 
the body and its role in fighting against cancer and diseases like AIDS. MENK was 
reported to induce maturation of DCs by addition of surface molecules such as MHC 
class II, CD86 and CD40 on murine DCs, production of IL-2 and the down-
regulation of ACP inside DCs. MENK alone or in combination with IL-2 or IFN- γ 
also reported to CD4+ T cell expansion and CD4 molecule expression [239].  
4.2.4 MENK as cell growth regulator 
MENK also acts on zeta (ζ)-receptor and are known to regulate cell growth 
and tissue regeneration. Hence MENK is also called as the opioid growth factor 
(OGF) and zeta (ζ)-receptor is called opioid growth factor receptor (OGFr) [253]. 
The action of MENK is tonic, stereospecific, reversible, non-cytotoxic and non-
apoptotic. Further, MENK activity is not associated with differentiative, migratory, 
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and invasive or adhesive processes, anchorage-independent and occurs at 
physiologically relevant concentration [254].  
The mechanism by which OGF exhibits anti-proliferative action on cancer 
cells is illustrated (Figure 4-2). OGF binds to OGFr presented on the nuclear 
membrane [255]. The up-regulation of OGFr induces the expression of P21 (cell 
cycle suppressor), a cyclin-dependant kinase inhibitor. P21 complexes with cyclin 
dependant kinase (CDK2) and further prevents phosphorylation of retinoblastoma 
protein (Rb) protein which normally interact in the presence of CDK2. The free Rb 
protein inhibits the dimerization of E2F transcriptional factor (E2F dimers are 
responsible for progression of cell cycle from G1 to S phase) leading to negative 
control of cell growth [255].  
 
Figure 4-2 MENK Pathway 
CKIs are deficient in cancer cells particularly p16ink4a and p21WAF1/CIP1. 
Both p16ink4a and p21WAF1/CIP1 up regulation are required for OGF inhibitory 
action in normal cells where as up regulation of one of the CKIs are sufficient for 
OGF action on cell cycle of cancer cells [256]. It has also been postulated that cancer 
cells that regulates cell cycle by OGF pathway have adapted by depending on only 
one of CKIs [255]. 
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4.2.5 MENK for cancer therapeutics 
According to Cancer Research UK, pancreatic cancer account for 3% of all 
new cases in the UK as of 2012 [257]. It is the tenth most common cancer in the 
country.  Around 104,000 people in Europe and around 338,000 people worldwide 
were diagnosed with pancreatic cancer in 2012. The disease can be diagnosed only at 
its advanced stage and it is the main reason for treatment failure. Once diagnosed, 
around 4% of pancreatic cancer patients survive the disease for five years or more 
[257]. In England and Wales, during the year 2010-2011, the net survival of patients 
diagnosed with pancreatic cancer is 20.8% (1-year survival), 3.3% (5-year survival) 
and 1.1% (10-year survival) [257].  
Treatment options for pancreatic cancer include surgical intervention and 
chemotherapy or radiation [258]. However, with the disease being diagnosed at later 
stage, it will not be cured with resection. Gemcitabine is the first line therapy for 
patient with advanced pancreatic cancer. However the survival time is only  
5.65 months [259]. 
The anti-proliferative action of MENK was observed in vitro in various 
pancreatic cancer cell lines such as capan-1, BxPC-3, MiaPaCa-2 and Panc-1. It has 
also been observed that there was a marked delay in tumor appearance in the nude 
mouse pancreatic xenograft model [166]. A phase II clinical trial was conducted to 
test the efficacy of MENK in patients who had failed to respond to standard therapy 
for advanced pancreatic cancer. Intravenous administration of MENK, weekly twice 
at a dose of 250 µg/kg resulted in prolonged survival in patients by stabilizing the 
disease or slowing progression compared to historical controls like gemcitabine and 
5-fluorouracil [260].  
4.2.6 Challenges in oral delivery of MENK 
Met-enkephalin is a small molecular weight pentapeptide, with molecular 
weight 573 Da and an isoelectric point of 5.3 [261]. As Met-enkephalin has only anti 
proliferative action but not cytotoxic, standard therapy requires repeated intravenous 
administration of the peptide, which can be patient noncompliant [262]. Moreover, 
met-enkephalin is degraded by enkephalinases such as aminopeptidase N, 
endopeptidase, dipeptidyl peptidase 3, carboxypeptidase A6 and angiotensin 
converting enzyme [263]. More over the half-life of MENK in plasma is 12.8 min 
[264]. Their poor stability results in low bioavailability making it a poor candidate 
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for oral delivery. The aim of this study is to enhance the oral delivery of MENK 
using GCPQ nanoparticles. 
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4.3  Materials and Methods 
4.3.1 Materials 
Chemical Supplier 
Methionine Enkephalin Bachem, USA 
Dalargin Bachem, USA 
Glacial acetic acid Fisher, UK 
Acetonitrile (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Acetonitrile (HPLC grade) Sigma-Aldrich (Gillingham, UK) 
Trifluoroacetic acid (99%) Sigma-Aldrich (Gillingham, UK) 
Formic acid (⪰ 95%) Sigma-Aldrich (Gillingham, UK) 
Water (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Ammonium hydroxide Fisher, UK 
Sodium chloride Sigma-Aldrich (Gillingham, UK) 
Methanol (LCMS grade) Sigma-Aldrich (Gillingham, UK) 
Hydrochloric acid Fisher, UK 
Sodium hyaluronate Lifecore Biomedicals, USA 
L-Glutamine Invitrogen, UK 
Fetal bovine serum Invitrogen, UK 
Sodium hydroxide Sigma-Aldrich (Gillingham, UK) 
Monobasic potassium 
phosphate 
Sigma-Aldrich (Gillingham, UK) 
DMEM medium Invitrogen, UK 
Sephadex G-25 Fisher, UK 
Matrix gel BD Biosciences, Bedford, MA, USA 
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4.3.2 Methods 
4.3.2.1 Characterization of MENK peptide 
MENK having an isoelectric point of 5.3 can aggregate at pH close to 5.3. 
The aggregation behavior of MENK was characterized qualitatively and 
quantitatively by TEM and ITC. TEM gives an indication on the morphology of 
MENK aggregates and ITC suggests at what concentrations MENK forms micelles.  
a) TEM 
MENK acetate salt of different concentrations (5, 10 and 20 mg/mL) were 
prepared in water and characterized by TEM. 
b) CMC of MENK peptide by Isothermal titration Calorimetry 
To accurately determine the CMC of MENK free base, MENK acetate salt 
was purified from its acetate form by neutralization with a base. The MENK peptide 
(1.8 mmol) was added to ammonium hydroxide (40 mL, 1M) and incubated for  
30 min at room temperature. The reaction mixture was freeze dried to remove 
volatile ammonium acetate.  
ITC is used to understand self-association of colloids, using a demicellization 
experimental approach. It measures the changes in enthalpy when micelles first 
disassociate and re-associate above its critical micellar concentration in a diluent. 
The experiment involves stepwise titration of a micellar solution in a reaction cell 
containing diluent at a particular temperature to give the change in heat flow versus 
time. The reaction enthalpy is calculated by integrating the heat flow obtained during 
each titration. The first order derivative of reaction enthalpy versus the monomer 
concentration gives their CMC.  
The CMC of MENK free base was determined by isothermal titration 
calorimetry (ITC) [265] [266] [267]. Micellar solutions of free MENK were prepared 
at a concentration of 10 mg/mL in water. Before analysis, MENK solution and its 
diluent (water) were degassed using a vacuum pump for 10 min. The reaction cell, 
diluent cell and the syringe were also washed with 10% decon and water.  
The MENK micellar solution was loaded into the syringe and inserted into the 
reaction cell containing water. The demicellisation experiment was carried out by 
titrating 50 injections of 5uL aliquots of pure MENK (17.4 mM) at temperature 25˚C 
with water. The heat flow during the demicellisation process was measured as a 
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function of time, and the peak obtained during each titration was integrated to give a 
sigmoid curve. The CMC was obtained by derivatization of reaction enthalpy against 
the MENK concentration [267]. Thermodynamics parameters such as the enthalpy of 
demicellisation (ΔHdemic), Gibbs free energy change (ΔGdemic) and the entropy 
change (TΔSdemic) can be derived from ITC experiment [266]. The enthalpy of 
demicellisation can be calculated directly from the enthalpogram by taking the 
difference between the enthalpy after the first and last injection of the sample 
(ΔHdemic). The Gibbs free energy change (ΔGdemic) is calculated from the equation,  
ΔGdemic = RT ln (CMC) 
Where, R = gas constant (8.3144 Jmol-1 K-1), T= temperature in K (25˚C = 298 K) 
and CMC in mole fraction units. The entropy change (TΔSdemic) can be obtained by 
the equation, 
TΔSdemic = ΔHdemic - ΔGdemic 
4.3.2.2 MENK GCPQ Formulation 
MENK GCPQ B2 formulations were prepared and characterized by different 
methods.  
4.3.2.2.a Solubility method  
 MENK and GCPQ is solubilized first and brought to the pH of the isoelectric 
point of MENK. It is hypothesized that MENK can aggregate at the pH of the 
isoelectric point and form particles with GCPQ. This hypothesis is tested at two 
ratios; 1:2.6 for MENK-GCPQ (B1) IV formulation and 1:5 for MENK GCPQ (B2) 
oral formulation. The ratios and concentrations used for IV and oral formulations 
were based on formulations previously made using LENK and GCPQ [53].  
Preparation of MENK GCPQ B1 IV formulation: The intravenous formulation of 
MENK (5 mg/mL) and GCPQ (13 mg/mL) of mass ratio 1:2.6 were prepared by first 
dissolving MENK in 30% acetic acid and GCPQ in 0.9% NaCl. The MENK and 
GCPQ solutions were added together and the pH was increased to 5.6. The formulation 
was probe sonicated (MSE sonicator, UK) for 15 min at 15 amps in the presence of 
ice.  
As a control, MENK IV formulation was prepared by same method without 
adding GCPQ. 
Preparation of MENK-GCPQ oral B2 formulation: MENK-GCPQ oral formulation 
was prepared as method mentioned in section 4.3.2.2.a of mass ratio 1:5 using 
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concentrations 10 mg/mL of MENK and 50 mg/mL of GCPQ. As a control, MENK 
oral formulation was prepared by same method without adding GCPQ. 
4.3.2.2.b Direct reconstitution without probe sonication 
This method involves direct reconstitution of MENK and GCPQ B1 in water 
to evaluate whether the MENK-GCPQ B1 particles are formed by hydrophobic 
interaction. 
MENK (10 mg) and GCPQ B1 (30 mg) were added to 1 mL of water and 
vortexed until a clear dispersion was obtained. The pH of the formulation was 
adjusted to 6 and characterized.  
4.3.2.2.c Film method 
 It is hypothesized that the peptide and GCPQ B1 are at close proximity and 
forms particles when reconstituted in water. MENK solution was prepared by mixing 
MENK (10 mg) in methanol (500 µL) and glacial acetic acid (72 µL). GCPQ (50 
mg) was solubilized in methanol (500 µL). The GCPQ B1 and MENK solution were 
mixed and dried in a rotary vacuum evaporator at 37˚C until a thin film was formed.  
The formulation was freeze-dried to remove methanol completely.  
 After 48 h, the freeze-dried product was reconstituted in water and vortexed 
until a homogeneous formulation was obtained. The pH of the formulation was 
adjusted to 6 and characterized.  
4.3.2.2.d Preparation of MENK-GCPQ B1 formulation by complex co-acervation 
method 
Complex coacervation is a process where oppositely charged molecules 
complex due to electrostatic interaction. Since MENK and GCPQ B1 are like 
charged below neutral pH, MENK was first complexed with anionic polymer 
followed by complexation with cationic GCPQ B1 polymer. The particles thus 
formed were size characterized.  
A stock solution of MENK (25 mg/mL) was prepared in 30% acetic acid. 
Hyaluronic acid (HA) at a concentration 34.8 mg/mL of different molecular weights 
4.7 kDa, 16 kDa and 35 kDa was prepared in water. MENK (2.5 mg/mL) and HA 
complexes were mixed at molar ratios (1:0.001, 1:0.01, 1:0.1, 1:1 and 1:10). The size 
and PDI of MENK-HA complexes with each HA molecular weight were 
characterized. 
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After screening for desired molecular weight of HA, size, stability and zeta 
potential of MENK-HA (16 kDa) complexes of molar ratios ranging from 1:0.0005, 
1:0.001, 1:0.002, 1:0.004, 1:0.008, 1:0.02, 1:0.04, 1:0.08 and 1: 0.1) were also 
characterized. 
MENK-HA (16 kDa) complexes prepared at molar ratios 1:0.04 were 
formulated with GCPQ B1 at different mass ratios (1: 1.25, 1: 2.5, 1:5 and 1:10) and 
size characterized before and after probe sonication.  
4.3.2.3 Characterization of MENK and MENK-GCPQ formulations 
4.3.2.3.a TEM 
The morphology of MENK GCPQ (B1 & B2) formulations was determined 
using transmission electron microscope (Philips CM 120 Bio Twin Transmission 
electron microscope) with an AMT digital camera (5 mega pixels; AMT Deben, UK 
Ltd).  
A drop of MENK GCPQ (B1 & B2) formulation was placed on a grid and blotted 
with a tissue paper. A drop of uranyl acetate (1% w/v) staining solution was also 
added to the grid and TEM images were recorded.  
4.3.2.3.b Particle size 
The particle sizes of MENK GCPQ (B1 & B2) formulations were 
characterized by dynamic light scattering (DLS) technique (Malvern Zetasizer Nano 
ZS ZEN3600, Malvern Instruments Ltd, Worcestershire, UK). Formulations (1 mL) 
were dispensed into a low volume disposable cuvette and size distribution graphs 
were recorded. 
4.3.2.3.c Charge 
The zeta potential of MENK GCPQ (B1 & B2) formulations was measured 
using the diffusion barrier technique. MENK oxidizes on interaction with metal 
electrodes. Diffusion barrier technique involves isolation of small sample volume 
from the electrode in order to prevent denaturation of protein at the electrodes [268]. 
Sample diluent (NaCl -10 mM, 800 µL) was added in a zeta cell. Each MENK 
GCPQ formulation (200 µL) was added to the bottom of the cell and the zeta 
potential was characterized by DLS. 
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4.3.2.4 Encapsulation efficiency of MENK GCPQ (B1 & B2) formulation 
Encapsulation efficiency of the MENK GCPQ (B1 & B2) formulations were 
determined by centrifugation and column chromatography method.  
4.3.2.4.a Method 1 
Encapsulation efficiency MENK GCPQ (B1 & B2) formulations were 
determined by centrifugation method. Sample aliquots (20 µL) were withdrawn from 
the formulation, before and after centrifugation and quantified by HPLC.  Following 
centrifugation, it was expected that the MENK-GCPQ nanoparticles remains in the 
supernatant and the large MENK particles forms a pellet. For encapsulation 
efficiency, MENK GCPQ formulations were centrifuged at 5000 RPM for 10 min at 
room temperature. The supernatant of each formulation (20 µL) was diluted in 
mobile phase (980 µL) and analysed by HPLC. The encapsulation efficiency of the 
formulation was calculated by formula,  %  Encapsulation  efficiency     =    Concentration  of  MENK  after  centrifugationConcentration  of  MENK  before  centrifugation×100 
4.3.2.4.b Method 2 
Encapsulation efficiency of MENK-GCPQ B2 formulation was also 
determined by column chromatography method. Here, the column is packed with 
cross-linked dextran matrix with an exclusion limit of 5000 Da. It was hypothesized 
that non-encapsulated MENK with molecular weight of 573 Da passes through the 
pores of the matrix, whereas MENK encapsulated in GCPQ B2 with a molecular 
weight of 12 kDa avoid the pores of the bead and elute earlier. The differences in the 
elution time of unencapsulated MENK and encapsulated MENK was used to 
determine the encapsulation efficiency of MENK-GCPQ B2 formulation.  
The sephadex G-25 was reconstituted in water (1g/5 mL) and allowed to 
swell for 1 h at 90˚C and was then packed in a glass column. The column was loaded 
with samples of MENK or MENK-GCPQ B2 formulations (100 µL, 10 mg/mL). A 
volume of water was gradually added without disturbing the sephadex particles and 
the flow-through was collected every 3 min (2 mL volume approx). The water level 
was maintained at a constant level throughout the experiment to achieve a consistent 
flow rate. Sixty fractions were collected and the MENK content quantified by HPLC 
was plotted against the number of fractions. Encapsulation efficiency is determined 
by taking the ratio of total concentrations of fractions under each peak for MENK-
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GCPQ B2 formulation to the total concentrations of fractions under a single peak for 
MENK formulations. 
4.3.2.5 Enzymatic Stability of MENK GCPQ B2 formulations 
MENK-GCPQ B2 formulations were characterized to know if the GCPQ 
protects MENK peptide against enzymes in the gastrointestinal tract. 
4.3.2.5.a SGF 
SGF solution was prepared by dissolving sodium chloride (2 g) in water  
(500 mL). The pH of the solution was adjusted to 1.2 with HCl (7 mL) and made up 
to 1000 mL with water. 
MENK-GCPQ B2 nanoparticles (5 mg/mL, 500 µL) and MENK peptide 
solution (5 mg/mL, 500 µL) was incubated in simulated gastric fluid (SGF) or rat 
intestinal wash (4.5 mL) at 37˚C in a water bath rotating at 125 rpm. Samples (100 
µL) were withdrawn at different time points (0, 0.5, 1 and 2 h), diluted in mobile 
phase (900 µL) containing 16% acetonitrile: 85.98% water: 0.02% TFA and analysed 
by HPLC.  
4.3.2.5.b SIF 
SIF solution was prepared by dissolving monobasic potassium phosphate  
(6.8 g) and sodium hydroxide solution (0.2N, 77 mL) in water (250 mL). The pH of 
the solution was adjusted to 6.8 with sodium hydroxide (0.2 N) or hydrochloric acid 
(0.2 N) and finally diluted to 1000 mL. 
MENK-GCPQ B2 nanoparticles (5 mg/mL, 500 µL) and MENK peptide 
solution (5 mg/mL, 500 µL) was incubated in simulated intestinal fluid (SIF) (4.5 
mL) at 37˚C in water bath rotating at 125 rpm. Samples (100 µL) were withdrawn at 
different time points (0, 0.5, 1, 2 and 4 h), diluted in mobile phase (900 µL) 
containing 16% acetonitrile: 85.98% water: 0.02% TFA and analysed by HPLC.  
4.3.2.6 Quantification of MENK by HPLC 
4.3.2.6.a Preparation of Stock and Working standards 
MENK was quantified using high-performance liquid chromatography 
(HPLC). A stock solution of MENK was prepared by dissolving the peptide  
(2 mg/mL) in acetic acid (30% v/v). Calibration standards were prepared by diluting 
stock solution to working standards (S1 to S8) of concentrations ranging from 200 
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µg/mL to 1.56 µg/mL with acetonitrile (16% v/v) containing 0.02 % trifluroacetic 
acid (TFA). The standards were analysed by HPLC. All test compounds were 
quantified as method mentioned above. 
HPLC chromatogram for MENK was acquired using the following setup:  
Table 4-1 HPLC instrumentation condition for analysis of MENK 
HPLC Setup 
Instrument Agilent Technologies 1200 Series HPLC system 
Column Onyx C18 monolithic column (5 µm; 100 × 4.6 mm; Phenomenex UK) fitted with guard 
column (5 µm; 10 × 4.6 mm) 
Column temperature 37˚C 
Mobile phase 16% Acetonitrile + 0.02% TFA 
Flow rate  1.2 mL/min 
Injection volume 20 µL 
UV wavelength 220 nm 
Sample diluent 16% Acetonitrile + 0.02% TFA 
The calibration curve was obtained by plotting the concentrations of 
standards and its respective peak area from the chromatogram. The concentration of 
unknown analyte was calculated using linear equation y= mx+c. 
4.3.2.7 Analytical method for quantification of MENK in vivo by EIA 
EIA was used to quantify MENK in plasma sample (Figure 4-3). Briefly, the 
sample/standard and known concentration of biotinylated tracer competes to bind to 
Met-Enkephalin antiserum added on a coated immunoplates. Bt tracer binds with 
serum specific HRP or streptavidin conjugated horseradish peroxidase (SA-HRP). 
TMB (tetramethyl benzidine) in the presence of HRP enzyme reduces hydrogen 
peroxide to water giving a blue color. To stop the reaction, HCl (2N) was added that 
changes the color of the solution to yellow and measured at 650 nm.  Higher the 
intensity of yellow colored solution lowers the quantity of peptide and vice versa.  
 
Figure 4-3 Schematics of Enzyme Immuno Assay 
Enzyme immunoassay (EIA) for the quantification of methionine enkephalin 
in plasma was performed as per the protocol described by the manufacturer 
(Bachem, USA). Briefly, the standard/sample (50 µL) and anti-serum (25 µL) were 
  159
added on to an Immunoglobulin G (IgG)-coated immunoplate and incubated for  
1 h. Bt tracer (25 µL) was then added to each well and incubated for 2 h. The 
immunoplate was washed 5 times with EIA buffer (300 µL). Streptavidin–HRP  
(100 µL) was added to all wells and incubated for 1 h. The immunoplates was 
washed 5 times followed by the addition of TMB solution (100 µL) in each well. 
Blue color was developed on incubation for 30-60 min. To stop the reaction, HCl  
(2 N, 100 µL) was added and absorbance was recorded at 650 nm. 
4.3.2.8 Quantification of MENK by LCMS-QQQ 
4.3.2.8.a Validation of LCMS method – Preparation of standards 
A stock solution of MENK was prepared by dissolving the peptide (2 mg) 
in 30% acetic acid. Seven calibration standards of concentrations ranging from  
10000 ng/mL to 200 ng/mL were prepared by dilution of stock solution in methanol.  
A stock solution of internal standard (dalargin) was also prepared in methanol  
(200 ng/mL). Dalargin is an analogue of leucine enkephalin with a molecular weight 
(725.83 Da).   
4.3.2.8.b Preparation of plasma for calibration standards  
A CD rat was culled in a CO2 culling chamber and blood was withdrawn by 
cardiac puncture. The blood sample was collected in a vacutainer (BD Vacutainer™ 
- spray coated with anti-coagulant K2 EDTA) and centrifuged at 2000 g for 10 min 
at 4˚C. Plasma was carefully withdrawn with micropipette tips and stored at – 80˚C 
in a freezer until LCMS analysis. 
4.3.2.8.c Preparation and extraction of calibration standards from plasma 
matrices 
 The internal standard (5 µL) and calibration standards (5 µL) were spiked 
into the tubes containing plasma (50 µL). Blank was prepared by spiking only 
internal standard (5 µL) in to plasma (50 µL). For the extraction, methanol (140 µL) 
was added to standards to precipitate plasma proteins followed by vortexing for 30 
min. The precipitated plasma proteins were removed by centrifugation at 11000 g for  
10 min and supernatant was quantified by LCMS. 
  160
4.3.2.8.d Quantification of endogenous MENK in mouse plasma 
Overnight fasted CD-1® mice (n=10) were culled and the plasma was 
collected as method mentioned in 4.3.2.8.b. Internal standard (5 µL) was added to 
each plasma sample (50 µL) and the extraction was carried out with methanol  
(140 µL). The precipitated plasma proteins were removed by centrifugation at  
11000 g for 10 min and the supernatant was quantified by LCMS.   
4.3.2.8.e Quantification of MENK by LCMS-QQQ 
MENK was quantified in plasma using LCMS QQQ. The configurations are 
listed as follows: 
a) Instrument configuration 
Pump : Agilent G1312B 
Autosampler : Agilent G1367E 
Column : Agilent G1367E 
Mass spectrometer : Agilent 6460 triple quadrupole LCMS system 
Software : Agilent chem station (B.06.00) 
b) Chromatography 
LC parameters for separation and identification of MENK is as follows: 
Parameters Plasma 
Column Onyx monolithic C18 column 
(100×2 mm) 
Oven temperature 40˚C 
Injection volume 10 µL 
Mobile phase  Solvent A: 0.1% FA in water 
Solvent B: Acetonitrile 
Gradient program 
Plasma 
Time (min) 0 4 5 6 6.10 7.5 
% of solvent B 5 30 95 95 5 5 
Flow rate 0.4 mL/min 
c) Source Optimization 
MENK and internal standard (dalargin) were optimized using a source 
optimizer program in LCMS. The parameter that gave the highest signal to noise 
ratio was used to develop LCMS method. 
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d) Mass Spectrometry 
Table 4-2 Source Parameters - LCMS-QQQ 
Source Parameters 
Ionization mode ESI jet streaming positive 
Sheath gas temperature (˚C) 400 
Sheath gas flow (L/min) 11 
Drying gas flow (L/min) 12 
Drying gas temperature (˚C) 290 
Nebulizer gas (psi)  20 
Capillary voltage (V) 3500 (positive and negative) 
Nozzle voltage (V) 0 
EMV (V) 200 
 
Table 4-3 MRM parameters – LCMS-QQQ 
Test item MENK Dalargin 
 Quantifier Internal standard for 
plasma sample 
MRM transition 574- 425 726 – 136.1 
Fragmentor voltage (V) 255     130 
Collision energy (eV) 81      10 
MS1 and MS2 resolution (nm) Unit Unit 
Cell acceleration voltage (V) 7 7 
Dwell time (ms) 200 200 
Polarity Positive Positive 
4.3.2.9 Pharmacokinetics of MENK-GCPQ formulations 
CD-1® mice were fasted overnight and randomized in to 5 groups (n=5 per 
group) each receiving the respective formulations;  
Table 4-4 Dosing schedule for MENK pharmacokinetics studies 
Formulation MENK GCPQ Diluent Volume Ratio Peptide 
dose 
MENK GCPQ 
IV 
5 mg/mL 13 mg/mL 0.9% 
NaCl 
100 µL 1: 2.6 15 mg/kg 
MENK IV 5 mg/mL - 0.9% 
NaCl 
100 µL - 15 mg/kg 
MENK GCPQ 
ORAL 
10 mg/mL 50 mg/mL 0.9% 
NaCl 
200 µL 1: 5 100 mg/kg 
MENK ORAL 10 mg/mL - 0.9% 
NaCl 
200 µL - 100 mg/kg 
Control  - - 0.9% 
NaCl 
100 µL - - 
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At each time point (5, 15, 20, 45, 60, 90 and 180 min for IV and 30, 60, 120 
and 240 min for oral formulations) mice were euthanized and blood samples were 
collected by cardiac puncture. Samples were processed as method mentioned in 
4.3.2.8.b and analysed by LCMS. 
4.3.2.10 Pharmacodynamics of MENK-GCPQ formulations 
MiaPaCa-2 cells were cultured for at least two weeks in vitro before tumour 
implantation. The cells were cultured in DMEM medium supplemented with 5% 
FBS and 0.05% sodium pyruvate in 300 cm2 size flask. The cells were trypsinized, 
centrifuged and resuspended in a mixture of DMEM medium and matrix gel  
(BD Bioscience, U.S.A) in the ratio 1:1 at a concentration of 1 million/100 µL. Two 
million cells (200 µL) were injected on the left flank of Swiss Nude mice (Charles 
River, U.K). The volume of the tumour was recorded using vernier calipers for  
10 days before treatment. The body weights of the mice were also recorded 
throughout the experiment. 
Five days after tumor implantation, the animals were randomized in to five 
groups (n = 5 per group). Every mouse in each group received 100 µL of the 
respective formulation:  
Table 4-5 Dosing schedule for MENK pharmacodynamics studies 
Formulation MENK GCPQ Diluent Volume Ratio Peptide 
dose 
MENK 
GCPQ IV 
5 mg/mL 13 mg/mL 0.9% NaCl 100 µL 1: 2.6 15 mg/kg 
MENK IV 5 mg/mL - 0.9% NaCl 100 µL - 15 mg/kg 
MENK 
GCPQ 
ORAL 
10 mg/mL 50 mg/mL 0.9% NaCl 100 µL 1: 5 50 mg/kg 
MENK 
ORAL 
10 mg/mL - 0.9% NaCl 100 µL - 50 mg/kg 
Control  - - 0.9% NaCl 100 µL - - 
The above formulations were given over 12 alternate days. The volumes of 
the tumours were recorded using vernier calipers during and after the treatment.  
Tumour volume (mm3) = Length (mm) * Width (mm2) * 0.5 
The body weight of the treated mice were also recorded and compared with 
mice that received no treatment.  
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4.4  Results 
4.4.1 Morphology of MENK peptide  
TEM images of MENK at different concentrations (Figure 4-4a) show that 
the peptide form aggregate of sizes 200 to 500 nm that are spherical in shape at 5 
mg/mL concentration, the aggregates at 10 mg/mL concentration are thread like 
structure and at 20 mg/mL concentration, the presence of crystals can be observed. 
The aggregates are formed when the attractive force between the solute molecules 
were stronger that the forces in the solution that disrupts aggregate formation (Figure 
4-4b). This acts like a nucleation site, which is the first step for crystal formation. 
When more solute molecules are added, crystal formation takes place (Figure 4-4c). 
The measured pH of MENK in water at any given concentration was 4.7.  
 
a)  
 
b)  
 
c)  
Figure 4-4TEM images showing morphology of MENK at different concentrations a) MENK 
(5 mg/mL) in water, b) MENK (10 mg/mL) in water, c) MENK (20 mg/mL) in water.  
4.4.2 CMC of MENK peptide 
The aggregation of peptide is concentration dependent. It is important to 
know the critical micellar concentration (CMC) of MENK to understand the 
concentrations at or above which MENK aggregates to form nanoparticles. The 
dilution enthalpogram of MENK are shown in Figure 4-5. The enthalpogram can be 
divided into three segments; the first segment represents the disassociation of 
aggregate to give monomers when diluted in sample cell. As the concentration of the 
monomers in the sample cell increases, first aggregate was formed at the start of the 
transition (ST – blue line). This can be observed by a change in slope of 
enthalpogram that denotes the CMC of MENK. The aggregation continued until the 
end of transition (ET). The CMC of MENK determined by ITC is 0.32 mM (Figure 
4-5). The differences between the two parallel red lines give ∆ Hdemic. For MENK, 
∆ Hdemic is -1255 Joules/mol. Demicellisation of MENK was an exothermic 
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process, which required the removal heat, thus aggregation of MENK would be 
endothermic, having the same magnitude of enthalpy but with an opposite sign. 
The Gibbs free energy was -19938 J/mole denoting thermodynamically stable 
aggregates. The aggregation reaction of MENK is entropy driven at room 
temperature with T∆S calculated as 18683 J/mol. 
 
Figure 4-5 Dilution enthalpogram of demicellisation of MENK (10 mg/mL) in water at 25ºC in 
50 steps of 5μL injection volume. 
4.4.3 In vitro Characterization of MENK-GCPQ IV and oral formulation by 
solubilization method 
MENK aggregates was first solubilized by dissolving in 30% acetic acid and 
then added to GCPQ (B1 or B2) solution prepared with 0.9% NaCl. The pH of the 
solution was increased gradually with sodium hydroxide (0.1 M) and it was expected 
that the MENK encapsulate in GCPQ during aggregation at pH 5.3. Probe sonication 
was used to further enhance the encapsulation of MENK in GCPQ. The MENK-
GCPQ IV and oral formulation (B1 & B2) were characterized for their size and 
charge and the results were compared. The ratio of MENK GCPQ formulation for IV 
and oral delivery were 1:2.6 and 1:5 as previously reported for LENK GCPQ 
formulation [53]. The concentration of the MENK (5 mg/mL) GCPQ (13 mg/mL) IV 
formulation and MENK (10 mg/mL) GCPQ (50 mg/mL) oral formulation were back 
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calculated from the MENK dose and volume to be administered in vivo in mice 
(Table 4-5).  
4.4.3.1 MENK-GCPQ formulations - Morphology 
MENK-GCPQ (B1) IV formulation prepared at ratio 1:2.6 had two 
populations; an irregular shaped particles around 60 nm and defined spherical 
particles around 20 nm (Figure 4-6). However, when the ratio of MENK-GCPQ (B2) 
formulation was increased to 1:5 only spherical particles around 20 nm was observed 
(Figure 4-7). An increase in the concentration of GCPQ for oral formulation could be 
a reason for MENK-GCPQ formulation forming homogeneous sized particles at  
ratio 1:5.  
 
Figure 4-6 MENK-GCPQ (B1) IV formulation 
prepared at ratio 1:2.6 and 
concentrations 5 mg/mL and  
13 mg/mL showing defined 
spherical particles around 20 nm 
and irregular shaped particles 
above 50 nm. 
 
Figure 4-7 MENK-GCPQ (B2) Oral 
formulation prepared at ratio 1:5 
and concentrations 10 mg/mL 
and 50 mg/mL showing defined 
spherical particles around 20 nm. 
4.4.3.2 Size characterization of MENK GCPQ IV (B1) and oral (B2) formulations 
by DLS 
MENK was soluble in 30 % acetic acid solution and their particle size 
observed was around 1 nm. MENK control was prepared by method similar to 
MENK-GCPQ formulation without adding GCPQ. MENK control was prepared by 
solubilizing in 30% acetic acid (300 uL) and reconstituted in 0.9% NaCl (700 uL). 
The final pH was adjusted to 5.6. The size of MENK control was around 222 nm. 
MENK-GCPQ (B1) IV formulation had particle size around 391 nm that was larger 
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than MENK-GCPQ (B2) oral formulation with particle size 16 nm (Figure 4-8). 
MENK-GCPQ (B1) IV formulation has lower degree of palmitoylation (16%) than 
MENK GCPQ  (B2) oral formulation having a degree of palmitoylation of 19%. The 
high palmitoylation of GCPQ B2 could cause strong interaction between the GCPQ 
and MENK and resulted in small particle size. High concentration of GCPQ B2 used 
for oral formulation (ratio 1:5) could also be the reason for smaller particle size 
compared to IV formulation, which has lesser concentration of GCPQ B1 with ratio 
1:2.6.  
PDI (0.578) of MENK (30% acetic acid) shows that some aggregates of 
MENK do exist in the solution and the MENK control has PDI of 0.974 suggesting 
that the MENK aggregates are heterogeneous. MENK-GCPQ B1 IV formulation of 
population with two different sizes was observed in TEM and hence the PDI was 
higher (0.648). Although, MENK-GCPQ B2 oral formulation had uniform sized 
small particles in TEM, PDI by DLS measured was 0.842. However, TEM results are 
qualitative and the presence of very small fraction of aggregates or large sized 
particles could increase the PDI of the formulation.  
 
Figure 4-8 Size characterization of MENK GCPQ formulations by DLS. Formulations were 
characterized and compared by DLS; MENK (5 mg/mL in acetic acid solution), 
MENK Control (5 mg/mL in acetic acid and 0.9% NaCl, pH 5.6), MENK (5 
mg/mL)-GCPQ (B1) (13 mg/mL) IV formulation at ratio 1:2.6 prepared in acetic 
acid and sodium chloride solution, pH 5.6 and MENK (5 mg/mL)- GCPQ (B2) (25 
mg/mL) oral formulation at ratio 1:5 prepared in acetic acid and sodium chloride 
solution, pH 5.6. 
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4.4.3.3 Surface charge of MENK GCPQ formulation by DLS 
The surface charge of MENK and MENK GCPQ formulations were 
characterized by DLS. MENK formulation has zeta potential of +18 mV whereas 
MENK-GCPQ (B1) IV and MENK-GCPQ (B2) oral formulation has zeta potential 
of +48.8 mV and +41 mV. It was previously reported that the zeta potential was 
found to be independent of particle concentration [157]. This can be observed in the 
graph, where, increase in the concentration of GCPQ used in preparing  
MENK-GCPQ IV (B1) and oral formulation (B2) has no effect on the zeta potential 
of the respective formulation. The degree of quaternization of MENK-GCPQ oral 
formulation (B2) was 12 % that was lower that degree of quaternization of  
MENK-GCPQ (B1) IV formulation B1 (14%). This could have also resulted in 
larger zeta potential value for MENK GCPQ (B1) IV formulation compared to 
MENK-GCPQ (B2) oral formulation.  
 
Figure 4-9 Surface charge characterization of MENK and MENK-GCPQ IV and oral 
formulation analysed by DLS. MENK (5 mg/mL in acetic acid and 0.9% NaCl,  
pH 5.6), MENK (5 mg/mL)-GCPQ (B1) (13 mg/mL) IV formulation at ratio 1:2.6 
prepared in acetic acid and sodium chloride solution (pH 5.6), MENK (5 mg/mL)- 
GCPQ (B2) (25 mg/mL) oral formulation at ratio 1:5 prepared in acetic acid and 
sodium chloride solution (pH 5.6). 
4.4.3.4 Analytical method for quantification of MENK in vitro by HPLC 
MENK in vitro samples were quantified by HPLC. The HPLC chromatogram 
for MENK was obtained with a single peak eluting at 3.2 min (Figure 4-10). The 
standard curve was also plotted with concentrations of MENK ranging from 1.56 
µg/mL to 20 µg/mL against their area under the curve obtained for each 
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concentration. The linear equation for MENK calibration curve was y=14.55X 
+1.6774 with R2= 0.9999 (Figure 4-11). 
 
 
Figure 4-10 HPLC chromatogram for MENK showing time on x-axis and absorbance unit on 
y-axis with retention time for MENK at 3.2 min. 
 
Figure 4-11 Calibration curve of MENK analyzed by HPLC with concentrations of MENK 
from 1.56 μg/mL to 200 μg/mL plotted on x-axis against AUC on y-axis. 
4.4.3.5 Encapsulation efficiency of MENK-GCPQ formulation  
4.4.3.5.a HPLC 
Encapsulation efficiency of MENK-GCPQ (B1) IV formulation was 93.63% 
and MENK-GCPQ (B2) oral formulation was 99% (Figure 4-12). The increase in the 
ratio of MENK to GCPQ (1: 2.6 to 1:5) could have resulted in increased 
encapsulation of MENK in GCPQ B2 oral formulation.  
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Figure 4-12 Encapsulation efficiency of MENK GCPQ (B1 & B2) formulations prepared at 
ratio 1:2.6 (blue) and 1:5 (red). 
4.4.3.5.b Column Chromatography 
Encapsulation efficiency of MENK-GCPQ B2 oral formulation was also 
analysed by column chromatography method. Here MENK or MENK GCPQ B2 
formulations are passed through a glass column packed with sephadex G25 resin. 
With differences in the retention of free MENK and MENK-GCPQ B2 nanoparticles, 
it was expected that MENK-GCPQ B2 nanoparticles have longer retention time 
compared to MENK only formulation. Sixty fractions were collected for each 
formulation and the concentrations were quantified by HPLC. However, the result 
shows that the MENK and MENK GCPQ B2 formulation had similar retention time 
(Figure 4-13). The disassociation of MENK-GCPQ B2 formulation while passing on 
the column matrix could be the reason for no differences in the elution time between 
encapsulated and non-encapsulated MENK. 
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Figure 4-13 Determination of encapsulation efficiency of MENK (10mg/mL) –GCPQ B2  
(50 mg/mL) (1:5) formulation by size exclusion chromatography. Each data 
point represents concentration of MENK in MENK (blue) or MENK GCPQ B2 
formulation (red) from the fraction collected. 
4.4.3.6 Colloidal Stability of MENK GCPQ B2 Oral Formulation 
MENK peptide by its very nature is resistant to pepsin and hence MENK and 
MENK GCPQ B2 formulations were stable in SGF (Figure 4-14). However MENK 
peptide is susceptible to pancreatic enzymes. In SIF, MENK-GCPQ B2 oral 
formulation was unstable as that of MENK only formulation suggesting that GCPQ 
B2 does not offer stability against SIF (Figure 4-15).  
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Figure 4-14 HPLC analysis of stability of MENK (5 mg/mL)-GCPQ B2 formulation (black) 
prepared at ratio 1:5 and MENK (5 mg/mL) (blue) in SGF maintained at pH 1.2 
and temperature 37˚C.  
 
Figure 4-15 HPLC analysis of stability of MENK (5 mg/mL)-GCPQ B2 formulation (black) 
prepared at ratio 1:5 and MENK (5 mg/mL) (blue) in SIF maintained at pH 6.8 
and temperature 37˚C. 
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4.4.4 Other methods of preparing MENK GCPQ formulations 
MENK was formulated by other methods with GCPQ B1 and their physical 
characteristics were evaluated.  
4.4.4.1 MENK GCPQ B1 formulation by complex co-acervation method 
Characterization of MENK and GCPQ B1 nanoparticle surface charge at different 
pH 
Surface charge of MENK, GCPQ B1 and MENK-GCPQ B1 formulations 
were measured at different pH using DLS. MENK has positive zeta potential at its 
isoelectric point (5.6). GCPQ B1 and MENK GCPQ B1 formulations were also 
found to be more positive compared to MENK only formulation. At pH (5.6), both 
MENK and GCPQ B1 carried positive surface charge (Figure 4-16). So there could 
be electrostatic repulsion between peptide and the polymer. An alternative method to 
avoid charge-based repulsion is complex coacervation method.  
 
Figure 4-16 Zeta potential of MENK (2.5 mg/mL) – GCPQ B1 (12.5 mg/mL) formulation 
prepared in water at ratio (1:5) (blue) compared with MENK (2.5 mg/mL in 
water) (Red) and GCPQ B1 (12.5 mg/mL in water) (green). 
MENK and GCPQ B1 have positive zeta potential between acidic and neutral 
pH. In order to favor interaction between MENK and GCPQ B1 polymer, MENK 
was first complexed with hyaluronic acid (HA), an anionic polymer to obtain 
negative surface charge and then complexed with positively charged GCPQ B1. The 
complexes were size characterized at different stages. First, the molecular weight of 
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HA used for coating MENK was assessed. Three different molecular weight of HA 
(4.7 kDa, 16 kDa and 35 kDa) were complexed with MENK using different molar 
ratios (Figure 4-17 & Figure 4-18). MENK complexed with small molecular weight 
HA (4.7 kDa) formed particles from MENK-HA ratio 1: 0.001 to 1:0.1 Above 
MENK-HA ratio 1:0.1, MENK was solubilized by HA. Increasing the molecular 
weight of HA to 16 and 35 kDa, resulted in MENK-HA solution at a ratio as low as 
1:0.1. This suggests that with increase in the molecular weight and ratio of HA, 
MENK can be solubilized. Also the PDI of MENK HA complex increased with 
increase in the molecular weight and ratio of HA used. For complex coacervation, 
MENK should form particles with HA and hence lower ratios and molecular weight 
are preferred. The pH of the MENK-HA complexes was around 2.7. HA with 
molecular weight 16 kDa was used to complex MENK peptide.  
 
Figure 4-17 Size of MENK-HA complex analysed by DLS (n=3). Graph showing size on  
y-axis and MENK (2.5 mg/mL) complexed with HA of different molecular weight 
4.7 kDa (black), 16.1 kDa (red) and 35 kDa (blue) prepared from ratio 1:0.001 
to 1:10. 
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Figure 4-18 PDI of MENK-HA complex by DLS (n=3). Graph showing size on y-axis and 
MENK (2.5 mg/mL) complexed with HA of different molecular weight 4.7 KDa 
(black), 16.1 kDa (red) and 35 kDa (blue) prepared from ratio 1:0.001 to 1:10. 
The minimum amount of HA (16 kDa) required to complex MENK were 
analysed by characterizing the stability of MENK HA complexes of different molar 
ratios for one day. From size and PDI results, MENK HA complexes of molar ratios 
1:0.04 were found to be stable (Figure 4-19 & Figure 4-20). MENK complexed with 
HA at ratios less than 1:0.01 did not form stable particles on day 1 (Figure 4-19).  
The PDI of the complexes were also increased in one day (Figure 4-20). The 
negative zeta potential for MENK-HA complexes (above ratio 1:0.001) also confirm 
that HA was coated on MENK peptide (Figure 4-21). From the DLS size data 
MENK-HA complex prepared at ratio 1:0.04 was used for further studies. This ratio 
was preferred as it is the minimum amount of HA required to keep the complex 
stable for one day.  
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Figure 4-19 Stability of MENK-HA (16 kDa) complexes on day 0 (black) and day 1 (red) 
prepared at ratio from 1: 0.0005 to 1: 0.1 and characterized by DLS – Size (n=3) 
 
Figure 4-20 Stability of MENK-HA (16 kDa) prepared at ratio from 1: 0.0005 to 1: 0.1 and 
characterized by DLS - PDI (n=3) 
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Figure 4-21 Zeta potential of MENK HA (16 kDa) complex prepared from ratio 1: 0.0005 to 1: 
0.1 (n=3) 
4.4.4.1.a Preparation and characterization of MENK-HA-GCPQ B1  
MENK-HA complex of molar ratio 1:0.04 was complexed with GCPQ B1 at 
different mass ratio 1:1, 1:2.5 and 1:5 and size characterized. The pH of the resulting 
complexes was around 3. Particles of nanometric sizes were obtained for MENK-
HA-GCPQ B1 formulations (Figure 4-22 & Figure 4-23). An increase in the positive 
zeta potential of MENK-HA-GCPQ B1 formulation was observed before and after 
probe sonication suggesting that GCPQ B1 was coated on MENK-HA complexes  
(Figure 4-24). However, increasing the pH of the formulations above 4, results in 
formation of precipitates. This suggests that the MENK-HA-GCPQ B1 formulations 
were not stable over pH 4. Precipitation could be a result of uncoated MENK-HA 
complexes at higher pH. The concentrations and molecular weight of GCPQ B1 used 
should be optimized for further studies.  
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Figure 4-22 Size characteristics of MENK-HA-GCPQ B1 complex prepared at ratio [1: (0.04): 
1 to 1: (0.04): 5] and characterized by DLS (n=3) 
 
Figure 4-23 PDI of MENK-HA-GCPQ B1 complex prepared at ratio [1: (0.04): 1 to 1: (0.04): 
5] and characterized by DLS (n=3) 
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Figure 4-24 Zeta potential of MENK-HA-GCPQ B1 complex prepared at ratio [1: (0.04): 1 to 
1: (0.04): 5] and characterized by DLS (n=3) 
4.4.4.2 MENK GCPQ B1 formulations by direct reconstitution and film method 
MENK was also formulated with GCPQ B1 by other methods such as direct 
reconstitution and film method. In direct reconstitution method, MENK and GCPQ 
B1 were added as powder and directly probe sonicated by suspending them in water. 
This was to avoid charge-based repulsion between MENK and GCPQ B1 as it was 
seen with other formulation prepared previously.  
Film based method was also prepared by dissolving MENK and GCPQ B1 in 
their respective solvent, mixed and evaporated to form a thin film. The film was then 
reconstituted in water and probe sonicated. This method was to ensure that MENK 
and GCPQ B1 were at homogeneously distributed while probe sonication. 
Formulations prepared by above methods were size characterized and their stability 
in SIF were analysed.  
4.4.4.2.a Size Characterization and stability of MENK GCPQ B1 formulations 
The sizes of MENK GCPQ B1 formulations prepared by direct reconstitution 
and film method were in nanometric range of PDI ranging from 0.3 to 0.6 
(Table 4-6). However, these formulations were unstable in SIF (Figure 4-25) that 
were similar to MENK, MENK-GCPQ IV or oral formulations. 
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Table 4-6 Size characterization of MENK-GCPQ formulation prepared by film and direct 
reconstitution method 
Formulation Size PDI 
Direct reconstitution of 
MENK GCPQ B1 (n=3) 
156.9 ± 47.16 0.569 ± 0.238 
MENK GCPQ B1 film 
method (speed vac) (n=3) 
70.48 ± 1.707 0.384 ± 0.013 
 
Figure 4-25 Stability of MENK-GCPQ B1 formulations prepared by film and direct 
reconstitution method and incubated in SIF at 37˚C for 240 min. 
For in vivo studies, MENK GCPQ (B1 & B2) IV and oral formulation 
prepared by solubilisation method were used. 
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4.4.5 Analytic method for quantification of MENK by Enzyme Immuno Assay 
(EIA) 
The sensitivity of EIA was first tested on MENK standards prepared in water. 
In the standards prepared from 500 ng/mL to 1.95 ng/mL (Figure 4-26), no signal 
was obtained above a concentration of 31.25 ng/mL that could be seen from the semi 
log plot as a flat line. At a concentration of 31.25 ng/mL, MENK binds completely to 
the available antiserum in the immunoplates producing no signal. Any concentration 
above 31.25 ng/mL will be the same due to saturation of antiserum by peptide. 
 
 
Figure 4-26 Semi log plot of Met-Enkephalin standards in water (1.95 ng/mL to 500 ng/mL) 
 
The standards (500 ng/mL – 1.95 ng/mL) were spiked in to plasma  
(Figure 4-27) and the plot obtained from EIA experiment shows a similar trend in the 
curve. Here the saturation of the anti-serum binding sites was observed at a 
concentration of only 7.18 ng/mL. However, the absorbance above a concentration of 
7.18 ng/mL was in a range within 0.3 to 0.6 absorbance units compared to MENK in 
water that showed absorbance of zero above 31.25 ng/mL. This shows that there 
were background interferences from plasma samples that produced intensity signal at  
450 nm.  
  181
 
Figure 4-27 Semi log plot of Met-enkephalin standards spiked in plasma (1.95 ng/mL to  
500 ng/mL) 
 
Figure 4-28 Semi log plot of Met-enkephalin spiked in 10 times diluted plasma samples 
The standard curve (640 ng/mL to 0.01 ng/mL) was also repeated with 
MENK standards spiked in ten times diluted plasma samples (Figure 4-28). The 
result shows that at a concentration below 2.5 ng/mL difference in absorbance was 
not significant that the method is not sensitive below that concentration. The semi 
log plot was shallow and it would be difficult to compare between samples in vivo at 
different time point. In vivo, if the plasma samples were diluted ten times, which will 
eventually dilute the peptide of interest the absorbance obtained will be below the 
limit of detection. These constraints have limited the use of EIA for only in vitro 
samples than in vivo. A robust analytical method was required to measure peptide of 
interest in biological matrix.  
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4.4.6 Analytical method for quantification of MENK in vivo by LCMS 
4.4.6.1 Optimization of Source parameters 
Source and MRM parameters in LCMS were optimized for MENK peptide to 
obtained better signal. The MENK signal to noise ratio (S/N ratio) for each source 
parameters such as capillary voltage, nebulizer gas, drying gas flow, drying gas 
temperature, sheath gas flow and sheath gas temperature (Figure 4-29) were 
optimized and the value at which maximum S/N ratio obtained were used to create 
the final LCMS method. Source parameters are essential for formation of fine 
droplets and dessolvation of clustered ions from the LC column. Optimization of 
source parameters maximizes the sensitivity of the signal obtained. The optimum 
source parameters for MENK peptide are summarized in Table 4-7. 
Table 4-7 Optimized source parameters for MENK in plasma 
Source Parameters 
Ionization mode ESI jet streaming positive 
Sheath gas temperature (˚C) 400 
Sheath gas flow (L/min) 11 
Drying gas flow (L/min) 12 
Drying gas temperature (˚C) 290 
Nebulizer gas (psi)  20 
Capillary voltage (V) 3500 (positive and negative) 
Nozzle voltage (V) 0 
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Figure 4-29 Optimization of source parameters for MENK in plasma
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4.4.6.2 MENK standard curve 
MENK and dalargin (internal standard) peaks were obtained at elution time 
of 4.9 and 4.7 min in a total run time of 7 min (Figure 4-30). Calibration curve was 
plotted with standards ranging from 20 ng/mL to 600 ng/mL. The linear equation for 
the calibration curve was y= 0.008x+0.2135 with R2 = 0.99733 (Figure 4-31). The 
LLOQ for MENK was observed to be 20 ng/mL. For pharmacokinetic studies, a new 
standard curve was run every day and compared with the respective samples.  
 
 
Figure 4-30 Retention times of MENK (4.9 min) and Dalargin (4.7 min) 
 
Figure 4-31 MENK standard curve in plasma 
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4.4.6.3 Endogenous MENK in mice plasma 
The concentration of endogenous MENK in mouse plasma (n=10) was 
measured by LCMS-QQQ (Table 4-8). Only one in 10 mice had concentration 
around 22.32 ng/mL, which is close to LLOQ of MENK in plasma (20 ng/mL).  
Table 4-8 Quantification of endogenous MENK in mice plasma by LCMS-QQQ 
 
Mice Concentration of endogeneous MENK (ng/mL) 
S1 Below LLOQ 
S2 Below LLOQ 
S3 Below LLOQ 
S4 Below LLOQ 
S5 Below LLOQ 
S6 Below LLOQ 
S7 Below LLOQ 
S8 22.32 
S9 Below LLOQ 
S10 Below LLOQ 
 186 
4.4.7 In vivo Pharmacokinetics of MENK-GCPQ B1 IV formulation 
MENK concentrations in plasma were monitored following intravenous 
administration of MENK or MENK GCPQ B1 formulations (MENK- 15 mg/kg) in 
mice (n= 5 per group). Significant differences between MENK and MENK GCPQ 
B1 formulations were observed at time point 15 min and above (two way anova, p< 
0.0001) (Figure 4-32). MENK concentrations were not detected in plasma, 15 min 
after administration of MENK formulation, where as, at the same time point, MENK 
concentrations in plasma were observed to be 298 ± 48.84 ng/mL for MENK GCPQ 
B1 formulation. The MENK-GCPQ B1 formulation was stable when measured until 
180 min. A sharp decrease in the concentration of MENK in MENK-GCPQ B1 
formulation at first time point could be result of non-encapsulated MENK in MENK-
GCPQ B1 nanoparticles.  
 
 AUC (ugh/L) T max C max (ng/mL) 
MENK GCPQ B1 47944.9 ± 6670.89 5 min 3727.40 ± 1003.42 
 
Figure 4-32 Pharmacokinetics of MENK (15 mg/kg) and MENK GCPQ B1 ratio 1:2.6 (15 
mg/kg) formulations in plasma (n=5) Concentration of MENK dose was 15 
mg/kg. Concentration of MENK in plasma quantified using LCMS-QQQ 
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4.4.8 In vivo Pharmacokinetics of MENK-GCPQ B2 Oral Formulation 
CD-1 mice were administered with 100 mg/kg MENK or MENK GCPQ B2 
formulation and plasma MENK concentrations at different time points were analyzed 
by LCMS-QQQ (Figure 4-33). MENK concentrations were not detected in plasma 
after 30 min and four mice have variable MENK concentrations ranging from 724.40 
ng/mL to 23.51 ng/mL in mice plasma at 60 min time point. One mouse at each time 
point 120 and 240 min had MENK concentration in plasma around 52 and 91 ng/mL.  
No concentrations of MENK in plasma were observed for mice treated with 
MENK alone formulation and analysed at time points ranging from 30 to 240 min.  
 
Figure 4-33 In vivo pharmacokinetic study of MENK (100 mg/kg)-GCPQ B2 (1:5) oral 
formulation (n=5). Each data point represents the concentration of MENK in 
mouse plasma at time points 30 (purple), 60 (orange), 120 (green) and  
240 min (blue) as analysed by LCMS-QQQ.  
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4.4.9 In vivo Pharmacodynamics of MENK-GCPQ B1 IV formulation 
Tumour-bearing CD1 mice (sub-cutaneous injected with MiaPaCa-2) were 
intravenously (15 mg/kg) administered (12 doses over a period of 29 days) with 
MENK or MENK-GCPQ B1 IV formulation. Tumour regression was monitored 
against the untreated xenografts (control) for 39 days before and after treatment. Two-
tumour bearing mice treated with MENK IV formulations had to be withdrawn from 
the study during the course of study (11th and 16th day) due to tail hemorrhage. These 
data were not considered in tumour regression data analysis and statistical 
significance was analysed only for time points that has complete data sets (i.e. n=5). 
(Figure 4-34).  
 
Figure 4-34 Pharmacodynamics of MENK (15 mg/kg)-GCPQ B1 formulation (n=5) in green, 
MENK (15 mg/kg) formulation (n=5) in red and control (0.9% NaCl) (n=5) in 
black intravenously administered two days once in nude mice bearing 
MiaPaCa-2 Xenograft. Tumour volume was measured for treatment period of 
29 days and continued up to day 39. Two way anova - MENK GCPQ B1 IV 
formulation significantly different from control on day 35 (# p< 0.05) and MENK 
IV formulation significantly different from the MENK GCPQ B1 IV formulation 
on day 8 (& p< 0.01) and 11 (&&& p< 0.01). Missing data sets were excluded 
from statistical analysis. 
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An alternative method is to use Kaplan-Meier test to calculate the survival of 
the tumour bearing mice after treatment. The advantage of this estimator is that, this 
method can take in to account of censored data, particularly when a subject is 
withdrawn from the study before the final outcome is measured. The tumour bearing 
mice treated with MENK and MENK-GCPQ B1 IV formulation had mean survival 
time of 39 days against control, which was only 29 days (Figure 4-35). 
 
Figure 4-35 Survival analysis of MENK (15 mg/kg) IV (red), MENK (15 mg/kg)-GCPQ B1 
(1:2.6) IV (green) and control (black) formulation by Kaplan Meier estimator. 
Survival line drops for every animal that reaches a relative tumour growth rate 
above 5 on the respective date. 
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4.4.10 In vivo Pharmacodynamics of MENK-GCPQ B2 Oral Formulation 
The tumour regression in mice administered with MENK-GCPQ oral 
formulation was higher than the MENK oral formulation (Figure 4-36). This 
suggests that, the GCPQ B2 enhanced oral delivery of MENK peptide to the tumours 
resulting in delayed tumour growth. One tumour bearing mouse treated with MENK-
GCPQ B2 oral or MENK formulation was withdrawn from the study (after day 16) 
due to poor administration. Therefore, statistically significant differences (p < 0.05) 
were only observed only at day 13 and 16.  
 
Figure 4-36 Pharmacodynamics of MENK (50 mg/kg)-GCPQ B2 formulation (n=5), MENK  
(50 mg/kg) formulation (n=5) and control (0.9% NaCl) (n=5) orally administered 
two days once in nude mice bearing MiaPaCa-2 xenograft. Tumour volume was 
measured for treatment period of 29 days and continued up to day 39. Two way 
anova - MENK oral formulation significantly different from control on day 11 
(*p<0.01), MENK GCPQ B2 oral formulation significantly different from control 
on day 14 (# p< 0.01), 16 (# p< 0.01), 18 (## p< 0.01), 21 (### p< 0.01), and  
23 (### p< 0.01) and MENK oral formulation significantly different from the 
MENK GCPQ B2 oral formulation on day 14 (& p< 0.01) and 16 (&& p< 0.01). 
Missing data sets were excluded from statistical analysis.  
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The survival time was calculated using Kaplan-Meier estimator. Survival 
analysis of tumour bearing mice with different treatment shows that the tumor 
bearing mice treated with MENK-GCPQ B2 oral formulation has the mean survival 
time of 39 days (experiments concluded at 39 days), followed by MENK oral and 
control with a mean survival time of 35 and 29 days respectively (Figure 4-37). This 
confirms the efficacy of MENK GCPQ B2 oral formulation in tumour regression 
over other MENK peptide alone formulations. 
 
Figure 4-37 Survival analysis of MENK (50 mg/kg) oral (red), MENK (50 mg/kg)-GCPQ B2 
(1:5) IV (green) and control (black) formulation by Kaplan Meier estimator. Mice 
having relative tumour growth rate above 5 was withdrawn from the study. 
Survival line drops for every animal that reaches a relative tumour growth rate 
above 5 on the respective date.  
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4.4.11 Body weight comparison 
The body weight of tumour bearing mice was also measured during the 
course of treatment (Figure 4-38), and no significant difference between the control 
mice and mice that received MENK or MENK GCPQ (B1 or B2) oral/IV 
formulation were observed. It was also observed that the body weights of mice 
bearing tumour were not less than 15% of their initial body weights with or without 
treatment.  
This suggests that the tumour burden, mode of administration and treatment did not 
affect the body weight of mice.  
 
Figure 4-38 Body weight comparison between mice administered orally or intravenously with 
MENK/MENK GCPQ (B1 & B2) formulations (n=5) compared with control (n=5). 
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4.5  Discussion 
MENK or opioid growth factor is an endogenous opioid peptide, reported to 
have shown anti-proliferative action on pancreatic cancer cells by up regulation of 
P21 pathway [255]. Since this action is transient, standard therapy requires repeated 
administration of MENK via infusion [260]. Although MENK treatment in human 
reported no toxic side effects [260] compared to standard chemotherapies, repeated 
administration via infusion can lead to medication non-compliance. An alternative 
approach is to use non-invasive methods such as oral delivery of Met-enkephalin. 
However, oral delivery of Met-enkephalin is hampered due to its poor 
physiochemical properties such as limited solubility and stability in the gut and 
plasma.  
In the present study, oral delivery of MENK using GCPQ nanoparticle was 
demonstrated. GCPQ was previously reported to improve the oral availability of 
poorly soluble hydrophobic drugs [146] and peptide [53] by forming nanoparticles. 
Previous report suggests that MENK is sparingly soluble in water and a dose-limiting 
factor for intravenous delivery [269]. So the solubility characteristic of MENK was 
evaluated. For the first time we have reported that met-enkephalin exhibits different 
morphological characteristics at different concentrations. Met-enkephalin self 
assembles to form nanoparticles in aqueous solution at a concentration as low as  
160 µg/mL (Figure 4-5) as determined by ITC and by TEM (Figure 4-4) at higher 
concentrations (5 mg/mL). These nanoparticles aggregates above a concentration of 
10 mg/mL and forms precipitate when analyzed at 20 mg/mL. Formation of 
nanoparticles by methionine enkephalin was similar to observation made previously 
with leucine enkephalin that formed nanoparticles of size around 170 nm in aqueous 
solution [53]. It was also observed by DLS measurement that particle formation by 
MENK is pH dependent where MENK solubilizes in 30% acetic acid (pH 2.5) and 
forms nanoparticles at pH 5.3.  
For formulation of MENK with GCPQ micelles, two batches of GCPQs were 
used. MENK was formulated with GCPQ B1 for IV formulation and with GCPQ B2 
for oral formulation by solubilization method. MENK was also formulated with 
GCPQ B1 by other methods such as complex coacervation, film formation and direct 
reconstitution method.  
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GCPQ B2 of palmitolyation and quaternization of 19% and 12% was used for 
preparing MENK-GCPQ oral formulation. GCPQ B1 of palmitoylation and 
quaternization of 16% and 14% were used for preparing MENK-GCPQ IV 
formulation. 
MENK-GCPQ (B1 & B2) nanoparticle were prepared by first solubilizing 
MENK in acetic acid (30% v/v) in order to prevent self-assembled micelle 
formation. To the solubilized MENK solution, GCPQ solution was added, followed 
by increase in pH of the formulation to 5.3. It was hypothesized that when MENK 
aggregates with increase in pH, it could favor encapsulation of MENK in GCPQ 
nanoparticles. The ratios (1:2.6 and 1:5) used for preparing MENK-GCPQ (B1 & 
B2) IV and oral formulations were same as previously reported ratios for LENK-
GCPQ IV and oral formulations [53]. With increase in the concentration of GCPQ 
(B1 & B2) used for IV and oral formulation the size of the particles reduced from 
391 nm (Figure 4-6) to 16 nm (Figure 4-7). MENK GCPQ (B1 & B2) oral and IV 
formulations also had positive surface charge of +41mV and +48 mV (Figure 4-9) 
depending on the quaternization level (12% and 14%) of GCPQs used respectively.  
Stability of MENK-GCPQ B2 oral formulation was tested in vitro in SIF 
fluid. It was observed that MENK-GCPQ oral formulation did not improve its 
stability in SIF fluid. 
MENK-GCPQ B1 formulations were also prepared by other methods. First 
the surface charge of MENK at different pH was monitored. It was found that 
MENK carries positive charge at its isoelectric point because of its self-assembling 
nature. There are possibilities of electrostatic repulsion between the positively 
charged MENK and GCPQ B1 nanoparticles at pH 5.3. So alternative strategies such 
as film method and complex co-acervation were used. Yuri et al first reported 
formation of ultrathin film by layer by layer assembly of positively charged proteins 
within negatively charge poly(styrene sulfonate) (PSS) polymer through electrostatic 
interaction [270]. This technique was further exploited in drug delivery for targeted 
release [271] [272]. In film method, MENK and GCPQ B1 were dissolved separately 
in a suitable solvent, mixed and evaporated to form a thin film. The film was 
reconstituted in water so that the MENK and GCPQ B1 at its proximity form 
nanoparticles. However the formulation prepared by film method did not improve the 
stability of MENK in SIF (Figure 4-25).  
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Complex coacervation is a pH induced complexation process prepared by 
electrostatic interaction between oppositely charged particles. Complex coacervation 
between silk fibroin/hyaluronic acid [273], chitosan/hyaluronic acid [274] and 
lysozyme/hyaluronic acid [275] has been previously reported to improve stability of 
protein formulation or as drug carrier. Complex coacervation method involves 
coating of MENK particles with negatively charged hyaluronic acid (HA), which 
was then coated with positively charged GCPQ B1 nanoparticles. MENK-HA 
complex were successively obtained at 0.04 molar ratios (Figure 4-19, Figure 4-20). 
However, when the complex were coated with GCPQ B1 (Figure 4-22) and 
increased its pH the complex precipitated. Precipitation could be a result of exposure 
of MENK-HA complexes to higher pH that were not coated by GCPQ B1 particle. 
Further studies needs to be conducted to justify this hypothesis.  
MENK-GCPQ (B1 & B2) IV and oral formulation prepared by solubilization 
method were tested in vivo. MENK is an endogenous peptide and its basal level in 
plasma should be determined to quantify the MENK peptide in plasma following oral 
and IV administration. 
EIA quantification of MENK spiked in plasma was challenging due to matrix 
effect (Figure 4-27). Quantification using LCMS-QQQ provided the suitable 
alternative for in vivo pharmacokinetic assay. LCMS-QQQ method is sensitive in 
detecting the concentration of MENK in plasma as low as 20 ng/mL. The concentration 
of endogenous MENK in plasma were below the LLOQ of MENK in plasma (20 
ng/mL) by LCMS-QQQ (Figure 4-31). Only one in ten mice had MENK 
concentration of 22 ng/mL in plasma (Table 4-8). Endogenous MENK concentration 
reported in human as 8 pg/mL [262] and 19.64 ± 1.71 pg/mL [276]. Also 
concentration of endogenous MENK in nude mice was reported to be only 0.16 ± 
0.03 ng/mL [277]. Several reports show quantification of MENK in plasma using 
radioimmunoassay (RIA) at pictogram levels [166, 278, 279]. However, there was 
also discrepancies MENK plasma level which was linked to differences in the RIA 
kit [278].  In order to achieve high sensitivity with LCMS-QQQ as that of RIA, the 
extraction protocol could be further optimized.  
The OGF-OGFr regulation was observed to be an important determinant of 
pancreatic neoplasia [280]. In mice bearing pancreatic tumour xenografts the 
concentration of OGFr remains stable irrespective of the size and stage of tumour 
progression. The plasma level of OGF was observed to be 3.4 to 7.9 folds less  
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(~ 50 pg/mL) for nude mice bearing pancreatic tumour xenograft compared to nude 
mice with no tumour (~ 250 pg/mL) [278]. This suggests that MENK is down 
regulated in the presence of tumour. The application of exogeneous MENK was 
necessary for tumour growth suppression. 
GCPQ improved the solubility of MENK by 3 folds for MENK-GCPQ IV 
formulation (15 mg/kg) and 10 folds for MENK-GCPQ oral formulation  
(50 mg/kg). Thus, by increasing the dose, frequency of administration was also 
reduced to once in two days. Previously administered MENK formulations were 
intravenously administered at a concentration of 5 mg/kg (thrice daily), which was 
three folds lower than the single dose of MENK-GCPQ formulation [166].   
In vivo pharmacokinetic data for MENK-GCPQ IV formulation shows 
significant concentrations in plasma compared to control. The concentrations of 
MENK observed in plasma were at nanogram levels compared to previous 
pharmacokinetic data of MENK that were only in picogram level [166]. It was also 
observed that the concentration of MENK in plasma (Figure 4-32) for the respective 
formulation was 3727 ng/mL at time 0 and dropped by 100 folds (298 ng/mL) within 
15 min and only a fraction of MENK concentration was stable in plasma up to  
3 h (170 ng/mL). As a result, it can be concluded that the above fractions were 
encapsulated in GCPQ while the remaining were non-encapsulated. This is plausible 
as the half-life of MENK is only 4-7.5 min in mouse. The half-life of MENK in 
plasma is different for different organism. Studies of the in vitro plasma degradation 
of methionine enkephalin for human, mouse and rat are 10-15 min [264], 4 – 7.5 min 
[281], [282] and 2-4 sec [283] respectively.  Studies conducted in SD rats also shows 
that, thirty sec after injection, the apparent volume of distribution and metabolic 
clearance rate of peptide were 53 mL and 10 mL/min respectively [283]. So, any  
un-encapsulated MENK in plasma would have been degraded or rapidly distributed 
or eliminated. The bio distribution of MENK and MENK-GCPQ nanoparticle in 
mice could be studied in the future.  
Pharmacodynamics study of MENK GCPQ formulation suggested that the 
mean survival time of MENK-GCPQ and MENK IV formulations (39 days) were 
higher than that of control (29 days) (Figure 4-35). This suggests that with the 
concentration of MENK achieved in plasma for MENK-GCPQ B1 IV formulation 
(Figure 4-32), it is possible to achieve significant tumour regression compared to 
control (Figure 4-34). However no significant differences in tumour volume and 
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mean survival time were observed between MENK and MENK-GCPQ B1 IV 
formulations (Figure 4-34). This suggests that, though MENK level in plasma was 
achieved at nanogram concentration using MENK-GCPQ B1 formulation, this 
concentration was not sufficient enough to cause significant therapeutic effect 
compared to MENK formulation. It was observed previously that the concentration 
of MENK in plasma after intravenous administration of MENK (5mg/kg) thrice daily 
was in picogram level (84 pg/mL). However, this concentration was sufficient to 
cause tumor suppression in 62% of mice treated with MENK formulation [166]. 
Hence, it could be possible that with respect to MENK-GCPQ IV formulation, the 
OGFr was saturated by MENK and excessive concentration of MENK in plasma 
would have been cleared from the blood. The binding affinity of OGFr was 1.5 nM 
and the binding capacity of OGFr was around 20 fmol/mg of protein [278]. The 
binding affinity and binding capacity of OGFr in MiaPaCa-2 were not influenced by 
size and state of tumour differentiation [278]. It was also observed that following 
intravenous administration of MENK, the binding capacity of OGFr were reduced by 
58% compared to control in mice bearing BxPC-3 cells [166]. Hence other routes of 
administration that releases MENK slowly in to the systemic circulation is preferred 
over intravenous administration.  
The above results were contradictory to in vitro results on the encapsulation 
efficiency of MENK-GCPQ formulation suggesting that 93% of MENK was 
encapsulated in GCPQ (Figure 4-12). Since there were no correlations between in 
vitro and in vivo result, an alternative approach using size exclusion chromatography 
was used to determine the encapsulation efficiency of MENK GCPQ B2 
nanoparticle. It was expected that free MENK and MENK encapsulated GCPQ B2 
elute as different peaks. However, for MENK and MENK GCPQ B2 formulation, 
MENK peak eluted at the same time (Figure 4-13). Free MENK behaving as 
nanoparticle could be the reason for discrepancy in the result. The actual 
encapsulation efficiency of MENK-GCPQ B2 formulation could not be confirmed by 
either method.  
The pilot studies were conducted to measure the concentration of MENK 
following oral administration of MENK-GCPQ B2 formulation.  Pharmacokinetics 
of MENK GCPQ B2 oral formulation did show measurable concentration of MENK 
in plasma. However there was variability in MENK plasma concentrations between 
the mice. The results suggest that only three out of five mice had concentrations of 
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MENK in plasma around 724 ng/mL, 75 ng/mL and 23 ng/mL at 60 min time point. 
At other time points, (120 and 240 min) only one in five mice had concentrations of 
52 and 91 ng/mL respectively (Figure 4-34). These variations could have resulted 
from differences in MENK-GCPQ B2 nanoparticle absorption across the enterocytes. 
However, in mice administered with MENK alone, no concentrations were detected 
in plasma.  
Pharmacodynamics of MENK-GCPQ B2 oral formulation shows 
encouraging results. Tumor regression data shows significant therapeutic effect for 
MENK-GCPQ B2 oral formulation over MENK only formulation (day 14 and 16) 
and control (day 14 to 23) ((Figure 4-36). The mean survival time also was higher for 
MENK GCPQ B2 oral formulation (39 days) compared to MENK (35 days) and 
control (29 days) (Figure 4-37).  
The MENK-GCPQ B2 formulation did not offer stability against SIF with 
pancreatin in vitro. However, the pharmacodynamic and pharmacokinetics results for 
the same formulation were encouraging. It could be possible that the MENK-GCPQ 
B2 formulation in vivo adheres to the mucus membrane thereby reducing the particle 
exposure to intestinal enzymes. Also, it was previously reported that GCPQ interacts 
with bile components and recirculate between liver and small intestine [160]. This 
explains the discrepancies between in vitro and in vivo results.  
The therapeutic effect of MENK-GCPQ B2 oral formulation was promising 
although there was variability in the concentration of MENK detected in plasma.  
It should also be noted that in the previous studies, MENK level in tumour were  
24 fold greater in MENK treated mice than control. However for the same treatment, 
the plasma MENK level were 8.6 fold lower than control [166]. For the current 
study, therapeutic effect was achieved for MENK GCPQ B2 oral formulation, 
although, significant MENK concentrations were not observed in mice plasma. The 
MENK level in tumor after oral administration of MENK-GCPQ B2 should be 
carried out and compared against the MENK formulation in the future studies.  
In the above studies, only GCPQ B1 and B2 were studied. It would be 
interesting to know if GCPQ B3 will show improved uptake of MENK peptide as 
seen with Laby peptide. 
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4.6  Summary and future work 
In this study, therapeutic effect of methionine enkephalin in mice bearing 
Mia-Pa-Ca-2 tumour xenograft was achieved following oral administration of 
MENK GCPQ B2 nanoparticles. With MENK-GCPQ B2 nanoparticle, a single daily 
oral dose of 50 mg/kg was sufficient to achieve therapeutic effect compared to 
standard therapy, which requires MENK administration at a dose of 5 mg/kg three 
times daily. We have also achieved significant MENK level in plasma up to 3 h 
following IV administration of MENK-GCPQ B1 nanoparticle. These results are 
encouraging, while taking in to account of its half-life, which is 4 to 7.5 min in 
mouse. Further, we have reported for the first time that, MENK self assembles to 
form nanoparticles and the challenges that it presents in forming nanoparticles with 
GCPQ. In future, it is necessary to understand what percentages of MENK are 
encapsulated in GCPQ B2 nanoparticles and what is the fate of MENK-GCPQ 
nanoparticle following oral administration. The pharmacokinetics of MENK-GCPQ 
B2 oral formulation could be studied in rats by collecting plasma aliquots for all time 
points from single rat. So, the variability in using individual mice for each time point 
can be minimized. It was not possible to relate the MENK plasma level to tumour 
growth suppression. The MENK basal level in plasma is subjective to change in the 
presence or absence of tumour xenograft and with or without treatment. Hence, it is 
important to measure MENK level in tumours following oral administration of 
MENK-GCPQ B2 formulation. It was previously reported that the combined effect 
of gemcitabine and MENK enhanced growth inhibition of MiaPaCa-2 transplanted in 
to athymic mice [167]. So, it would be interesting to study the combined effect of 
MENK-GCPQ nanoparticles and gemcitabine on MiaPaCa-2 cells.  
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5 Conclusion 
5.1  Polymer architecture 
Quaternary ammonium palmitoyl glycol chitosan (GCPQ) has been reported 
to solubilize hydrophobic drugs and peptide and thereby enhancing their oral 
bioavailability. GCPQ is an amphiphilic polymer that includes glycol chitosan 
backbone, hydrophobic palmitoyl group and hydrophilic quaternary ammonium 
group. GCPQ polymer of three different batches were synthesized and characterized. 
The molecular weight (Mn) of the different batches 1, 2 and 3 of GCPQ polymers 
were around 8 KDa, 13 kDa and 33 KDa. The first two batches were synthesized by 
old method of GCPQ synthesis as per protocol previously described by Qu et al [127]. 
The major disadvantage of this method is that the rate of palmitoylation reaction 
cannot be controlled, as the palmitoylation reactions are setup where degraded glycol 
chitosan and palmitic acid N hydroxysuccinimide were added as weight ratios. 
However, a new method of GCPQ synthesis was adopted to control the 
palmitoylation reaction. Here, the reactants, degraded glycol chitosan and palmitic 
acid N hydroxysuccinimide were used as molar ratio to get expected degree of 
palmitoylation. The molecular weight of GCPQ B3 polymer was observed to be 
higher than the molecular weight of GCPQ B1 and B2. This could be due to the 
hydrophobic characteristics of the polymer itself, which could have resulted from 
differences in the attachment of palmitoyl chain to the GC backbone between two 
methods of synthesis. It was hypothesized that the polymer forms intra-molecular 
associaton in GPC mobile phase (65:35 of methanol and acetate buffer). Increase in 
the composition of methanol in mobile could dissolve GCPQ B3. This could be 
confirmed in the future studies. 
5.2  Amphiphilic characteristics of GCPQ polymer 
The degree of palmitoylation and degree of quaternization for different 
batches of GCPQ varied with low palmitoylation (16%) and high quaternization 
(14%) for GCPQ B1, high palmitoylation (19%) and high quaternization (12%) for 
GCPQ B2 and high palmitoylation (22%) and low quaternization (8%) for GCPQ 
B3. The peptides were formulated with GCPQ of different batches and their in vitro 
and in vivo characteristics were compared. The present study shows that these 
characteristics had been observed to have an influence on the nature of the polymer 
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itself, their formulation with the peptide, in vitro colloidal stability and in vivo oral 
absorption across the enterocytes.  
5.3  Characterization of GCPQ nanoparticles 
Particle sizes 
GCPQ B2 in water forms nanoparticles of size as large as 400 nm with a PDI 
greater than 0.8. However, addition of sodium chloride solution to GCPQ B2 of 
increasing molarity (10mM to 300mM) reduces the particle sizes to 150 nm. These 
results are contradictory to previous studies where the introduction of salts in the 
nanoparticle formulations modifies the surface charge of the particles. This results in 
particle aggregation due to decrease in the electrostatic repulsion between particles. 
Future studies need to be conducted in order to understand the interaction of salt with 
GCPQ nanoparticles. Probe sonication of GCPQ B2 at 15 amps for 15 min resulted 
in the formation of GCPQ B2 micelles of size around 20 nm and PDI 0.2 as observed 
with TEM and DLS. It was also observed that the probe sonication did not have any 
effect on the molecular weight of the GCPQ B2 polymer as characterized by GPC-
MALLS.  
Surface charge GCPQ micelles 
The surface charge of GCPQ micelles gives information on the colloidal 
stability of the polymer at different pH. GCPQ has exceptional colloidal stability due 
to presence of quaternary ammonium group. An example of how the surface charge 
of GCPQ changes with different pH was recorded with GCPQ B2 having 
quaternization of 12%. The primary amines and the secondary amines of the GCPQ 
polymer remains protonated at acidic pH and hence most positive zeta potential was 
observed (+50.4 mV). An increase in the pH of the GCPQ B2 formulation causes 
deprotonation of amines at alkaline pH. This can cause aggregation of the polymer. 
However, due to the presence of quaternary ammonium group the formulation 
remains positively charged (+ 15mV) at pH as high as 9. It could be interesting to 
know the effect of degree of quaternization on the colloidal stability of GCPQ B2 at 
different pH in future studies.  
Colloidal stability of GCPQ micelles in simulated gastric medium and intestinal 
medium 
 Characterization of surface charge of GCPQ B2 at different pH suggests that 
the colloidal stability of the GCPQ B2 polymer is pH dependent. The GCPQ B2 
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stock solution (25 mg/mL) was diluted 10 times in SGF and SIF fluid to final 
concentration of 2.5 mg/mL The dilution does not affect the colloidal stability of 
GCPQ B2 micelles as it known from previous studies that the CMC of GCPQ B2 
micelles was only 19uM [134]. The colloidal stability was carried out to understand 
how does the composition of SIF or SGF fluid such as the presence of bile salts and 
or proteins affect the colloidal stability of GCPQ B2 in simulated gastro intestinal 
medium. This study helps to predict how the GCPQ B2 micelles behave in vivo after 
its oral administration. GCPQ B2 micellar aggregation was found to be increasing 
with time in fed state intestinal fluid and to a lesser extend in fasted state intestinal 
fluid. This shows that presence of pancreatin and oleates in fed state intestinal fluid 
can induce the aggregation of GCPQ B2 micelles at a faster rate compared to fasted 
simulated intestinal fluids. It was also observed from the number based distribution 
that only a fraction of GCPQ B2 (1%) aggregates resulting increased PDI and Z-
average results. This results confirm the previous observation of GCPQ B2 
interacting with the bile components and recirculate between liver and small intestine 
[160]. 
5.4  Peptide GCPQ nanoparticles 
MENK is an anti cancer peptide of molecular weight 573 Da having poor 
stability in the gastrointestinal tract. The peptide requires repeated IV administration 
due to its anti-proliferative effect on cancer cells. Since repeated IV administration of 
peptide could be non-compliance to patient, an alternative non-invasive approach 
such as oral administration is preferred.  
Labyrinthopeptin is an anti-nociceptive peptide with molecular weight 1923 
Da has poor solubility in sodium chloride solution (0.9 mg/mL). The peptide has 
poor oral bioavailability, which sets its limitation for using it for chronic treatment.  
Both the peptides of different physiochemical properties were formulated 
with different batches of GCPQ and the results were compared.  
Influence of GCPQ polymer characteristics on GCPQ peptide formulation 
Characterization of Laby GCPQ B2 formulation suggests that ratio of peptide 
to polymer used has effect on particle formulation. The minimum GCPQ required to 
formulation Laby GCPQ B2 formulation was optimized to be 1:3 which was lower 
than previously made peptide GCPQ formulation prepared at ratio 1:5. 
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The degree of palmitoylation of GCPQ (B1 & B2) polymer also affects the 
size of the particles formed with polymer having low palmitoylation of 16% formed 
large particles around 500 nm and polymer having high palmitoylation of 19% 
formed particles as small as 20 nm. This observation was consistent with both Laby 
GCPQ (B1 & B2) as well as MENK GCPQ (B1 & B2) formulation. Any increase in 
the palmitoylation percent (22%) causes further increase in the size of the Laby 
GCPQ B3 formulation to 84 nm.  
The encapsulation efficiency of the Laby GCPQ (B1, B2 and B3) formulation 
were around 89%. It was not possible to conclude the encapsulation efficiency of 
MENK-GCPQ formulations as MENK itself forms aggregates with a CMC of 0.320 
mM. Alternative methods of determining the encapsulation efficiency of the MENK 
in GCPQ formulation could be studied in the future.  
Influence of GCPQ polymer characteristics on the colloidal stability of peptide 
GCPQ formulation 
The ratio of palmitoyltion and quaternization did influence the colloidal 
stability of Laby GCPQ formulation. High palmitoylation (22%) and low 
quaternization (8%) GCPQ B3 affected the colloidal stability of Laby GCPQ B3 
formulation in SIF and HBSS by forming aggregates. Whereas, Laby GCPQ 
formulation made with low palmitoylation (16%) and high quaternization (14%) of 
GCPQ B1 and high palmitoylation (19%) and high quaternization (12%) of GCPQ 
B2 were observed to be colloidally stable.  
The proteolytic stability of MENK-GCPQ B2 formulation in SIF with 
pancreatin was characterized in vitro. The MENK-GCPQ B2 (P-19% and Q-12%) 
particles were not observed to be stable in SIF with pancreatin. GCPQ nanoparticles 
has been reported to interact with the bile components and recirculate between liver 
and small intestine. The constituents of in vitro SIF medium did differ from in vivo 
conditions, as under in vitro condition only the effect of pH and stability against 
pancreatin were studied. However, in vivo, digestive juice is composed of bile 
secretions, pancreatic juices that could interact with MENK-GCPQ B2 formulation 
before adhering to the mucus membrane.  
Influence of GCPQ polymer characteristics on the oral uptake of peptide GCPQ 
formulation 
Therapeutic effect of Laby GCPQ B2 and MENK GCPQ B2 oral formulation 
having palmitoylation and quaternization of 19% and 12% was tested in vivo. Results 
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suggest that for Laby GCPQ B2 oral formulation, Laby GCPQ B2 nasal formulation 
and MENK GCPQ B2 oral formulation significant therapeutic effects was achieved 
against their respective peptide alone formulation.  
The concentration of MENK level in plasma for MENK-GCPQ B1 IV 
formulation was higher than MENK only formulation. However, no significant 
therapeutic effect was observed for MENK-GCPQ IV formulation against MENK 
only formulation. This could be due to saturation of OGFr receptor at a very low 
concentration and the excess MENK was cleared from the blood.  
The pharmacokinetics of Laby GCPQ oral formulation prepared with GCPQ 
B1 P16% and Q14% resulted in poor concentration of the peptide in the blood. This 
result suggests that the ratio of palmitoylation and quaternization used could change 
the absorption of particles across the enterocytes. From the results observed with 
both the peptides a hypothesis could be formulated. 
High quaternization of GCPQ B1 polymer carrying large positive charge could 
have interacted with mucin polymer and the excess positive charge on the GCPQ B1  
(Q-14%) nanoparticle resulted in electrostatic repulsion leading to detangling of the 
mucus layer. This could be the reason for poor concentration of the peptide in plasma 
for Laby GCPQ B1 formulation made with GCPQ B1 having P16% and Q14%.  
Also Laby GCPQ B3 formulation was observed to show high concentration of 
Laby in plasma after oral and nasal administration. The effect of GCPQ B3 
hydrophobicity with palmitoylation of 22% on uptake across the enterocytes could 
be studied in the future. The in vivo results clearly shows that a balance between 
palmitoylation and quaternization of GCPQ is necessary to control oral absorption of 
the peptides.  
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7 Supplementary 
7.1.1 Size Distribution of Laby GCPQ formulations 
 
Figure 7-1 Size distribution by number for Laby formulation 
 
Figure 7-2 Size distribution by number for Laby GCPQ formulation (1:1) 
 
Figure 7-3 Size distribution by number for Laby GCPQ formulation (1:2) 
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Figure 7-4 Size distribution by number for Laby GCPQ formulation (1:3) 
 
Figure 7-5 Size distribution by number for Laby GCPQ formulation (1:4) 
 
Figure 7-6 Size distribution by number for Laby GCPQ formulation (1:5) 
 
